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ZUSAMMENFASSUNG
ZUSAMMENFASSUNG
Der Transkriptionsfaktor CCAAT/enhancer-binding Protein β (C/EBPβ) reguliert die Ex-
pression zahlreicher Gene, welche die Proliferation, Differenzierung und Seneszenz in hä-
matopoietischen Zellen, Adipozyten, Hepatozyten und Leukämiezellen kontrollieren. Um
diese mannigfaltigen Aufgaben zu erfüllen interagiert C/EBPβ mit zahlreichen Kofaktoren
und Proteinen der Transkriptionsinitiations- und Transkriptionsrepressions-Maschinerie. Da
das funktionale Netzwerk von C/EBPβ und seinen zahlreichen Kooperationspartnern bis
heute nicht vollständig entziffert ist, ist es das Ziel dieser Arbeit das Netzwerk aus In-
teraktionspartnern und C/EBPβ regulierten Proteinen in Leukämiezelllinien und darüber
hinaus zu erforschen und aufzudecken. Das Interaktom von C/EBPβ wurde mittels einer
Kombination aus einem membranbasierten Peptid-Interaktions Testverfahrens (APS) und
endogener Immunprezipitationen mit gekoppelter MS-Analyse untersucht. Außerdem wurde
die Proteinmenge von C/EBPβ und die potentiell von C/EBPβ regulierten Proteine mit-
tels proteomischer MS-Analyse in C/EBPβ Knock-out- und Leukämiezelllinien untersucht.
Die Daten dieser Arbeit erweitern das Wissen über das Protein-Interaktom von C/EBPβ
und zeigen zahlreiche neue Interaktoren, sowie potentielle Protein-komplexe als C/EBPβ
Interaktoren auf. Die Protein-Interaktionsversuche ergaben epigenetische und allgemeine
transkriptionsregulierende Proteine, sowie Chromatinstruktur modellierende Faktoren, die mit
C/EBPβ interagieren. Überdies eröffnen die Versuchsergebnisse Interaktionen von C/EBPβ
mit Proteinen, deren Aufgabe die Regulation von mitotischem Chromatin und des Zellzyklus-
ses ist. Die Interaktionsdaten beinhalten auch Proteine, die in RNA-Polymerase Komplexen,
dem SWI/SNF-Chromatinremodeling Komplex oder MLL-Histonemethyltransferase Komple-
xen vorkommen. Zusätzlich konnten neue Interaktionen von C/EBPβ mit Kondensin- und
Kinetochorproteinen beobachtet werden. Die Daten dieser Studie eröffnen überdies neue
Interaktionen von C/EBPβ mit DNA Reparatur (DNA damage response) und Apoptose
assoziierten Proteinen. Interessanterweise konnten auch Komponenten des Spliceosomes und
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Proteine, die mit RNA-Prozessierung assoziiert sind, als Interaktoren von C/EBPβ identifiziert
werden. Diese Beobachtungen deuten auf Funktionen des Transkriptionsfaktors C/EBPβ hin,
die über die Regulation von Genexpression und Chromatinorganisation hinausgehen. Mit
Hilfe der proteomischen-MS Untersuchungen konnten überdies potentielle C/EBPβ regulierte
Proteine identifiziert werden, die in Energie-Metabolismus und Kinase-Signalwegen invol-
viert sind. Zusammenfassend ermöglicht diese Studie nicht nur die Verifikation von bereits
bekannten Proteininteraktionen von C/EBPβ, sondern eröffnet zahlreiche weitere zukünftige
Forschungsfelder bezüglich des funktionellen Netzwerkes des Transkriptionsfaktors C/EBPβ
in Leukämien, sowie anderen Zellarten und Geweben.
Stichwörter: C/EBPβ, konservierte Proteindomänen/CRs, transkriptionelle Regulation,
Protein-Protein Interaktionsnetzwerk, Leukämie, Metabolismus
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 5
SUMMARY
SUMMARY
The basic leucine zipper transcription factor CCAAT/enhancer-binding protein β (C/EBPβ)
regulates the expression of multitudinous genes that control the proliferation, differentiation
and senescence of haematopoietic cells, adipocytes, hepatocytes and leukemia cells. To facili-
tate its multifaceted functions C/EBPβ interacts with a collection of cofactors and proteins
of the transcription initiation as well as the gene repression machinery. Since the functional
network of C/EBPβ and its numerous cooperation partners is still incomplete this study
attempted to analyze interaction partners and downstream proteins of C/EBPβ in leukemia
cells and beyond. A combinatory approach of an array based peptide-interaction screening
(APS) and endogenous shotgun IP-MS from leukemia cell lines was applied to elucidate the
interactome of C/EBPβ. Moreover, C/EBPβ abundance and potential C/EBPβ regulated
proteins were determined by MS proteomics in C/EBPβ knockout and leukemia cell lines.
The data presented here largely expands previous knowledge of the C/EBPβ interactome
and discloses a plethora of novel C/EBPβ interactors and potential protein complexes. The
interaction screenings revealed proteins associated with the general and epigenetic regulation
of transcription, with chromatin remodeling and mitotic chromatin organization as well as cell
cycle regulation. Among those interactors were members of the RNA-Polymerase complexes,
the SWI/SNF chromatin remodeling complex or MLL histone methyltransferase complexes.
Additionally, new interactions of C/EBPβ with condensin and kinetochore proteins could
be elucidated. The data also reports of novel C/EBPβ interactors involved in DNA damage
response and apoptosis. In addition, components of the spliceosome and RNA-processing
were detected, suggesting extended functions of C/EBPβ beyond gene and chromatin regula-
tion. Furthermore, potential C/EBPβ regulated proteins involved in energy metabolism and
kinase pathways were discovered. Altogether this study verifies known and reveals various
novel spheres of activity of the transcription factor C/EBPβ and augments the network of
previous reported functions and cooperation partners. The here collected data discloses new
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subjects for further research concerning the role and functional network of C/EBPβ during
cell differentiation and in leukemia.
Keywords: C/EBPβ, conserved protein domains/CRs, transcriptional regulation,
protein-protein interaction network, leukemia, metabolism.
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INTRODUCTION
INTRODUCTION
1.1 Transcription factors
The expression of genes is initiated and regulated by a multitude of cellular signaling
pathways. Transcription factors act at the tip of these pathways recruiting components of
the transcription machinery and associated co-factors to gene promoters.
Transcription factors are often characterized and grouped into families according to their
highly conserved DNA-binding domains that recognize specific sites on DNA. The majority of
those protein families possess either DNA recognizing helix-turn-helix motifs, helix-loop-helix
motifs, homeodomains, leucine zippers, zinc fingers or other metal ion-binding domains (for
overview see: Pabo and Sauer, 1992). Most of the DNA binding proteins attach to DNA at
the major groove of the helical structure forming hydrogen bounds with the phosphodiesters
of the DNA-backbone. Some DNA binding proteins interact with the sugar group of the
nucleobases, preferably with purines such as guanine (for overview see: Pabo and Sauer,
1992). The number of possible binding sites on DNA is increased by the ability of homo and
especially heterodimer formation between transcription factors.
1.2 Family of basic leucine zipper DNA-binding domain pro-
teins
One of the families of transcription factors that are able to form homo- and heterodimers is
the family of basic leucine zipper domain proteins. The basic leucine zipper consists of two
subdomains: the DNA binding basic region and the leucine zipper domain. The leucine zipper
facilitates homo- and hetero dimerization with other proteins carrying leucine zipper domains.
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Basic leucine zipper domains are also called “bZIP”(basic-zipper) domains due to the before
mentioned dual domain structure. BZIP domains are usually 60-80 amino acids long while
the basic region covers about 30 amino acids (Hope and Struhl, 1986; Landschulz et al., 1988).
The bZIP domain carries two α-helical structures forming a coiled-coil structure that contacts
the major groove of B-helical DNA. The DNA affinity of the basic region arises mostly from
its high content of charged arginine and lysine residues (Agre et al., 1989; Kerppola and
Curran, 1991).
1.3 The CCAAT box and the family of CCAAT/enhancer-
binding proteins
Mammalian promoters are characterized by several conserved sequence boxes that are
identified and bound by specific transcriptional regulator proteins (Chodosh et al., 1988).
One of those elements is the evolutionary highly conserved CCAAT box motif that is a
common element in eukaryotic class 2 promoters and usually locates between -50 and -110
bp in front of the transcriptional start site (Bi et al., 1997; Chodosh et al., 1988; Dorn et al.,
1987; Hatamochi et al., 1988; McKnight and Tjian, 1986; Raymondjean et al., 1988).
A protein family that was discovered to bind to CCAAT box motifs as well as enhancer
core elements is the family of CCAAT/enhancer-binding proteins (C/EBPs) (Landschulz et al.,
1988; Johnson et al., 1987). The family of CCAAT/enhancer-binding proteins consists of six
transcription factors C/EBP α, β, δ, ε, γ and ζ that bind with their C-terminal DNA-binding
domain (DBD) to homologous sites on DNA (Osada et al., 1996; Mahoney et al., 1992; Akira
et al., 1990; Ryden and Beemon, 1989; Figure 1 and 2).
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bZIPTransactivation Domain
1 2 6543 7
C/EBPβ
C/EBPε
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C/EBPδ
C/EBPα
Figure 1: The C/EBP family members α, β, δ and ε share 9 highly conserved regions (CRs) forming
a transactivation domain (TAD; depicted in green) that spans from CR1-4, a regulatory domain (RD;
depicted in red) which encloses CR 5-7, a DNA binding domain and a basic leucine-zipper (bZIP;
CR8-9; depicted in yellow) domain. The CRs are divided by interspersed low complexity regions
(LCRs; depicted in grey). The scheme is modified after Ramji and Foka, 2002 and Leutz et al., 2011.
The C/EBP family members share a conserved C-terminal bZIP (Figure 1), which
enables the formation of homo- and heterodimers among the C/EBP family members or
with other bZIP transcription factors like those of the ATF family (Tsukada et al., 1994;
2011; Vallejo et al., 1993; Vinson et al., 1993; Landschulz et al., 1989). Homodimerization
of two C/EBP proteins facilitates binding to the general C/EBP recognized CCAAT box
DNA-sequence “A/GTTGCGC/TAAC/T” or the ideal “ATTGC-GCAAT” motif (Landschulz
et al., 1988; Mahoney et al., 1992; Miller et al., 2003; Figure 2). The number of possible DNA
motifs that could be recognized is extended even more by the possibility of heterodimerization
of two different bZIP domain proteins (Huber et al., 2012; Podust et al., 2001; Tsukada et
al., 1994; 2011).
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-4 -3 -2 -1 4
TTA ACG TGAT CAG TCCAC TG5’- 3’
321
Figure 2: DNA binding domain and recognition motif of C/EBP family members. A) Depicted is
the proposed structure of a C/EBPα homo-dimer with DNA. The leucine zipper (LZ) domains are
depicted in red, the basic regions, which contact the DNA, are colored in orange and the extended
basic regions (EBR) that span beyond the DNA are depicted in yellow (the DNA backbone is depicted
in blue, the sugar structures in grey) (derived from Miller et al., 2003). B) Complement DNA sequence
of the proposed binding site of C/EBPα (Miller et al., 2003). C) The general DNA sequence consensus
motif proposed for the C/EBP family by Mahoney et al., 1992.
Knockout experiments suggest that C/EBPβ and α are the most essential members of
the C/EBP family. Knockout of these two C/EBPs demonstrates early embryonic lethality
and defective tissue specification (Begay et al., 2004). Besides partially redundant functions
of the C/EBPα/β proteins, deletion mutants of either gene caused organ specific defects like
disturbed skin functions, liver regeneration or innate immunity (Hirai et al., 2006; Screpanti
et al., 1995; Tanaka et al., 1995).
The CEBPB gene encodes an intron-less transcript which is translated into three
isoforms, namely the long LAP* and LAP and the short LIP isoform (Dey et al., 2012;
Ramji and Foka, 2002; Descombes and Schibler, 1991; Figure 3). The CEBPB gene contains
three in-frame start codons and an upstream open reading frame (uORF) that is located out
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of frame between the initiation codons of the LAP* and LAP isoforms. The transcription
of the short LIP isoform is mediated by the uORF element that induces leaky scanning
after transcription initiation at the promoter followed by re-initiation of transcription at the
ORF-internal third start codon (Wethmar et al., 2010; Xiong et al., 2001; Calkhoven et al.,
2000). Alternative translation of the CEBPB gene depends on the activity of the translation
initiation machinery and in particular on mTOR activity (Esteves et al., 2012; Calkhoven et
al., 2000).
bZIPTransactivation Domain
1 2 6543 7
C/EBPβ
CR
Regulatory Domain
LAP*
LAP
LIP
Figure 3: The C/EBPβ protein possesses 9 highly conserved regions (CRs) grouping into the
transactivation domain (TAD; depicted in green; covering CR1-4) a regulatory domain (RD; depicted
in red; enclosing CR 5-7) a DNA binding domain and a basic leucine-zipper domain (bZIP; depicted
in yellow) (modified after Leutz et al., 2011). The conserved regions are intermitted by interspersed
low complexity regions (LCRs; depicted in grey). Depicted are the three C/EBPβ isoforms LAP*,
LAP and LIP. The LAP* and LAP isoforms share the last 8 C-terminal CRs, while the N-terminal
CR1 is exclusively present in the LAP* isoform. The truncated LIP isoform shares the conserved
region 7 of the regulatory domain and the bZIP domain with the other two isoforms, but lacks the
complete transactivation domain (Scheme is modified after Ramji and Foka, 2002).
The long C/EBPβ LAP* and LAP isoforms harbor the transactivation domain (Figure
3) and are understood to be effective activators of target genes (Kowenz-Leutz and Leutz,
1999; Williams et al., 1995). The truncated LIP isoform completely lacks the transactivation
domain (TAD) and part of the regulatory domain (RD) domain. LIP has been shown to
act as a dominant negative regulator of the two long activating C/EBPβ isoforms (Zahnow,
2009; Ramji and Foka, 2002) and C/EBPβ target genes (Smink and Leutz, 2010; Smink et
al., 2009). Moreover, the ratio between the long LAP* and LAP isoforms and the short LIP
isoform affects the regulation of C/EBPβ target genes influencing various cell differentiation
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processes and tumorigenesis (Seagroves et al., 1998; Luedde et al., 2004; Nerlov et al., 2007;
Smink and Leutz, 2010; Smink et al., 2009).
1.4 C/EBP transcription factors share a modular structure
The C/EBP transcription factor family members C/EBPα, β, δ and ε share nine highly
conserved regions. The conserved regions (CRs) of all family members form a transactivation
domain (TAD), a regulatory domain (RD), a DNA binding domain and a basic leucine-zipper
(bZIP) domain (Ramji and Foka, 2002; Figure 1). The TAD of C/EBPβ includes the N-
terminal first four conserved regions (CR1-4, contained in the activating isoforms LAP* and
CR2-4 present in LAP; Figure 3) and is understood to mediate the interaction with various
proteins and protein-complexes. The TAD of C/EBPβ was shown to mediate the interaction
with the SWI/SNF chromatin remodeling complex, which shuffles nucleosomes along the
DNA and thereby facilitates the binding of the gene transcription machinery. In this context,
the LAP*-isoform specific CR1 region is essential for granulocytic transdifferentiation by
facilitating SWI/SNF recruitment (Stoilova et al., 2013). Moreover, the TAD CR1 region was
suggested to mediate the interaction of LAP* with Myb facilitating the transactivation of
myeloid genes like mim-1/ LECT2 (Kowenz-Leutz et al., 1999). The TAD region of C/EBPβ
was shown to be essential for the interaction with the histone acetyltransferases (HATs)
CBP/p300 (Mink et al., 1997; Guo et al., 2001; Kovacs et al., 2003). The interplay between
C/EBPβ and the HATs leads to target gene activation. C/EBPβ has been linked to gene
repression as well (Di-Poi et al., 2005; Descombes and Schibler, 1991). In accordance with this
the TAD of C/EBPβ not only mediates the interaction with proteins that positively regulate
gene expression but also with transcriptional repressors. The TAD of C/EBPβ is known
to interact with transcriptional co-repressors like NCOR2 that recruits histone deacetylases
(HDACs) to gene promoters facilitating transcriptional silencing (Ki et al., 2005). Finally,
the TAD containing LAP* and LAP isoforms, but not the truncated LIP isoform, have the
ability to induce transdifferentiation of B-cells to myeloid cells (Stoilova et al., 2013).
The regulatory domain (RD) contained in all three isoforms (Figure 3) harbors the
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conserved regions five, six and seven. The RD is considered to serve as a negative internal
regulator sequence counteracting the activating function of the TAD (Williams et al., 1995).
Indeed the deletion of the RD of C/EBPβ (CR5,6,7) entails an enhanced transdifferentiation
potential concerning B-cell to myeloid transdifferentiation (Stoilova et al., 2013). This is
emphasized by the observation that a deletion of the RD (CR5,6,7) or at least CR5 and CR7
amplifies the transactivation potential of C/EBPβ significantly. In contrast to this the CR6
domain appears to be opposing the repressive effect of the CR5 and 7 by stabilizing an active
conformational state of C/EBPβ (Kowenz-Leutz et al., 1994). The RD is also known to be the
target for posttranslational modifications that regulate C/EBPβ activity and protein-protein
interactions (Leutz et al., 2010; Kowenz-Leutz and Leutz, 1999; Nakajima et al., 1993).
1.5 C/EBPβ is regulated by a multitude of PTMs
Numerous signaling pathways like the Ras, STAT, TNFα and TGFβ pathway regulate C/EBPβ
functions through various posttranslational modifications (PTMs) like phosphorylation, acety-
lation or methylation (Leutz et al., 2011; Kowenz-Leutz et al., 2010; Ramji and Foka, 2002;
Buck et al., 2001). Protein-protein interactions of C/EBPβ are influenced by PTMs. These
PTMs can be subdivided into modifications that attract or repel protein-protein interactions
or do not affect protein interplay at all. Multitudinous arginine and lysine methylations as
well as lysine acetylations and SUMOylation of C/EBPβ have been described (Leutz et al.,
2010; Berberich-Siebelt et al., 2006; Eaton et al., 2003; Kim et al., 2002).
The most extensively described PTMs of C/EBPβ are phosphorylations of serine or threonine
residues. For example the phosphorylation of C/EBPβ CR7 at Thr235 (human; Thr-189
in rat; Thr-188 in mouse; RD) by the receptor tyrosine kinases ERK1/2, which is part of
the Ras/MAPK signaling pathway (Nakajima et al., 1993; Figure 4). This modification was
shown to influence further modifications of C/EBPβ as well as its activity. The C/EBPβ
phosphorylation by ERK1/2 blocks the transcriptionally repressive methylation of C/EBPβ
at Arg3 (R3) by CARM1/PRMT4. The C/EBPβ Thr235 phosphorylation leads to a confor-
mational change enabling the interaction with transcriptional activators like the Mediator-
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and the SWI/SNF-complexes (Kowenz-Leutz et al., 2010; Mo et al., 2004; Sato et al., 2004;
Kowenz-Leutz and Leutz, 1999). The interaction with the SWI/SNF complex is essential for
subsequent activation of myeloid and adipogenic C/EBPβ target genes, as well as adipogenic
differentiation (Kowenz-Leutz et al., 2010).
In addition, TGFβ-signals induce the phosphorylation of C/EBPβ on Ser105 (rat)
(Thr217 in mouse) by the MAPK-downstream kinase RSK2 and stimulate hepatocyte prolifer-
ation (Buck et al., 1999). The protein kinase C (PKC) was revealed to phosphorylate C/EBPβ
at Ser105 as well, enhancing the transactivation activity of the LAP isoform (Trautwein et
al., 1993). The phosphorylation of C/EBPβ by GSK-3 at Ser184 (mouse) is considered to be
important concerning target gene activation by the LAP isoform (Piwien-Pilipuk et al., 2001).
This GSK-3 phosphorylation marks increased C/EBPβ transcriptional activity, whereas the
modification by the protein kinase C (PKC) especially on Ser299 is understood to prohibit
C/EBPβ DNA binding ability (Mahoney et al., 1992). Modifications of C/EBPβ are also
important for its cellular localization. The phosphorylation at Ser299 by protein kinase A
(PKA) is essential for nuclear translocation of C/EBPβ (Chinery et al., 1997; Trautwein et
al., 1994; 1993). C/EBPβ is also a target of the cell cycle kinases CDK2 and CDC2 that
were shown to phosphorylate Ser-64 (rat) and the ERK1/2 target site Thr-189 (rat; Thr-188
mouse) in a cell cycle dependent manner (Shuman et al., 2004; Figure 4).
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ERKGSK-3 β
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TAD RD bZIP
Figure 4: Different cellular signal transduction pathways induce the phosphorylation of C/EBPβ at
threonine 179 and/or 188 (mouse) in the regulatory domain (RD). Depicted are exemplary interleukin
involving pathways activating GSK-3β and the MAPKinase ERK1 as well as cell cycle associated
signals inducing phosphorylation of C/EBPs by ERK1 or the Cyclin-dependent kinase 2 (cdk2). The
scheme is modified after Tsukada et al., 2011.
The activity of C/EBPβ can be negatively regulated by methylation of lysines and
arginines. The repressive arginine methylation at C/EBPβ R3 by CARM1/PRMT4 pro-
hibits interaction of C/EBPβ with the SWI/SNF complex, as described before. The lysine
methylation of K39 in the TAD of C/EBPβ by the histone H3K9 methyltransferase G9a was
shown to repress C/EBPβ target gene activation as well. This mechanism was confirmed by
a lysine-to-alanine exchange at K39 that prohibited this modification and simultaneously
hyper-activated expression of the C/EBPβ target gene mim-1/LECT2 (Pless et al., 2008).
1.6 C/EBPβ interacts with epigenetic modifiers to regulate
gene expression
C/EBPβ plays a significant role in cell differentiation, proliferation and tumor development
and promotion in various cell types suggesting a regulation of its activity by numerous PTMs
and substantial cooperation with a multitude of different proteins. In particular C/EBPβ
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was associated with myeloid differentiation, bone metabolism as well as with adipogenesis
amongst others by regulating the expression of various genes (Esteves et al., 2013; 2012; Smink
and Leutz, 2010; Smink et al., 2009; Zwergal et al., 2006; Gorgoni et al., 2002; Ramji and
Foka, 2002; Screpanti et al., 1995). C/EBPβ was shown to interact with various epigenetic
regulators like histone modifying proteins or chromatin remodeling complexes to fulfill its
transcriptional regulatory tasks in cell differentiation and disease (Ki et al., 2005, Di-Poi
et al., 2005). C/EBPβ is known to interact with the HATs CBP/p300 (Kovacs et al., 2003;
Mink et al., 1997).
As mentioned before, C/EBPβ is capable of transcriptional repression as well (Descombes
and Schibler, 1991; Di-Poi et al., 2005; Tsukada et al., 2011). Negative regulation of gene
expression can be mediated by the removal of histone acetylations and activating histone
tail methylations, followed by the establishment of transcriptionally repressive histone tail
methylations. C/EBPβ was shown to repress PPARβ expression by recruiting a histone
deacetylase 1 (HDAC-1) containing repressor complex to the PPARβ promoter (Di-Poi et al.,
2005). The study of Ki et al. described the interaction of the C/EBPβ TAD with the histone
deacetylase recruiting co-repressors NCOR2/SMRT and NCOR1 (Ki et al., 2005).
1.7 The role of C/EBPβ in differentiation
C/EBPβ plays a role in myelopoiesis and macrophage functions, emergency granulopoiesis and
neoplastic transformation (Hirai et al., 2006; Tanaka et al., 1995; Natsuka et al., 1992). The
three different isoforms of C/EBPβ, as well as the their ratio to each other, achieve different
functions during mammary gland development (Seagroves et al., 1998), liver regeneration
(Luedde et al., 2004) and bone metabolism (Smink and Leutz, 2010; Smink et al., 2009).
C/EBPβ plays a vital role in osteogenesis by cooperating with the transcription factors
Runx2 or ATF4 during osteoblast differentiation (Tominaga et al., 2008; Hata et al., 2005).
The translation of the truncated C/EBPβ LIP isoform is upregulated during osteoblast
differentiation and LIP interacts with RUNX2 to promote the differentiation of osteoblasts
(Hata et al., 2005). C/EBPβ is a target gene of the mTOR pathway and low mTOR levels
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lead to enhanced expression of the two long C/EBPβ isoforms simultaneously decreasing
LIP transcription. This enhanced translation of the activating LAP* and LAP isoforms
induces MafB expression, a transcription factor vital for different developmental processes.
MafB suppresses osteoclastogenesis by interacting with several inhibiting transcription factors
(Smink and Leutz, 2010; Smink et al., 2009).
C/EBPβ plays an important role in mammary gland development, proliferation and
functional differentiation of mammary epithelial cells. The two studies of Robinson et al. and
Seagroves et al. report impaired mammary ductual morphogenesis and inhibited expression
of the characteristic milk proteins β-casein and WAP in the mammary gland of C/EBPβ
knockout mice (Seagroves at al., 1998; Robinson et al., 1998). Female C/EBPβ knockout
mice not only exhibit impaired mammary gland development but also present reproductive
defects. The abundance of C/EBPβ is vital for ovarian follicle development and therefore
plays an important role in female reproduction (Sterneck et al., 1997).
Enforced expression of C/EBPβ induces reprogramming or transdifferentiation of B-cell
precursors to cells resembling inflammatory macrophages. Expression of C/EBPβ in B-cell
precursors induces the expression of the granulocyte/monocyte marker Gr-1, Mac-1 and
the mature macrophage marker F4/80 in about 60 of all transfected cells, whereas the
expression of CD19 is downregulated (Xie et al., 2003). The study of Xie et al. showed that
enforced expression of C/EBPβ, in contrast to C/EBPα, is associated with increased cell
proliferation. Furthermore, the different isoforms of C/EBPβ exhibit distinctive functionality
in transdifferentiation of blood cells. The long isoforms LAP* / LAP, but not the N-
terminally truncated LIP isoform, are capable of transdifferentiating primary mouse B
lymphoid progenitors into myeloid cells (Stoilova et al., 2013). The study of Stoilova et al.
elucidated the requirement of the LAP* specific CR1 region for induced transdifferentiation
of primary B-lymphocytes to the granulocytic lineage. In concordance with this C/EBPβ
was shown to be required for C/EBPα independent emergency granulopoiesis after cytokine
stimulation or fungal infection (Hirai et al., 2006). The survey of Hirai et al. revealed
that C/EBPβ, in contrast to C/EBPα, facilitates proliferation of granulocytic progenitors
accompanied or even benefited by delayed c-Myc downregulation. Summarizing, Hirai and
colleagues suggested that C/EBPα is crucial for the maintainance of a stable number of
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granulocytes, whereas C/EBPβ is mainly activated under emergency conditions to elevate
the numbers of mature granulocytes. Another survey suggests that it is not necessarily the
C/EBPα or β isoform itself that induces granulocytic differentiation of myeloid precursors,
but the time point and the level of C/EBPα and β expression that regulates the differentiation
process (Jones et al., 2002). The study by Jones et al. investigated myeloid differentiation
in mice carrying the CEBPB gene sequence inside the deleted CEBPA gene locus. These
mice showed an unusually elevated C/EBPβ expression in bone marrow cells that probably
originated from the knockin sequence inside the CEBPA locus. In contrast to C/EBPα
knockout mice, the bone marrow levels of myeloid proteins stayed unaffected in the C/EBPα
knockout-C/EBPβ knockin mice and no effects on the hematopoietic system could be observed.
According to these results the authors propose a redundant function of C/EBPα/β proteins
in the myeloid lineage (Jones et al., 2002).
1.8 The role of C/EBPβ in cancer
The transcription factor C/EBPβ plays multifaceted roles in several types of cancer. Whereas
some studies associate C/EBPβ with tumor cell proliferation, metastasis and survival others
suggest a role in oncogene induced senescence and apoptosis (Pal et al., 2009; Piva et al., 2006;
Robinson et al., 1998). C/EBPβ has also been suggested to regulate proliferation in different
cancer and cell types by directly interfering with cell cycle regulators delaying S-phase entry
(Gutsch et al., 2011; Luedde et al., 2004; Seagroves et al., 1998).
Increased expression of C/EBPβ mRNA appears especially in aggressive types of breast
cancer. The upregulation of C/EBPβ correlates with poor prognosis, metastasis and high
tumor grade (Van de Vijver et al., 2002; Zahnow, 2009). Estrogen-receptor-negative and
highly proliferative breast cancers often show an increased ratio of C/EBPβ LIP:LAP isoforms
(Zahnow, 2009; Arnal-Estape et al., 2010). This was also examined by the studies of Zahnow
et al. showing that overexpression of LIP in mammary epithelial cells contributed to increased
proliferation, hyperplasia and tumor formation. On top of that, decreasing the LIP:LAP ratio
via enforced LAP expression reverted proliferation and malignant transformation of breast
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cancer cells (Zahnow et. al., 2001; Zahnow, 2009). The same procedure induced senescence
and reduced MYC expression in response to TGFβ in breast cancer cells (Arnal-Estape et
al., 2010). Moreover, the study implicated that CUGBP1, a member of the HER2 receptor
pathway, increases the translation of the LIP isoform. Based on this knowledge, the authors
propose the suppression of LIP expression by the HER2 pathway inhibitor Trastuzumab as a
potential breast cancer therapeutic.
C/EBPβ is associated with tumor invasiveness in colorectal cancer. The expression of the
long C/EBPβ isoforms (LAP* and LAP) was shown to be significantly increased in colorectal
cancer samples of Duke’s stages A (submucosa invasion) and to a lesser degree in stages B
(penetration of intestinal wall and invasion of adjacent organs) and C (lymph node invasion)
compared with normal colon mucosa. Moreover, the short LIP isoform was markedly increased
in colorectal tumors of Duke’s stage B (Rask et a., 2000).
C/EBPβ is highly expressed in various types of leukemia. Several studies indicate
C/EBPβ to stimulate proliferation and survival in Anaplastic large cell lymphoma (ALCL),
multiple myeloma (MM) and myeloid lymphomas as well as in the leukemia derived cell
lines SU-DHL-1 (ALCL), HL60 (premyelocytic leukemia), U937 (histiocytic lymphoma) and
OPM2 (MM) (Studzinski et al., 2012; Anastasov et al., 2010; Piva et al., 2010; 2006; Pal et
al., 2009; Blenk et al. 2008; Quintanilla-Martinez et al., 2006).
The proliferation of the anaplastic lymphoma kinase positive (ALK+) ALCL cell line
SU-DHL-1 was shown to be vitally dependent on C/EBPβ, as its knockdown resulted in
a total block of proliferation. Moreover, the study revealed that the proliferation of SU-
DHL-1 cells partially depends on the activating Thr235 phosphorylation of C/EBPβ by the
MAPK-pathway kinases ERK1/2 (Anastasov et al., 2010). Further studies showed that
the NPM-ALK kinase as well as the STAT3 pathway positively regulate the transcription
of C/EBPβ in SU-DHL-1 cells. On top of that, the authors suggested that C/EBPβ plays
a significant role in the survival of SU-DHL-1 cells (Piva et al., 2006; 2010; Quintanilla-
Martinez et al., 2006). Another study of the Quintanilla-Martinez group analyzed C/EBPβ
regulated genes in the ALK+- ALCL cell lines SU-DHL-1, Karpas 299 and KiJK after
shRNA knockdown of C/EBPβ (Bonzheim et al., 2013). They could identify more than
100 genes that were significant differentially regulated in SU-DHL-1 and KiJK cells after
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C/EBPβ knockdown. The majority of genes shown to be regulated by C/EBPβ, grouped
into the GO:terms immunity, apoptosis or cell proliferation. In addition to that, C/EBPβ
was identified to bind to the promoters of the BCL2A1, G0S2 and DDX21 gene associated
with cell proliferation, cell survival and the inflammatory response. The knowledge of the
C/EBPβ regulatory network in ALCL cells is expanded by the observation of Bergalet et al.
that demonstrated that C/EBPβ mRNA is posttranscriptionally controlled by NPM-ALK in
SU-DHL-1 cells. NPM-ALK enhances the interaction of the mRNA binding protein HuR
with the C/EBPβ mRNA, entailing increased mRNA stability and translation (Bergalet et
al., 2011). Taken together, those results show a complex regulation of C/EBPβ expression
in ALK+-ALCL cells and at the same time imply that C/EBPβ gene regulatory function is
pivotal for the proliferation of these lymphomas.
C/EBPβ has not only been investigated concerning its earlier discussed functions in
myeloid cells and their differentiation but also in myeloid leukemia. Monocytic differentiation
of the premyelocytic leukemia cell lines HL60 (acute premyelocytic leukemia; AML) and U937
(Histiocytic / Non-Hodgkin lymphoma) can be initiated by the MAPK-pathway activator
PMA/TPA and has been previously shown to be C/EBPβ dependent (Ji and Studzinski,
2004; Chen et al., 1996). Further studies revealed that 1,25-Dihydroxyvitamin D3 (1,25D3)
and some of its analogs (deltanoids) can induce C/EBPβ dependent monocytic differentiation
of premyelocytic leukemia and HL60 cells (Studzinski et al., 2005; Ji and Studzinski, 2004; Ji
et al., 2002).
Moreover, C/EBPβ was reported to play a role in multiple myeloma (MM) proliferation
and survival. Bone marrow samples of multiple myeloma patients exhibited high levels of
C/EBPβ mRNA in MM cells expressing the plasma cell marker CD138. Additionally, MM
cell lines like U226 and the OPM2 cell line were reported to express the activating C/EBPβ
LAP isoform (Pal et al., 2009). The study of Pal et al. observed increased expression of
anti-apoptotic BCL2 and IRF4, modulators of MM malignancy, after C/EBPβ binding to
their gene promoters. The enforced expression of C/EBPβ enhances the proliferation of MM
cells. Summarizing, the authors suggested an anti-apoptotic and proliferation enhancing
function of C/EBPβ in MM malignancies.
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MATERIAL AND METHODS
2.1 Materials
2.1.1 Chemicals
Acetonitrile hypergrade for MS (Merck Millipore, Billerica, MA, USA)
Ampicillin sodium salt (Carl Roth, Karlsruhe, Germany)
Chloramphenicol (Sigma-Aldrich, St. Louis, MO, USA)
1,4-Dithiothreitol DTT (Merck Millipore, Billerica, MA, USA)
Disodium hydrogen phosphate (Na2HPO4) (SERVA, Heidelberg, Germany)
Ethylenediaminetetraacetic acid (EDTA/Na2EDTA-2H2O) (Calbiochem/EMD/Merck Milli-
pore, Billerica, MA, USA)
EGTA (Ethylenglycol-bis(aminoethylether)-N,N,N´,N´-tetraacetic acid) (Carl Roth, Karl-
sruhe, Germany)
Formic acid (Merck Millipore, Billerica, MA, USA)
Glacial acetic acid (C2H4O2)(Carl Roth, Karlsruhe, Germany)
Glycerol (C3H803)(Carl Roth, Karlsruhe, Germany)
Hydrochloric acid (HCL), 37 (Carl Roth, Karlsruhe, Germany)
HEPES ([N-2- hydroxyethylpiperazine-N’-2-ethanesulfonic acid)(Merck Millipore, Billerica,
MA, USA)
Magnesium chloride (MgCl2) (Carl Roth, Karlsruhe, Germany)
Methanol (Carl Roth, Karlsruhe, Germany)
Monopotassium phosphate (KH2PO4) (Carl Roth, Karlsruhe, Germany)
Non-fat milk powder (Merck Millipore, Billerica, MA, USA)
Nonidet P40 Substitute (NP-40) (Sigma-Aldrich, St. Louis, MO, USA)
Protease-Inhibitor-Cocktail (complete, EDTA-free) (Roche, Penzberg, Germany)
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PMSF (Sigma-Aldrich, St Louis, MO, USA)
Polybrene (Sigma-Aldrich, St Louis, MO, USA)
Potassium chloride (KCl) (Merck Millipore, Billerica, MA, USA)
Reprosil-Pur120 C18-AQ 3 µm beads (Dr. Maisch GmbH, Ammerbuch, Germany)
Sodium dodecyl sulfate (SDS) (Carl Roth, Karlsruhe, Germany)
Sodium chloride (NaCl) (Carl Roth, Karlsruhe, Germany)
Sodium hydroxide (NaOH) (Carl Roth, Karlsruhe, Germany)
SpikeTides TQL (JPT Peptide Technologies, Berlin, Germany)
Thiourea (Carl Roth, Karlsruhe, Germany)
Tris/tris(hydroxymethyl)aminomethane) (Sigma- Aldrich, St. Louis, MO, USA)
TurboFect (Thermo Fischer Scientific, Waltham, MA, USA)
Tween 20/ Polysorbate 20 (Sigma-Aldrich, St. Louis, MO, USA)
Universal Proteomics standard 2 (Sigma-Aldrich, St. Louis, MO, USA)
Urea (VWR International, Geldenaaksebaan, Belgium)
2.1.2 Enzymes
Anti-C/EBPβ antibody C19 rabbit polyclonal IgG (Santa Cruz; sc-150), was purchased from
Santa Cruz Biotech (Santa Cruz, CA, USA).
Benzonase Nuclease, ultrapure (Sigma Aldrich; E8263), was purchased from Sigma Aldrich
(St. Louis, MO, USA).
Lys-C was purchased from Wako (Osaka, Japan).
Modified trypsin, sequencing grade was purchased from Promega (Madison, WI, USA).
2.1.3 Peptides
C/EBP peptides
Murine C/EBP peptides (Swiss-Prot P28033) were purchased from PSL GmbH (PeptideSpe-
cialtyLaboratories GmbH, Heidelberg, Germany) and obtained from Dr. Michael Beyermann
(Leibniz-Institut für Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP),
Berlin, Germany; vide Table 1).
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Table 1: Sequences of murine C/EBP peptides used for the different APS approaches. The peptides
were hybridized to UniPEx libraries as described in the method section.
Name (murine C/EBP peptide)
conserved region  
of C/EBP family
amino acid sequence
purchased from PSL
C/EBPbeta aa1-41 "CR1-2" CR1-2 MHRLLAWDAACLPPPPAAFRPMEVANFYYEPDCLAYGAKAA - Biotinyl
C/EBPbeta aa49-72 "CR3" CR3 AAEPAIGEHERAIDFSPYLEPLAP - Biotinyl
C/EBPbeta aa153-173 "CR7"
N-terminus of 
CR7
MAAGFPFALRAYLGYQATPSG - Biotinyl
C/EBPepsilon aa1-62 "CR2-4" CR2-4 MSHGTYYECEPRGGQQPLEFSGGRAGPGELGDMCEHEASIDLSAYIESGEEQLLSDLFAVGX - Biotinyl
purchased from AG 
Beyermann - applyed as mix 
"CR4-7"
C/EBPbeta aa 79-111 CR4-5 Biotinyl-APAHHDFLSDLFADDYGAKPSKKPADYGYVSLG
C/EBPbeta aa 128-172
CR6 - N-terminus
of CR7
Biotinyl-PPAALKAEPGFEPADSKRADDAPAMAAGFPFALRAYLGYQATPSG
C/EBPbeta aa 152-196 CR7 Biotinyl-MAAGFPFALRAYLGYQATPSGSSGSLSTSSSSSPPGTPSPADAKA
2.1.4 Protein libraries
UniPEx protein expression libraries were purchased from imaGenes (Source BioScience,
Berlin, Germany). A library set consisted of 2 Arrays (22 cm x 22 cm PVDF membranes,
#9027/9028) on which 15,300 UniPEx E. coli colonies are spotted that express human
in-frame ORF constructs of 7,390 human genes (on average each gene is expressed by 2.4
colonies = coverage of 2.4 of the 7,390 genes). The expression colonies of each gene are
spotted in a double spot pattern inside one spotting scheme to reduce false positive signals
during final signal evaluation.
2.1.5 Cell lines
cell line name cell line / cancer classification source
U937 histiocytic lymphoma DSMZ no.:ACC 5; Deutsche Sammlung von Mikro-
organismen und Zellkulturen (DSMZ), Braun-
schweig, Germany
SU-DHL-1 anaplastic large cell lymphoma
(ALCL)
DSMZ no.: ACC 356; Deutsche Sammlung
von Mikro-organismen und Zellkulturen (DSMZ),
Braunschweig, Germany
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HL60 acute myeloid leukemia (AML) DSMZ no.: ACC 3; Deutsche Sammlung von
Mikro-organismen und Zellkulturen (DSMZ),
Braunschweig, Germany
JEKO-1 B-cell lymphoma DSMZ no.: ACC 553; Deutsche Sammlung von
Mikro-organismen und Zellkulturen (DSMZ) ,
Braunschweig, Germany
OPM2 multiple myeloma The cell line was kindly provided by Prof. Dr.
Bernd Doerken (MDC, Berlin).
PlatE/HEK derived from human embryonal
kidney-293T cell line
The cell line was generated by Morita et al. from
HEK 293T cells as described by Morita et al., 2000
C/EBPβ-/- MEF murine embryonal fibroblast The cell line was derived from C/EBPβ-/- 129 Ola
X C57Bl/6 animals (Sterneck et al., 1997).
2.1.6 Retroviral vectors
The C/EBPβ expression plasmids are based on the chicken sequence (gene bank # EMBLZ
21646) resembling the isoforms LAP* and LAP. The C/EBPβ LAP* start site was optimized
to a Kozak consensus sequence by exchanging a glutamine at position 2 to glutamic acid.
All C/EBPβ sequences are present in a MIEG3-vector (an improved murine stem cell virus
(MSCV)-based bi-cistronic retroviral giving a very bright EGFP fluorescence (Williams et al.,
2000)) and were described before in detail by Stoilova et al., 2013.
Additionally, vectors encoding the viral Gagpol and Envelope (Env) were used as
described before in detail by Stoilova et al., 2013.
2.1.7 Equipments
AB Sciex Nano Spray II source (AB Sciex, Washington, DC, USA)
Avanti Centrifuge J-26 (Beckman Coulter, Brea, CA, USA)
Bachofer Sonoplus HD70 Ultrasonic device (Bachofer, Germnay)
Binder Inkubator (Binder, Tuttlingen, Germany)
Centrifuge Varifuge 3.0R (Heraeus, Hanau, Germany)
Centrifuge 5417R (Eppendorf, Hamburg, Germany)
FACS Canto II (BD DivaSoftware; BD Becton Dickinson, Franklin Lakes, NJ, USA)
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Eksigent nano LC-ultra 1D (Eksigent, Dublin, CA, USA)
Odyssey Scanner (LI-COR, Lincoln, NE, USA)
Orbitrap electrospray ion source (Thermo Fischer Scientific, Odense, Denmark)
Proxeon EASY nLC II (Thermo Fischer Scientific, Odense, Denmark)
Q-Exactive mass spectrometer (Thermo Fischer Scientific, Waltham, MA, USA)
QTRAP 5500 (AB Sciex, Washington, DC, USA)
Rocking platform (Polymax 1040; Heidolph Instruments, Schwabach, Germany)
2.2 Methods
2.2.1 Array peptide screening (APS)
Hybridization of UniPEx protein macroarrays was performed as described before (Pless et al.,
2011), except for using of 0,2 µM biotin coupled peptides, incubated with macroarrays for 2h
at room temperature (RT) and the detection with 1 µg/ml streptavidin coupled IRDye800cw
or IRDye680lt (LI-COR, Lincoln, NE, USA) with incubation for 1h. Detection was performed
at 700 nm or 800 nm with LI-COR Odyssey CLx laser scan device (LI-COR, Lincoln, NE,
USA). Briefly: Macroarrays were washed with 96 ethanol and subsequently several times
with ddH2O and equilibrated in TBS-T-T. Residual expression colony material was removed
gently with a soft tissue (Kim-wipe). Macroarrays were rinsed 3 times, then washed twice for
10 min at RT in TBS-T-T and afterwards 3 times for 3 min and twice for 10 min at RT in
TBS on a rocking platform at 30 r.p.m.. Macroarrays were blocked for 2 h at RT in blocking
solution on a rocking platform at 10 r.p.m.. After removal of blocking solution macroarrays
were incubated with 0,2 µbiotin coupled peptide bait for 2 h at RT on a rocking platform at
10 r.p.m. Afterwards macroarrays were washed 4 times for 10 min at RT in TBS-T and twice
for 10 min at RT in TBS on a rocking platform at 30 r.p.m.. For detection macroarrays were
incubated with 1 µ/ml streptavidin coupled IRDye800cw or IRDye680lt for 1 h on a rocking
platform at 10 r.p.m.. Subsequently macroarrays were washed 4 times for 10 min at RT in
TBS-T and twice for 10 min at RT in TBS on a rocking platform at 30 r.p.m.. The signal
detection was acquired with an Odyssey Laser scan device (LI-COR, Lincoln, NE, USA)
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at 800 nm or 700 nm wavelength. Image scan files were evaluated manually but software
assisted using AIDA Image Analyzer software (Raytest, Straubenhardt, Germany).
Blocking solution
3  non-fat milk powder (Merck Millipore, Billerica, MA, USA) in TBS-T (filtrated)
TAE (Tris-acetate-EDTA)
50M stock solution:
242 g Tris base
57.1 ml glacial acetic acid
37.2 g Na2EDTA-2H2O
add H2O to 1 liter
Working solution, pH 8.5:
40 mM Tris-acetate
2 mM Na2EDTA-2H2O
Tris-HCl [tris(hydroxymethyl)aminomethane], 1 M
121 g Tris
add H2O to 1 l
pH adjustment with HCl
Tris-buffered saline (TBS)
100 mM Tris-HCl, pH 7.5
0.9  (150 mM) NaCl
Tris-buffered saline plus Tween (T-TBS)
0.1  Tween 20 in Tris-buffered saline (TBS)
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2.2.2 Cell culture
U937, SU-DHL1, HL60 and JEKO-1 and OPM2 cell lines were maintained at 5  CO2, 37 ℃
and in RPMI 1640 (Invitrogen, Carlsbad, CA, USA), 10  heat-inactivated fetal calf serum
(FCS), 1  penicillin/streptomycin in a Binder Inkubator (Binder, Tuttlingen, Germany).
MEF and PlateE/HEK cell lines were maintained in DMEM (Invitrogen, Carlsbad, CA, USA)
with 10  heat- inactivated fetal calf serum (FCS) and 1  penicillin/ streptomycin at 5 
CO2, 37 ℃ in a Binder Inkubator (Binder, Germany).
Cell culture solutions
Penicillin/Streptomycin (PAA/GE Healthcare, Little Chalfont, UK)
100 x Trypsin-EDTA (PAA/GE Healthcare, Little Chalfont, UK)
DMSO (Merck Millipore, Billerica, MA, USA)
Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Life technologies/Thermo
Fischer Scientific, CA, USA)
Dulbecco’s modified Eagle medium (DMEM) + Glutamax (Gibco, Life technologies/Thermo
Fischer Scientific, CA, USA)
Fetal Bovine Serum (FCS; PAA/GE Healthcare, Little Chalfont, UK)
2.2.3 Cell lysate preparation
Whole cell lysates
Whole cell lysates were prepared as triplicates from 1x10E7 cells per sample. Lysates were
prepared from PBS washed 1x10E7 cells of SU-DHL-1, HL60, JEKO-1 or U937 cell lines
in lysis-buffer 1. After 10 min incubation at 4 ℃ on a wheel at 10 r.p.m. the lysates were
treated with an ultrasonic device twice on ice for 20 sec and centrifugated for 20 min at 13
000 r.p.m. and 4 ℃. Supernatants were used for immunoprecipitation.
Nuclear enrichment of cell lysates
Nuclear enriched lysates were prepared as triplicates from 1x10E7 cells per sample. Nuclear
enrichment of lysates from 1x10E7 cells of SU-DHL-1 or OPM2 cell lines were prepared as
previously described (Schreiber et al., 1989). Briefly: 1x10E7 SU-DHL-1 or OPM2 cells were
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washed with PBS, resuspended in 400 µl buffer A per 1x10E6 cells and incubated for 15
min on ice. Nonident P-40 was added (final conc. 0.1), lysates were vortexed for 2 sec and
crude nuclei were pelleted by centrifugation for 30 sec at 13 000 r.p.m. Crude nuclei were
resuspended in buffer C in 50 µl per 1x10E6 cells and incubated for 15 min at 4 ℃ on a shaker
and subsequently treated with an ultrasonic device twice for 20 sec on ice followed by centrifu-
gation for 5 min at 13 000 r.p.m. at 4℃. The supernatant was used for immunoprecipitations.
Dithiothreitol (DTT), 1 M
15.45 g DTT in 100 ml H2O
stored at -20℃
EDTA (ethylenediamine tetraacetic acid), 0.5 M, pH 8.0
186.1 g Na2EDTA-2H2O in 700 ml H2O
pH adjustment with NaOH
add H2O to 1 l
KCl, 1 M
74.6 g KCl
H2O to 1 l
MgCl2, 1 M
20.3 g MgCl2-6H2O
H2O to 100 ml
NaCl, 5 M
292 g NaCl
add H2O to 1 l
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10 X PBS
1.4 M NaCl
0.027 M KCl
0.018 M KH2PO4
0.1 M Na2HPO4
Dissolved in deionized water, autoclaved and stored at RT.
Buffer A (low salt)
10 mM HEPES, pH 7.5
0.1 mM EDTA, pH 8
0.1 mM EGTA, pH 8
10mM KCl
1mM DTT
0.5 mM PMSF
protease inhibitors (Roche, Penzberg, Germany)
Buffer C (high salt)
20 mM HEPES, pH 7.5
1 mM EDTA, pH 8
1 mM EGTA, pH 8
400 mM NaCl
1mM DTT
0.5 mM PMSF
protease inhibitors (Roche, Penzberg, Germany)
Lysis/IP buffer 1 (for whole cell lysates)
20 mM HEPES, pH 7.5
150 mM NaCl
1 mM EDTA, pH 8
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1 mM EGTA, pH 8
20 Glycerol
1 U/ml Bezonase
1 mM dithiothreitol [DTT]
protease inhibitors (Roche, Penzberg, Germany)
IP buffer 2 (for nuclear enrichment)
20 mM HEPES, pH 7.5
200 mM NaCl
1 mM EDTA, pH 8
1 mM EGTA, pH 8
1 U/ml Bezonase
1 mM DTT
2.2.4 Immunoprecipitations (IP)
IPs of nuclear lysates of SU-DHL-1 or OPM2 cells or of whole cell lysates of HL60, JEKO-1,
SU-DHL-1 or U937 cells were performed with 1 µg/ml anti-C/EBPβ antibody (C19; Santa
Cruz) in IP-buffer 2 for 2 h at 4 ℃ on a wheel at 10 r.p.m.. Precipitations were collected with
3 mg protein G-coated Dynabeads (Life technologies/Thermo Fischer Scientific, CA, USA) for
5 min at 4 ℃ and washed twice afterwards. Beads were separated from the supernatant using
a magnetic rack. Beads were stored at -80 ℃ and subjected to mass spectrometry analysis.
Günther Kahlert (MDC) conducted the preparation and mass spectrometry measurements
that followed. Briefly: Proteins were released from the beads by adding laemmli-SDS buffer
and boiling the samples at 95℃ for 3 min. Then the proteins were methanol-chloroform precip-
itated (Wessel and Flügge, 1984) and reconstituted in urea buffer. Subsequently the samples
were subjected to a two-step in-solution digest as described by Sury et al., 2014 using Lys-C
and trypsin. The acquired peptides were desalted by StageTip purification (Rappsilber et
al., 2007). The eluted peptides were subjected to mass spectrometric analysis on a Q Exactive.
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Laemmli-SDS buffer
1.3  (w/v) SDS
10 mM TRIS, pH 6.8
0.1 M DTT
Urea buffer
10 mM HEPES, pH 8.0
6 M urea
2 M thiourea
2.2.5 Retrovirus production
Viruses were produced by transfection of PlatE/HEK cells (Morita et al., 2000). 4 h before
transfection 3x10E6 PlatE cells were seeded in a 10 cm dish in DMEM + Glutamax (Invit-
rogen, Carlsbad, CA, USA), 10 Fetal Bovine Serum (Gibco), 1 Penicillin-Streptomycin
(PAA/GE Healthcare, Little Chalfont, UK) and incubated at 37 ℃ and 5 CO2 (Binder
incubator). The transfection mix was prepared as follows:
• 15 ml DMEM + Glutamax, 10 FCS, 1 Penicillin-Streptomycin
• 5 µg retroviral vector pMSCV
• 10 µg plasmid encoding Gagpol
• 2 µg plasmid encoding Env
• 20 µl Turbofect
The mix was added drop wise to the PlatE cells and incubated for 12 h at 37 ℃, 5  CO2.
Subsequently the supernatant was discarded and 15 ml DMEM (DMEM + Glutamax, 10
FCS, 1 Penicillin- Streptomycin) was added. After 24h the supernatants were harvested and
replaced with 15 ml fresh DMEM (DMEM + Glutamax, 10 FCS, 1 Penicillin-Streptomycin).
The harvested supernatants were sterile filtered (for removal of cellular and other contam-
inants) and used for infection of C/EBPβ-/- MEF cells. The procedure of virus secretion
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 32
MATERIAL METHODS
(PlatE cells) and subsequent supernatant harvest was repeated a second time resulting in
two infection cycles
2.2.6 Infection and cell cultivation of MEF C/EBPβ-/- cells
For the virus infection, MEF C/EBPβ-/- cells were resuspended at 5x10E4 cells/ml in
DMEM+ Glutamax (Invitrogen, Carlsbad, CA, USA) medium and 1 penicillin/streptomycin
and transferred into 6-well plates 12 h prior to infection. Cells were infected twice, by adding
equal volume of sterile filtered retroviral supernatant (from PlatE cells) containing 8 µl
Polybrene (Sigma Aldrich, St. Louis, MO, USA). Plates were centrifuged for 90 min at 2100
r.p.m. at 37 ℃ in an Eppendorf centrifuge followed by 24 h incubation at 5  CO2, 37 ℃.
2.2.7 FACS sorting
Cells were washed with 1 X PBS twice and resuspended in ice cold 1 X PBS. Samples
were run in 1 X PBS on a FACS Canto II (BD Biosciences, BD DivaSoftware) and ana-
lyzed with the FlowJo software applying a sorting for GFP positive cells (FACS facility,
Dr. Hans-Peter Rahn, MDC). For each probe 1x10E7 cells were sorted and stored at 4 ℃.
Günther Kahlert (MDC) conducted the preparation and mass spectrometry measurements
that followed. Briefly: Cells were lysed immediately after FACS sorting with laemmli-SDS
buffer. Then the proteins were methanol-chloroform precipitated (Wessel and Flügge, 1984)
and reconstituted in urea buffer. Subsequently the same amounts of proteins were sub-
jected to a two-step in-solution digest as described by Sury et al., 2014 with the exception
that only Lys-C was used as a cleavage enzyme. The acquired peptides were desalted by
StageTip purification (Rappsilber et al., 2007). The eluted peptides were speed-vaced to
dryness and subsequently isotypically dimethyl labeled (Boersema et al., 2009). The labeled
peptides were combined and purified by StageTip purification. Thereafter the purified pep-
tides were fractionated by anion-exchange based fractionation onto StageTips (Wisniewski et
al., 2009). The eluted peptides were subjected to mass spectrometric analysis on a Q Exactive.
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 33
MATERIAL METHODS
2.2.8 MS-iBAQ proteomics of SU-DHL-1 cells
SU-DHL-1 cells were grown in cell culture as described before. Günther Kahlert (MDC)
conducted the preparation and mass spectrometry measurements that followed. Briefly: Cells
were lysed immediately with laemmli-SDS buffer. Then the proteins were methanol-chloroform
precipitated (Wessel and Flügge, 1984) and reconstituted in urea buffer. Universal Proteomics
standard 2 (UPS2) was added to the sample. The proteins were subjected to a two-step
in-solution digest as described by Sury et al., 2014 using Lys-C and trypsin. The acquired
peptides were desalted by StageTip purification (Rappsilber et al., 2007). The eluted peptides
were subjected to mass spectrometric analysis on a Q Exactive. UPS2 was used to compute
iBAQ intensities with MaxQuant 1.2.2.5 for SU-DHL-1 cells.
2.2.9 Bioinformatic analysis
Extended data and network analysis was performed using the DAVID online tool (Huang et
al., 2009; DAVID.abcc.ncifcrf.gov) to determine GO terms and functional domains (cutoff:
Benjamini-Hochberg 0.05).
The Cytoscape software inclusive the BisoGenet plugin (Martin et al., 2010; Shannon et al.,
2003) was used for network analysis and visualization.
Moreover the CORUM (Ruepp et al., 2008; 2010), UniProt (UniProt Consortium, 2013),
HIPPIE (Schaefer et al., 2011) and STRING databases (Jensen et al., 2009) were used
to determine functional associations, protein complexes and cellular networks of the here
detected protein interactions.
For further data analysis and visualization the R statistical software package was used (R
Core Team, 2013).
2.2.10 Mass spectrometry measurements and MS raw data evaluation
Mass spectrometry measurements and MS raw data evaluation was performed by Günther
Kahlert, MDC, Berlin.
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Mass spectrometry analysis of the FACS sorted infected MEF C/EBPβ -/- cells,
C/EBPβ IPs and SU-DHL-1 MS-iBAQ
Briefly: A Proxeon EASY nLC II using a 5-50  (v/v) acetonitrile gradient with 0.1  formic
acid with a flow rate of 200 nl/min was used for reversed-phase chromatography. In-house
packed reversed-phase columns packed with Reprosil-Pur120 C18-AQ 3 µm beads were used
for peptide separation. The SU-DHL-1 MS-iBAQ sample and the FACS sorted infected MEF
C/EBPβ-/- cell samples were measured in 8-hour runs and the C/EBPβ IP measurements
were conducted in 3-hour runs.
FACS sorted infected MEF C/EBPβ-/- cells, C/EBPβ IP samples from SUDHL-1,
HL60, U937, JEKO-1 and OPM2 cells and the iBAQ quantification of SU-DHL-1 cell line
were analyzed by MS and MS/MS acquisition on a Q Exactive mass spectrometer equipped
with an Orbitrap electrospray ion source. The data dependent mode with a mass window of
300 to 1700 m/z, a resolution of 60,000, the isolation window of 2.1 Th and a target value of
1x10E6 ions was selected for data acquisition. Higher-energy C-trap dissociation with the
normal collision energy of 25 was used for fragmentation. The 10 most abundant m/z with
a charge state of +1 were selected with a dynamic exclusion of 60 sec. MS/MS fragments
were collected using a fill time of 60 ms fort the SU-DHL-1 MS-iBAQ sample and the FACS
sorted infected MEF C/EBPβ-/- cell samples and a fill time of 120 ms for the C/EBPβ IP
measurements.
The MaxQuant Software Package Version 1.2.2.5 (Cox and Mann, 2008) using the
Andromeda search engine was used for matching the MS data to the Homo sapiens database
ipi.HUMAN.v3.72. Depending on the used cleavage enzyme Trypsin/P or Lys-C/P setting
was selected permitting two missed cleavage sites per peptide. The main search mass tolerance
was 6 ppm. The MS/MS search mass tolerance was set to 20 ppm selecting the top 10 MS/MS
peaks per 100 Da. The MaxQuant iBAQ setting was selected for quantification of the iBAQ
SU-DHL- 1 proteome and the MaxQuant label-free quantification setting was selected for the
data quantification of the C/EBPβ IPs.
Perseus 1.2.0.17 was used for analysis of the C/EBPβ IPs. For anti-C/EBPβ IPs from
whole cell lysates only proteins were chosen that were identified three times in one of the
groups. For anti-C/EBPβ IPs of nuclear enriched lysates only proteins were selected that
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were detected at least twice in one of the groups. Missing values were imputated. A cutoff for
significant C/EBPβ protein-protein interactions of p ≤ 0.02 for whole lysate IPs and FDR
≤ 0.05 for nuclear enriched IPs was determined (performed by Günther Kahlert, MDC, Berlin).
C/EBPβ quantity determination by SRM of SU-DHL-1 and U937
Briefly: For the C/EBPβ abundance determination in the SU-DHL-1 and the U937 whole
cell lysates were used. The proteins were methanol-chloroform precipitated (Wessel and
Flügge, 1984) and reconstituted in urea buffer. Heavy labeled peptides containing arginine10
(SpikeTides TQL) for C/EBPβ and ActinB were added before subjecting both cell lysates
to a two-step in-solution digest as described by Sury et al., 2014 using Lys-C and trypsin.
The acquired peptides were desalted by StageTip purification (Rappsilber et al., 2007). The
eluted peptides were subjected to mass spectrometric analysis.
Peptides were separated in hourly runs by an Eksigent nanoLC-ultra 1D using a 10-50
 (v/v) acetonitrile gradient with 0.06  formic acid. A flow rate of 250 nl/min was used.
In-house packed reversed-phase columns packed with Reprosil-Pur120 C18-AQ 3 µm beads
were used for peptide separation. Samples were measured on a QTRAP 5500 equipped with
an AB Sciex Nano Spray II source using a positive ion spray voltage of 2300 V. See also table
2 for details on the SRM method.
The MultiQuant 1.2 software (AB Sciex, Washington, DC, USA) was used for data
evaluation. C/EBPβ and Actin B heavy standards were used to verify the retention times and
peptide ion fragmentation patterns of the naturally occurring peptides. C/EBPβ area counts
were normalized to Actin B area counts for cell line comparison (performed by Günther
Kahlert, MDC, Berlin).
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Table 2: Selected reaction monitoring method for C/EBPβ abundance quantification. Table shows
the protein names (Protein), the relevant masses for the first quadrupole (Q1) and the third quadrupole
(Q3), the collision energy (CE) and the dwell time (Time) for both the transitions of the arginine10
containing peptides and the naturally occurring peptides. The identification (ID) shows the peptide
amino acid sequence targeted by SRM. Next to that, the mass-to-charge ration (m/z) and the fragment
ion y-series are annotated in the ID section.
Protein Q1 [Da] Q3 [Da] Time [msec] ID CE [Volts]
C/EBP 592.30 971.45 150 VLELTAENER (m/z +2) y8 31
592.30 842.41 150 VLELTAENER (m/z +2) y7 31
592.30 729.32 150 VLELTAENER (m/z +2) y6 31
587.30 961.45 150 VLELTAENER (m/z +2) y8 31
587.30 832.41 150 VLELTAENER (m/z +2) y7 31
587.30 719.32 150 VLELTAENER (m/z +2) y6 31
ActinB 571.76 922.43 5 GYSFTTTAER (m/z +2) y8 30
571.76 835.40 5 GYSFTTTAER (m/z +2) y7 30
571.76 688.33 5 GYSFTTTAER (m/z +2) y6 30
566.76 912.43 5 GYSFTTTAER (m/z +2) y8 30
566.76 825.40 5 GYSFTTTAER (m/z +2) y7 30
566.76 678.33 5 GYSFTTTAER (m/z +2) y6 30
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3.1 Determination of the impact of C/EBPβ on the cellular
proteome
The transcription factor C/EBPβ was described to regulate the expression of various genes
during the differentiation of myeloid cells and adipocytes, as well as in proliferation and tumor
progression in various cell types (Bonzheim et al., 2013; Esteves et al., 2012; 2013; Zwergal et
al., 2006; Gorgoni et al., 2002; Ramji and Foka, 2002; Screpanti et al., 1995). In order to
expand the knowledge of the cellular network regulated by the transcription factor C/EBPβ
we attempted to elucidate the influence of C/EBPβ on the cellular proteome. Therefore,
C/EBPβ-/- murine endothelial fibroblast (MEF) cells were retrovirally infected with C/EBPβ
constructs expressing the two long isoforms LAP* or LAP (C/EBPβ LAP*, C/EBPβ LAP;
Figure 5) that were previous analyzed concerning their trans-differentiation potential in
C/EBPβ-/- murine B-cell progenitors (Stoilova et al., 2013). The study of Stoilova et al.
showed a different outcome in the trans-differentiation of B-cell progenitors in which the
LAP* isoform induced trans-differentiation into granulocytic, macrophage and dendrite-like
cells while the LAP isoform failed to induce granulocyte differentiation. The survey showed
also a partially differential activation of characteristic myeloid genes by the LAP* and LAP
isoforms. As a fair amount of cells is necessary for the successful investigation of proteomes
by mass spectrometry we chose a C/EBPβ-/- murine endothelial fibroblast (MEF) cell line
instead of analyzing primary blood cell precursors from murine bone marrow as Stoilova et.
al. had done.
The murine retro viruses were produced in the human PlatE cell line by transfection
with vectors encoding the viral particles and the MIEG3 (MSCV-IRES-EGFP) C/EBPβ
expression vectors (as control an empty MIEG3 vector was used). The C/EBPβ-/- MEFs
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were infected with the murine retroviruses carrying C/EBPβ LAP* and LAP isoforms or
a control plasmid in two rounds (2 x 24 h; see Figure 5 and for further details material
and methods). After 48h of infection the MEF cells were harvested and GFP positive cells
were obtained by FACS sorting (FACS facility, Dr. Hans-Peter Rahn, MDC). After sorting,
whole cell lysates from GFP positive MEF cells were prepared immediately. The lysates were
Lys-C digested, followed by dimethyl-labeling and MS-proteomic analysis (Günther Kahlert,
MDC; Figure 5). Protein abundance was calculated as Log2 fold changes of proteins detected
with the LAP*/LAP infected cells versus the cells infected with the empty control vector or
between the LAP* and LAP infected cells. Proteins with a Log2 fold change ≥ 1 or ≤ −1
were considered as significantly regulated between the samples (MS analysis by Günther
Kahlert, MDC).
Virus production in PlateE cells
transfection of human PlateE cells with 
vectors encoding murine retrovirus
Infection of C/EBPβ-/-MEF cells
transfer of supernatant including secreted virus
to C/EBPβ-/- MEF cells
- 90 min centrifugation
-12 h incubation at 37°C, 5% CO2
repeat infection circle
(step 2-3)
hPlateE cells C/EBPβ-/- MEF cells
1 2
3
4
5
6
selection of infected, 
C/EBPβ/GFP positive cells
by FACS sorting (anti-GFP)
- immediate cell lysis
- Lys-C digest
- dimethyl labeling
- MS-proteomics
Figure 5: Workflow of the proteomics experiment with C/EBPβ-/- MEF cells. Depicted is a scheme
of the production of the retroviruses carrying the C/EBPβ LAP* or LAP or control constructs in
PlatE cells. The PlatE cells secrete the viruses after transfection with the vectors encoding the
viral components and MIG3 vectors containing C/EBPβ LAP* or LAP or control sequences. The
supernatants were used for 2 infection rounds of C/EBPβ-/- MEF cells. After two 24h-infection circles
the MEF cells were harvested and GFP positive cells were obtained by FACS sorting and transmitted
to MS proteomics analysis (for further details see material and methods section).
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The analysis of the C/EBPβ-/- MEF cells infected with the LAP* isoform revealed 97
proteins that were upregulated more than 2 fold and 20 proteins that were downregulated
more than 2 fold. The analysis of the cells infected with the LAP isoform revealed 122
proteins that were upregulated more than 2 fold and 107 proteins that were downregulated
more than 2 fold. 16 proteins were downregulated 2 fold by both LAP* and LAP Isoforms
and 67 significantly upregulated by both (Figure 6, Figure S1 and Table 3). The difference
between the up- or downregulated proteins by the LAP* or LAP isoform was rarely significant
(≥ 2 fold; Figure 6 and Figure S1). Therefore it was not possible to reveal the functional
difference between the two isoforms on a proteome level. This might be due to the fact that
only the 2649 most abundant proteins of the infected C/EBPβ-/- MEF cells were detected
with a ratio by this MS-proteomics approach.
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Figure 6: The heatmap on the following page (page 42) depicts a selection of proteins detected in
the proteomics experiment with C/EBPβ-/- MEF cells infected with the retroviral vectors carrying
either C/EBPβ LAP*, LAP or a control vector. The first two columns of the heatmap show the
Log2 fold change of the detected proteins (MS analysis by Günther Kahlert, MDC) from the cells
infected with C/EBPβ LAP* and LAP constructs versus cells infected with the control construct.
Signals with a Log2 fold change ≥ 1 or ≤ −1 were considered as significant. Proteins that were
detected with a significant Log2 fold change of ≤ −1 after C/EBPβ infection compared to the control
vector are depicted with a red scale. Proteins detected with a Log2 fold change of ≥ 1 after C/EBPβ
infection compared to the control vector are depicted with a green scale. Protein signals with an
insignificant Log2 fold change are depicted with a grey scale. The third column of the heatmap depicts
the Log2 fold change of the cells infected with the C/EBPβ LAP isoform versus the cells infected
with the LAP* isoform. Proteins that were detected with a significant log2 fold change of ≥ 1 after
LAP infection compared to the LAP* isoform are depicted with a yellow scale. Proteins detected
with a Log2 fold change of ≤ −1 ) after LAP* infection are depicted with a blue scale. Protein
signals with an insignificant Log2 fold change are depicted with a grey scale. The DAVID online
tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009) was used to determine GO:terms of the proteins
that were 2 fold upregulated by LAP* and/or LAP infection and a selection of assigned GO:terms is
annotated on the left side of the heatmap. A separate heatmap in Supplemental Figure S1 in the
supplement section depicts all detected proteins of this proteomics approach.
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MASS SPECTROMETRY PROTEOMICS OF C/EBPβ-/- MEF CELLS INFECTED WITH 
RETROVIRAL CONSTRUCTS OF HUMAN C/EBPβ LAP* OR HUMAN C/EBPβ LAP
 - SELECTION OF MOST SIGNIFICANT DIFFERENTIAL EXPRESSED PROTEINS - 
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The DAVID online tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009) was used to deter-
mine GO:terms of the proteins that were 2 fold upregulated by LAP* and/or LAP infection.
The main ranking terms were: “GO:0015031 protein transport”, “GO:0055114 oxidation
reduction”, “GO:0006468 protein amino acid phosphorylation” and “GO:0006091 generation
of precursor metabolites and energy” (Figure 6 and Table 3). The transport associated
proteins could be grouped into several different intracellular transport mechanisms among
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 42
RESULTS
them the two nuclear importin subunits Importin subunit α-1 (Kpna1; upregulated 2 fold by
LAP* and 1.5 fold by LAP) and Kpna4 (upregulated 29 fold by LAP* and LAP; Table 3).
Interestingly the GO-terms “oxidation reduction” and “generation of precursor metabolites
and energy” encompass proteins mainly involved in carbohydrate and amino acid metabolism
like the NAD dehydrogenases Ndufv3 (upregulated 1.8 fold by LAP* and 2.1 fold by LAP;
Table 3) and Ndufv2 (upregulated 3.5 fold by LAP* and 2.3 fold by LAP), the 1,5-anhydro-
D-fructose reductase Akr1cl2 (upregulated 2.4 fold by LAP*), ADP-dependent glucokinase
that phosphorylates D-glucose to D-glucose 6-phosphate (Adpgk; upregulated 1.6 fold by
LAP* and 2 fold by LAP), or the Krebs cycle associated Succinyl-CoA synthetase subunit α
(Suclg1; upregulated 5 fold by LAP* and 3.6 fold by LAP). Moreover, the gluconeogenesis
promoting phosphatase Pp4r3b (upregulated 7 fold by LAP* and 4 fold by LAP; Table 3)
and the cytochrome Cyb5b (upregulated 1.6 fold by LAP* and 2.9 fold by LAP; Table 3) are
significantly upregulated after C/EBPβ infection (Figure 6, Figure S1 and Table 3).
Further proteins that were associated with metabolism and upregulated more than
2 fold by C/EBPβ were the Fructose metabolism associated p35b (upregulated 1.3 fold by
LAP* and 2 fold by LAP; Table 3), the nucleotide metabolism associated 3(2),5-bisphosphate
nucleotidase 1 (Bpnt1; upregulated 5.6 fold by LAP* and 4.8 fold by LAP), the Pyruvate
carboxylase (Pc; upregulated 2 fold by LAP* and 1.3 fold by LAP; Table 3), the Pyruvate
dehydrogenase phosphatase regulatory subunit (Pdpr; upregulated by 5 fold by LAP* and 7
fold by LAP) and Cytochrome b5 type B (Cyb5b; upregulated by LAP).
Proteins associated with fatty acid metabolism like Long-chain fatty acid acyl-CoA
ligase 1 (Acsl1; upregulated by 2 fold LAP* and 1.4 fold by LAP) and Cpt1 (upregulated 3
fold by LAP* and 2 fold by LAP) that catalyzes the transfer of long-chain fatty acids between
CoA and carnitine prior to mitochondrial uptake were upregulated as well (Nyman et al.,
2011).
The GO-term “protein amino acid phosphorylation” includes several kinases of the
MAPK- and further kinase pathways like Jnk2/Mapk9, Jnk1/Mapk8, Fadk/Ptk2, Rock2,
Map2k2, Prkar2b, Pdgfra, the MAPKK activator Mapbpip as well as the Rock2 phosphatase
Ptpn11 that were mostly upregulated by both isoforms (Figure 6, Figure S1 and Table
3). The MS proteomics also revealed a significant (≥ 2 fold) up-regulation of the two
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known C/EBPβ target genes Xdh and Glrx (Gery et al., 2005) in the MEF cells infected
with the LAP* isoform. Findings that will be discussed later in this thesis will reveal that
C/EBPβ interacts with several components of the SWI/SNF chromatin-remodeling complex
like BAF180. Interestingly, the MS proteomics of the transfected MEF cells revealed the
significant upregulation of the two SWI/SNF family members Baf180 (upregulated 5 fold by
LAP* and 2.5 fold by LAP) and Smarcd1 (upregulated 1.9 fold by LAP* and 2.5 fold by
LAP; Figure 6, Figure S1 and Table 3) after C/EBPβ infection as well.
Table 3: The table on the following page (page 45) lists a selection of proteins that were signifi-
cantly up- or downregulated in C/EBPβ-/- MEF cells after C/EBPβ infection. The DAVID online
tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009) was used to determine GO:terms (column 3-4;
GO_BP_FAT, Benjamini-Hochberg ≤ 5 ) of the proteins that were ≥ 2 fold upregulated by LAP*
and/or LAP over-expression (column 5-7).
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UniProt AC. Name GO ID GOterm (GO_BP_FAT) log2 ratio LAP* vs. GFP
log2 ratio LAP 
vs. GFP
log2 ratio LAP 
vs. LAP*
A0AUM9 Eif2b3 GO:0006413 translational initiation -0.85144329 1.66698377 2.48913185
P48024 Eif1 GO:0006413 translational initiation -0.07514000 1.08290692 -0.76184904
Q8BMJ3 Eif1ax GO:0006413 translational initiation 1.87589799 1.03513120 -1.07755855
Q61466 Baf60a - SWI/SNF complex 0.92014083 1.34101794 0.18052981
Q8BSQ9 Baf180 - SWI/SNF complex 2.34457288 1.33233558 -1.01987231
Q8R307 Vps18 GO:0015031 protein transport 0.21636174 1.75928369 1.47674458
P61028 Rab8b GO:0015031 protein transport 0.35907131 1.36013950 1.61725146
Q80UZ2 Sdad1 GO:0015031 protein transport 1.91704979 2.37183762 0.52446493
Q6P1Y9 Exoc1 GO:0015031 protein transport 2.86874602 1.94542043 0.45459706
Q9D880 Tim50 GO:0015031 protein transport 0.66884528 1.02474519 0.21138606
P62259 Ywhae GO:0015031 protein transport 0.72071624 1.16008117 0.19547359
Q60960 Kpna1 GO:0015031 protein transport 1.04502352 0.59359281 0.06529657
Q91XD6 Vps36 GO:0015031 protein transport 2.16526881 1.72355856 -0.45987351
Q3UGH8 Kpna4 GO:0015031 protein transport 4.90967711 4.90631340 -0.52871888
Q6KAR6 Exoc3 GO:0015031 protein transport 1.12154595 0.67138396 -0.55968560
Q6A0C7 mKIAA0118 GO:0015031 protein transport 2.04896851 0.91249658 -0.76660274
Q9JHS3 Mapbpip GO:0006468 / GO:0000165 protein amino acid phosphorylation / MAPK cascade 0.25592366 1.13835577 0.55924706
Q7TSJ7 Mapk8 GO:0006468 / GO:0000165 protein amino acid phosphorylation / MAPK cascade 3.28346253 4.62538740 0.32065796
P35235 Ptpn11 GO:0006468 / GO:0000165 protein amino acid phosphorylation / MAPK cascade 0.76544988 0.99617178 0.08515268
Q9WTU6 Jnk2 GO:0006468 / GO:0000165 protein amino acid phosphorylation / MAPK cascade 3.15613770 2.36832137 -0.52383609
Q63932 Map2k2 GO:0006468 protein amino acid phosphorylation 1.03836594 1.40930946 0.48336436
P34152 Fadk GO:0006468 protein amino acid phosphorylation 1.53176821 0.72185384 -0.08100323
P70336 Rock2 GO:0006468 protein amino acid phosphorylation 2.15137178 2.39176772 -0.18023373
P31324 Prkar2b GO:0006468 protein amino acid phosphorylation 2.93213678 2.33222099 -0.51062148
Q9Z1W9 Spak GO:0006468 protein amino acid phosphorylation 2.11732934 1.21182212 -0.59795459
P26618 Pdgfra GO:0006468 protein amino acid phosphorylation 1.64547110 0.47061495 -1.14025303
P97346 Gn25 GO:0055114 oxidation reduction 0.76884067 1.29048338 0.46811407
P23591 P35b GO:0055114 oxidation reduction 0.43253188 1.05443175 0.01492654
P53395 Dbt GO:0055114 oxidation reduction 1.22329897 0.81015515 -0.37909459
B2RUJ7 Xdh GO:0055114 oxidation reduction 1.71158301 0.26963165 -1.41396069
Q8R127 Sccpdh GO:0055114 oxidation reduction 1.08481264 -0.27979159 -1.47533449
Q9DCT1 Akr1cl2 GO:0055114 oxidation reduction 1.30264075 -0.34267097 -1.84425077
P70245 Ebp GO:0008610 lipid biosynthetic process -0.15346256 -0.25635578 -0.08263699
Q8VDL4 Adpgk
GO:0006006 / 
GO:0006091
glucose metabolic process /generation of precursor 
metabolites and energy
0.66329907 1.01163876 -0.12538400
Q05920 Pc GO:0006006 glucose metabolic process 0.99523123 0.38879570 -0.53184421
Q9R0Q7 Ptges3
GO:0006091 / 
GO:0006006
generation of precursor metabolites and energy / 
glucose metabolic process
0.38261192 2.35656641 -0.00494247
Q9WUM5 Suclg1 GO:0006091 generation of precursor metabolites and energy 2.32716997 1.86266959 -0.02047214
Q9CQX2 Cyb5b
GO:0022900 / 
GO:0006091 / 
GO:0055114
electron transport chain / oxidation reduction 
/generation of precursor metabolites and energy
0.66475588 1.55586523 0.57056008
Q3U422 Ndufv3 
GO:0022900 / 
GO:0006091 / 
GO:0055114
electron transport chain / oxidation reduction 
/generation of precursor metabolites and energy
0.83139086 1.05880135 -0.05844292
Q9D6J6 Ndufv2
GO:0022900 / 
GO:0006091 / 
GO:0055114
electron transport chain / oxidation reduction 
/generation of precursor metabolites and energy
1.80496219 1.25174939 -0.28275460
Q9QUH0 Glrx
GO:0022900 / 
GO:0006091 / 
GO:0055115
electron transport chain / oxidation reduction 
/generation of precursor metabolites and energy
1.26897328 0.96450953 -0.33508032
Q8VBT0 Tmx1
GO:0022900 / 
GO:0006091 / 
GO:0055114
electron transport chain / oxidation reduction 
/generation of precursor metabolites and energy
1.41213115 0.27572226 -1.31980169
Q922R5 Pp4r3b 
GO:0045722 / 
GO:0019216 
positive regulation of gluconeogenesis / 
regulation of lipid metabolic process
2.00834346 2.92512594 1.01870538
D3Z041 Acsl1 GO:0008152 metabolic process 1.02353925 0.45995614 -0.60651790
Q9Z0S1 Bpnt1 - - 2.47910119 2.25951354 -0.59998678
Q7TSQ8 Pdpr GO:0006546 glycine catabolic process 2.36086990 2.79333409 0.10339692
P97742 Cpt1 GO:0001676 long-chain fatty acid metabolic process 1.65122394 1.00180224 -0.43561208
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3.2 APS - a method to explore the interactome of C/EBPβ
in an expression independent manner
The cooperation with cofactors is essential to transcription factors in the course of gene
regulation. Following the detection of downstream proteins whose expression is probably
influenced by the transcription factor C/EBPβ, we attempted to expand the functional
network of the transcription factor by elucidating potential cofactors that interacted with
C/EBPβ and could assist the transcription factor during target gene regulation and further
cellular tasks. Our group recently developed the array peptide screening (APS; Pless et al.,
2011) to determine protein interactomes and it was employed here to detect direct protein
interactions of conserved C/EBPβ TAD and RD regions. The APS technique is a high
throughput in-vitro interaction screening that uses libraries of membrane expressed and
fixated proteins that can be hybridized with the desired proteins or peptides. During this
survey APS screenings were performed by incubation of UniPEx protein libraries (imaGenes,
Source Bioscience) with chemically synthesized and C-terminally biotinylated C/EBP protein
fragments/peptides (PSL GmbH and AG Beyermann). A UniPEx protein library encompasses
15,300 E. coli colonies expressing 7,390 full-length human proteins (7,390 human genes as
ORF clones) that are spotted and fixated on two PVDF membranes (UniPEx libraries
#9027/28, imaGenes, Source Bioscience). Positive interactions of the hybridized peptides
with the membrane-expressed proteins were detected with fluorophore-labeled (IRDye, LI-
COR, Lincoln, NE, USA) streptavidin applying a laser based scanning technique (LI-COR
Odyssey CLx, LI-COR, Lincoln, NE, USA) (Figure 7; for further details vide the material
and methods section). The bacterial, clonal expression of human proteins enables due to
the lack of cellular cofactors the discovery of direct protein interactions and overcomes the
limited availability of minor cellular components. The hybridization of peptides containing
conserved peptide sequences facilitates a mapping of interactions to those regions.
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Figure 7: Workflow of the array peptide screening that was modified after Pless et al., 2011 (vide
materials and methods section). Chemically synthesized and biotinylated peptides covering the
conserved regions of C/EBPβ or C/EBPε (1,2) were hybridized to UniPEx protein macroarrays (3).
Excess peptides were removed by washing. Peptides that interacted with the macroarray proteins
were detected with streptavidin coupled fluorescent dyes and subsequent laser scanning (4). The
double-spotting pattern of the macroarray- proteins enables exclusion of false positive interaction
signals. The interacting proteins were identified with the AIDA Image Analyzer Software (Raytest,
Straubenhardt, Germany) and characterized by subsequent bioinformatic analysis (5).
In this study we performed several APS approaches with peptides covering C/EBPβ
CR1-2, C/EBPβ CR3 (partial TAD), C/EBPβ N-terminus of CR7 (partial RD), and a mixture
covering C/EBPβ CR4-5 + CR 6-7 + CR 7 (complete RD; Figure 8; for further details
vide material and methods section). As the entire TAD of C/EBPβ is too long for chemical
synthesis we used a peptide covering the complete TAD of C/EBPε (Figure 8) for an APS
screening. The C/EBPε TAD has shorter low complexity regions but shares the homologous
CR2, 3 and 4 with C/EBPβ and with other C/EBP family members (Figure 1). The usage
of a long C/EBP TAD sequence spanning three consecutive conserved regions aided the
detection of protein interactions that require longer recognition or interaction motifs.
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Figure 8: Array peptide screening (APS) was performed by hybridization of C/EBPβ peptides
covering the conserved regions of C/EBPβ and ε (CR1-7; covering the transactivation domain (TAD)
and regulatory domain (RD), but not the basic zipper domain (bZIP)) to UniPEx-peptide macroarrays.
Peptides of murine C/EBPβ TAD (CR1-2, aa1-41), (CR3, aa49-72), and murine C/EBPβ RD (N-
terminal part of CR7, aa153-173), (mixture of CR4-5, aa79-111; CR 6-7, aa128-172; CR 7 aa152-196),
and murine C/EBPε TAD (CR2-4, aa1-61) were used for APS.
The APS screening revealed 590 proteins that interacted with C/EBPβ and ε probes.
Among them were 64 proteins that have previously been found to interact with C/EBPβ
(Siersbaek et al., 2014; Steinberg et al., 2012; Lee et al., 2010b; Jiang et al., 2008; Ki et al.,
2005; Kowenz-Leutz and Leutz, 1999; Chang et al., 1998; Miau et al., 1998; Xia et al., 1997;
LeClair et al., 1992). 492 proteins interacted with the conserved TAD regions (CR1-2 and
CR3) of C/EBPβ, that are contained in the predominantly transcriptional activating LAP*
and LAP isoforms. 326 proteins were found to interact with the first two conserved regions
(CR1/2) and 171 with the CR3 region of the transactivation domain. The TAD of C/EBPε
that structurally entails CR2, 3 and 4 exhibited only 94 interactors. The low number of
C/EBPε TAD interactions might be a consequence of a more restricted accessibility of the
individual CRs due to the shorter low complexity regions, subtle amino acid differences or
because of specialized functions of C/EBPε. Altogether 492 proteins interacted with the
conserved regions of the C/EBPε TAD and CR1/2, CR3 of the C/EBPβ TAD (Figure 9).
The N-terminal part of the CR7 region (RD) interacted with 192 proteins and the CR4-7
peptide with 38 proteins (Figure 9). Approximately 10 of all identified proteins interacted
with peptides covering both TAD as well as RD of C/EBPs, suggesting multiple binding to
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Figure 9: Data analysis of Array peptide screening that was performed with peptides covering
the conserved regions of C/EBPβ and ε. A) Overlap of interactions found by APS covering the
C/EBP TAD (mC/EBPβ CR1-2 and CR3; mC/EBPε CR2-4) and RD (mC/EBPβ CR4-7mix and
CR 7). B) Selection of GO-terms of all interactors found by all APS approaches for all peptides of
C/EBPβ and ε. Protein-interactions were analyzed with the NIH DAVID tool with GO_BP_FAT,
Benjamini-Hochberg ≤ 5  (DAVID.abcc.ncifcrf.gov).
Subsequently GO:term analysis of the APS detected interactors was performed to aid
initial characterization and prioritization (Figure 9). Therefore the GO-term (GO_BP_FAT)
function of the DAVID online tool (DAVID.abcc.ncifcrf.gov; Huang and Berger, 2008) was
applied with an exclusion rate of Benjamini-Hochberg ≤ 5  (vide material and methods
section). The prime ranking GO:terms of the C/EBPβ interaction network contain the label
“transcriptional regulation”. The second abundant GO:terms suggested an involvement of
C/EBPβ and C/EBPε interactors in RNA metabolism like splicing and RNA processing.
Additionally, GO:terms showed an involvement in cell cycle regulation and myeloid functions
of C/EBPβ interactors (Figure 9).
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3.3 IP-MS analysis of endogenous C/EBPβ in leukemia cell
lines
The advantage of the APS technique is the detection of direct protein interactions due to
the lack of cellular environment. The bacterial protein expression of the APS technique is
independent of cell type specific protein expression levels and facilitates the simultaneous
analysis of multiple protein-protein interactions. To examine the interactions identified
by APS in a leukemia specific context, immunoprecipitations against endogenous C/EBPβ
followed by shotgun mass spectrometry (IP-MS) measurements (Günther Kahlert, MDC)
were performed using the leukemia cell lines SU-DHL-1 (Anaplastic large cell lymphoma,
ALCL), U937 (Histiocytic lymphoma/non-Hodgekin lymphoma, HL/NHL), HL60 (Acute
premyelocytic leukemia, AML), JEKO-1 (Mantle cell lymphoma, MCL), OPM2 (Multiple
myeloma, MM).The occurrence of the interactions in the analyzed cell lines is itemized in
detail in Table S1.
The leukemia cell line SU-DHL-1 was chosen due to the before discussed association of
C/EBPβ with growth and tumorigenicity of anaplastic large cell lymphomas (ALCL) and the
ALCL cell line SU-DHL-1 (Jundt et al., 2005; Quintanilla-Martinez et al., 2006; Piva et al.,
2006; 2010; Anastasov et al., 2010). The myeloid U937 and the premyelocytic HL60 cell line
were selected because of the before described function of C/EBPβ in phorbol ester induced
differentiation of U937 cells and in 1,25- dihydroxyvitamin D3 (1,25D) induced differentiation
of HL60 cells (Marcinkowska et al., 2006; Ji and Studzinski, 2004; Ji et al., 2002; Chen et al.,
1996). As C/EBPβ was shown to regulate the expression of transcription factors associated
with proliferation and survival in multiple myeloma (Pal et al., 2009) we analyzed the OPM2
cell line (MM) as well.
Prior to anti-C/EBPβ immunoprecipitations whole cell lysates of U937, JEKO-1, HL60
and SU-DHL-1 cell lines were prepared by ultrasonic induced cell-lysis in a detergent-free
buffer. Nuclear enriched cell lysates of OPM2 and SU-DHL-1 cells were prepared by lysis of
the outer cell membrane in a low salt buffer followed by a lysis of the crude nuclei fraction
in high salt buffer aided by ultrasonic irradiation (as described before by Schreiber et al.,
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1989 and in material and methods). Immunoprecipitations of endogenous C/EBPβ (with
an anti-C/EBPβ antibody) from whole cell lysates of U937, JEKO-1, HL60 and SU-DHL-1
and from nuclear enriched lysates of OPM2 and SU-DHL-1 cells were prepared as triplicates
and were analyzed by shotgun mass spectrometry (Günther Kahlert, MDC) using a label
free quantification approach (Hubner and Mann, 2011). The IP-MS analysis of U937 whole
cell lysates revealed 132 significant interactions with endogenous C/EBPβ (p-value ≤ 2) as
depicted in the volcano plot in Figure 10.
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Figure 10: Volcano plot of an anti-C/EBPβ IP-MS label-free shotgun approach from U937 whole
cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP samples
(triplicates) versus bead control (triplicates). Proteins detected either three times in the anti-C/EBPβ
or three times in bead control IP probes were considered as valid and were used for the analysis.
Missing values were imputated. The y-axis depicts the p-value of the t-test in a negative Log scale.
Protein-protein interactions with C/EBPβ with a t-test p-value of ≤ 2  were considered as significant
and are depicted in yellow. The protein-protein interactions with C/EBPβ with a t-test p-value of
≤ 1  are depicted in red. Proteins with a t-test p-value of ≥ 2  or bead control false positives are
considered as insignificant and are depicted in blue (Günther Kahlert, MDC Berlin). A) Volcano plot
of C/EBPβ interactions detected from U937 whole cell lysates. The significant protein interactions in
the upper right corner are depicted in further detail in B. B) Volcano plot only showing the significant
protein interactions of C/EBPβ. Detected proteins are colored due to their significance level and
named due to the human IPI database (Günther Kahlert, MDC Berlin).
The IP-MS analysis of JEKO-1 whole cell lysates revealed 130 significant interactions
with endogenous C/EBPβ (p-value ≤ 2) as depicted in the volcano plot in Figure 11.
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Figure 11: Volcano plot of an anti-C/EBPβ IP-MS label-free shotgun approach from JEKO-1 whole
cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP samples
(triplicates) versus bead control (triplicates). Proteins detected either three times in the anti-C/EBPβ
or three times in bead control IP probes were considered as valid and were used for the analysis.
Missing values were imputated. The y-axis depicts the p-value of the t-test in a negative Log scale.
Protein-protein interactions with C/EBPβ with a t-test p-value of ≤ 2  were considered as significant
and are depicted in yellow. The protein-protein interactions with C/EBPβ with a t-test p-value of
≤ 1  are depicted in red. Proteins with a t-test p-value of ≥ 2  or bead control false positives are
considered as insignificant and are depicted in blue (Günther Kahlert, MDC Berlin). A) Volcano plot
of C/EBPβ interactions detected from JEKO-1 whole cell lysates. The significant protein interactions
in the upper right corner are depicted in further detail in B. B) Volcano plot only showing the
significant protein interactions of C/EBPβ. Detected proteins are colored due to their significance
level and named due to the human IPI database (Günther Kahlert, MDC Berlin).
The IP-MS analysis of HL60 whole cell lysates revealed 88 significant interactions with
endogenous C/EBPβ (p-value≤ 2) as depicted in the volcano plot in Figure 12.
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Figure 12: Volcano plot of an anti-C/EBPβ IP-MS label-free shotgun approach from HL60 whole
cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP samples
(triplicates) versus bead control (triplicates). Proteins detected either three times in the anti-C/EBPβ
or three times in bead control IP probes were considered as valid and were used for the analysis.
Missing values were imputated. The y-axis depicts the p-value of the t-test in a negative Log scale.
Protein-protein interactions with C/EBPβ with a t-test p-value of ≤ 2  were considered as significant
and are depicted in yellow. The protein-protein interactions with C/EBPβ with a t-test p-value of
≤ 1  are depicted in red. Proteins with a t-test p-value of ≥ 2  or bead control false positives are
considered as insignificant and are depicted in blue (Günther Kahlert, MDC Berlin). A) Volcano plot
of C/EBPβ interactions detected from HL60 whole cell lysates. The significant protein interactions in
the upper right corner are depicted in further detail in B. B) Volcano plot only showing the significant
protein interactions of C/EBPβ. Detected proteins are colored due to their significance level and
named due to the human IPI database (Günther Kahlert, MDC Berlin).
The IP-MS analysis of SU-DHL-1 whole cell lysates revealed 217 significant interactions
with endogenous C/EBPβ (p-value≤ 2) as depicted in the volcano plot in Figure 13.
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Figure 13: Volcano plot of an anti-C/EBPβ IP-MS label-free shotgun approach from SU-DHL-1
whole cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP
samples (triplicates) versus bead control (triplicates). Proteins detected either three times in the
anti-C/EBPβ or three times in bead control IP probes were considered as valid and were used for the
analysis. Missing values were imputated. The y-axis depicts the p-value of the t-test in a negative
Log scale. Protein-protein interactions with C/EBPβ with a t-test p-value of ≤ 2  were considered as
significant and are depicted in yellow. The protein-protein interactions with C/EBPβ with a t-test
p-value of ≤ 1  are depicted in red. Proteins with a t-test p-value of ≥ 2  or bead control false
positives are considered as insignificant and are depicted in blue (Günther Kahlert, MDC Berlin). A)
Volcano plot of C/EBPβ interactions detected from SU-DHL-1 whole cell lysates. The significant
protein interactions in the upper right corner are depicted in further detail in B. B) Volcano plot only
showing the significant protein interactions of C/EBPβ. Detected proteins are colored due to their
significance level and named due to the human IPI database (Günther Kahlert, MDC Berlin).
The IP-MS analysis of SU-DHL-1 nuclear enriched cell lysates revealed 163 significant
interactions with endogenous C/EBPβ (FDR≤ 5) as depicted in the volcano plot in Figure
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Figure 14: Volcano plot of anti-C/EBPβ IP-MS label-free shotgun approach from SU-DHL-1 nuclear
enriched cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP
samples (triplicates) versus bead control (triplicates). Proteins that were detected at least twice in
either the anti-C/EBPβ IP triplicate or the bead control triplicate were chosen for the t-test. Missing
values were imputated. The y-axis depicts the FDR in a negative Log scale. Interactions with a FDR
level of ≤ 5  were considered as significant and are depicted in red. Proteins with a FDR ≥ 5 are
not considered as significant and are depicted in grey (Günther Kahlert, MDC Berlin). Detected
proteins are colored due to their significance level and named due to the human IPI database (Günther
Kahlert, MDC Berlin). The significant protein interactions with C/EBPβ are depicted and described
in further detail in Figure 17.
The IP-MS analysis of OPM2 nuclear enriched cell lysates revealed 33 significant
interactions with endogenous C/EBPβ (FDR≤ 5) as depicted in the volcano plot in Figure
15.
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Figure 15: Volcano plot of anti-C/EBPβ IP-MS label-free shotgun approach from OPM2 nuclear
enriched cell lysates. The x-axis shows the t-test difference of the interactions of the anti-C/EBPβ IP
samples (triplicates) versus bead control (triplicates). Proteins that were detected at least twice in
either the anti-C/EBPβ IP triplicate or the bead control triplicate were chosen for the t-test. Missing
values were imputated. The y-axis depicts the FDR in a negative Log scale. Interactions with a FDR
level of ≤ 5  were considered as significant and are depicted in red. Proteins with a FDR ≥ 5 are
not considered as significant and are depicted in grey (Günther Kahlert, MDC Berlin). Detected
proteins are colored due to their significance level and named due to the human IPI database (Günther
Kahlert, MDC Berlin).
The IP-MS analysis revealed a significant overlap between the of C/EBPβ protein
interaction partners in the different leukemia cell lines (Table 4). IP-MS revealed 25 interac-
tions as overlapping between the SU-DHL-1 whole cell extract and the nuclear enriched (NE)
SU-DHL-1 cell lysates and from here on the data of both IPs from SU-DHL-1 cells (whole
cell lysate and nuclear enrichment) are summarized together under the name of “IP-MS from
SU-DHL-1”.
As itemized in Table 4 and Figure 16 IP-MS revealed 37 proteins that interacted with
C/EBPβ in both lymphocytic derived leukemia cell lines SU-DHL-1 (ALCL) and JEKO-1
(MCL). Despite the differences between the lymphocytic derived leukemia cell line SU-DHL-1
and the histiocytic cell line U937 IP-MS detected 23 proteins that interacted with C/EBPβ
in both cell lines (Figure 16 and Table 4). Interestingly, only 12 proteins interactions overlap
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between the IP-MS data of JEKO-1 and U937 cells and 17 overlap between IP-MS data of
SU-DHL-1 and HL60 (Figure 16 and Table 4).
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Figure 16: Venn diagrams visualizing the number of overlapping proteins detected as endogenous
C/EBPβ interaction partners among the IP-MS experiments from the selected leukemia cell lines. The
interaction data is itemized in detail in Table 4 and Table S1.
Subsequently the IP-MS data of endogenous C/EBPβ interactions in the leukemia cell
lines was integrated with the direct protein interactions detected by APS binding to of the
conserved regions of C/EBPβ. As itemized in Table S1 and for IP-MS of nuclear enriched
lysates of SU-DHL-1 cells in Figure 17 the endogenous C/EBPβ immunoprecipitations revealed
a wealth of significant interactions compromising 86 published protein-interactors (Siersbaek
et al., 2014; Steinberg et al., 2012; Lee et al., 2010b; Jiang et al., 2008; Ki et al., 2005;
Kowenz-Leutz and Leutz, 1999; Chang et al., 1998; Miau et al., 1998; Xia et al., 1997; LeClair
et al., 1992) and verified 44 protein interactions detected by APS. Especially the endogenous
IP of nuclear enriched SU-DHL-1 lysates verified a significant number of previously reported
and/or APS detected interactions as depicted in Figure 17.
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Table 4: The table on the following pages (60-61) itemizes the protein-interactions of C/EBPβ that
were detected in at least two of the analyzed leukemia cell lines by IP-MS. Immunoprecipitations
of endogenous C/EBPβ (with an anti-C/EBPβ antibody) from whole cell lysates of U937, JEKO-1,
HL60 and SU-DHL-1 and from nuclear enriched lysates of OPM2 and SU-DHL-1 cells (column 6-11)
were prepared as triplicates and were analyzed by shotgun mass spectrometry using a label-free
quantification approach (Hubner and Mann, 2011). Column 2 lists the log10 of iBAQ intensity of
the MS-iBAQ quantification of the SU-DHL-1 cell line (MS-analysis by Günther Kahlert, MDC; vide
material and methods section).
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UniProt 
AC
iBAQ 
[log10 of 
iBAQ 
intensity] Name
HL60 
[whole 
cell 
lysate]
JEKO-1 
[whole 
cell 
lysate]
OPM2 
[nuclear 
enriched 
lysate]
U937 
[whole 
cell 
lysate]
SU-DHL-1 
[ whole 
cell lysate]
SU-DHL-1 
[nuclear 
enriched 
lysate]
P17676 7.5900 CEBPB TCF5 - Co-IP Co-IP Co-IP Co-IP Co-IP Co-IP
Q9H0C8 7.1884 ILKAP - - Co-IP Co-IP Co-IP Co-IP Co-IP Co-IP
Q9H6Z4 7.3333 RANB3 RANBP3 - Co-IP Co-IP Co-IP Co-IP Co-IP 0
O14980 8.0217 XPO1 CRM1 - 0 Co-IP Co-IP Co-IP Co-IP Co-IP
P13010 8.6857 XRCC5 G22P2 - 0 Co-IP Co-IP 0 Co-IP Co-IP
O43823 6.9873 AKAP8 AKAP95 - 0 Co-IP Co-IP 0 0 Co-IP
P0C0L5 - CO4B - - 0 Co-IP Co-IP 0 0 Co-IP
Q7LBC6 6.6277 KDM3B JMJD1B - 0 Co-IP Co-IP 0 0 Co-IP
Q92733 6.8760 PRCC TPRC - 0 0 Co-IP 0 Co-IP Co-IP
P26641 8.6992 EF1G EEF1G - Co-IP Co-IP 0 0 Co-IP Co-IP
E9PRY8 8.1325 E9PRY8 EEF1D - 0 Co-IP 0 0 Co-IP Co-IP
P12956 8.8269 XRCC6 G22P1 - 0 Co-IP 0 0 Co-IP Co-IP
P78527 8.0827 PRKDC HYRC - 0 Co-IP 0 0 Co-IP Co-IP
P26640 - SYVC VARS G7A 0 Co-IP 0 0 Co-IP Co-IP
P46060 7.5258 RAGP1 RANGAP1 KIAA1835 0 0 Co-IP 0 Co-IP 0
Q12905 8.6838 ILF2 NF45 - 0 0 Co-IP 0 Co-IP 0
Q9NYL4 7.8137 FKB11 FKBP11 FKBP19 0 0 Co-IP 0 Co-IP 0
P80303 7.4130 NUCB2 NEFA - Co-IP Co-IP 0 0 Co-IP 0
Q9BUL8 7.5315 PDC10 PDCD10 CCM3 Co-IP Co-IP 0 0 Co-IP 0
Q9NSP4 - CENPM C22orf18 - Co-IP Co-IP 0 0 Co-IP 0
Q9H9Q4 5.9103 NHEJ1 XLF - 0 Co-IP 0 Co-IP Co-IP 0
B7Z5E3 - B7Z5E3 - - 0 Co-IP 0 0 Co-IP 0
D3DUS9 - D3DUS9 DNM1L - 0 Co-IP 0 0 Co-IP 0
O60711 6.7463 LPXN LDLP - 0 Co-IP 0 0 Co-IP 0
O95684 7.1031 FR1OP FOP - 0 Co-IP 0 0 Co-IP 0
P04406 9.5663 G3P GAPDH GAPD 0 Co-IP 0 0 Co-IP 0
P07737 9.1337 PROF1 PFN1 - 0 Co-IP 0 0 Co-IP 0
P24534 8.2158 EF1B EEF1B2 EEF1B 0 Co-IP 0 0 Co-IP 0
P41250 8.3967 SYG GARS - 0 Co-IP 0 0 Co-IP 0
P49720 8.5113 PSB3 PSMB3 - 0 Co-IP 0 0 Co-IP 0
P62306 8.7701 RUXF SNRPF PBSCF 0 Co-IP 0 0 Co-IP 0
P62937 9.3061 PPIA CYPA - 0 Co-IP 0 0 Co-IP 0
Q86UY3 - Q86UY3 - - 0 Co-IP 0 0 Co-IP 0
Q96JB2 6.1842 COG3 SEC34 - 0 Co-IP 0 0 Co-IP 0
Q9UBT2 7.9537 SAE2 UBA2 - 0 Co-IP 0 0 Co-IP 0
Q9UQ13 5.8638 SHOC2 KIAA0862 - 0 Co-IP 0 0 Co-IP 0
P62244 8.9113 RS15A RPS15A - Co-IP 0 0 Co-IP Co-IP 0
Q9H8S9 7.4340 MOB1A C2orf6 - Co-IP 0 0 Co-IP Co-IP 0
P11172 7.5503 UMPS - - Co-IP 0 0 0 Co-IP 0
P19474 - RO52 TRIM21 RNF81 Co-IP 0 0 0 Co-IP 0
P55060 8.2769 XPO2 CSE1L CAS Co-IP 0 0 0 Co-IP 0
Q8TCG1 6.5320 CIP2A KIAA1524 - Co-IP 0 0 0 Co-IP 0
Q99623 8.6230 PHB2 BAP - Co-IP 0 0 0 Co-IP 0
Q9Y4R8 6.3775 TELO2 KIAA0683 - Co-IP 0 0 0 Co-IP 0
O43156 6.9478 TTI1 - - 0 0 0 Co-IP Co-IP 0
P19338 8.8166 NUCL NCL - 0 0 Co-IP 0 0 Co-IP
P42166 7.9299 LAP2A TMPO LAP2 0 0 Co-IP 0 0 Co-IP
P49792 6.8798 RBP2 RANBP2 NUP358 0 0 Co-IP 0 0 Co-IP
Q9UKX7 7.0178 NUP50 NPAP60L - 0 0 Co-IP 0 0 Co-IP
P52272 8.5349 HNRPM HNRNPM - 0 0 Co-IP 0 0 Co-IP
P04843 8.3652 RPN1 - - 0 0 Co-IP 0 0 Co-IP
O00299 8.8855 CLIC1 - G6 0 Co-IP 0 0 0 Co-IP
P12268 8.6713 IMDH2 IMPDH2 IMPD2 0 Co-IP 0 0 0 Co-IP
P22102 8.1383 PUR2 GART PGFT 0 Co-IP 0 0 0 Co-IP
P62195 8.1190 PRS8 PSMC5 SUG1 0 Co-IP 0 0 0 Co-IP
Q13200 8.0567 PSMD2 TRAP2 - 0 Co-IP 0 0 0 Co-IP
O95347 7.5986 SMC2 CAPE - Co-IP 0 0 0 0 Co-IP
Q9UJZ1 8.3277 STML2 STOML2 SLP2 Co-IP 0 0 0 0 Co-IP
Synonyms
SU-DHL-1
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UniProt 
AC Name
HL60 
[whole 
cell 
lysate]
JEKO-1 
[whole 
cell 
lysate]
OPM2 
[nuclear 
enriched 
lysate]
U937 
[whole 
cell 
lysate]
SU-DHL-1 
[ whole 
cell lysate]
SU-DHL-1 
[nuclear 
enriched 
lysate]Synonyms
P62805 10.1851 H4 HIST1H4A H4/A Co-IP 0 Co-IP 0 0 0
B8ZZN6 7.8841 B8ZZN6 SUMO1 - Co-IP Co-IP 0 0 0 0
Q96N11 5.6972 CG026 C7orf26 - Co-IP Co-IP 0 0 0 0
A6NHB5 5.0052 A6NHB5 - - 0 Co-IP 0 Co-IP 0 0
B5M451 - B5M451 - - 0 Co-IP 0 Co-IP 0 0
D3DPG0 - D3DPG0 - - 0 Co-IP 0 Co-IP 0 0
P42694 - HELZ - - 0 Co-IP 0 Co-IP 0 0
P53990 6.7855 IST1 - - 0 Co-IP 0 Co-IP 0 0
Q5JTZ9 5.7636 SYAM - - 0 Co-IP 0 Co-IP 0 0
Q7Z351 - Q7Z351 - - 0 Co-IP 0 Co-IP 0 0
B4DLZ8 - B4DLZ8 - - Co-IP 0 0 Co-IP 0 0
Q8N392 - RHG18 - - Co-IP 0 0 Co-IP 0 0
Q96AX1 5.0024 VP33A VPS33A - Co-IP 0 0 Co-IP 0 0
Q9UK61 5.9612 F208A FAM208A C3orf63 Co-IP 0 0 Co-IP 0 0
P33121 - ACSL1 FACL1 - 0 0 0 Co-IP Co-IP 0
P46459 7.3631 NSF - - 0 0 0 Co-IP Co-IP 0
P55160 6.3735 NCKPL NCKAP1L HEM1 0 0 0 Co-IP Co-IP 0
Q13724 7.4045 MOGS GCS1 - 0 0 0 Co-IP Co-IP 0
Q5VYK3 - ECM29 KIAA0368 - 0 0 0 Co-IP Co-IP 0
Q96ER3 6.9216 SAAL1 - - 0 0 0 Co-IP Co-IP 0
Q96QU8 - XPO6 KIAA0370 - 0 0 0 Co-IP Co-IP 0
Q9BVI4 7.0331 NOC4L - - 0 0 0 Co-IP Co-IP 0
Q9BXW9 6.4636 FACD2 FANCD2 FACD 0 0 0 Co-IP Co-IP 0
Q9BZZ5 7.7939 API5 MIG8 - 0 0 0 Co-IP Co-IP 0
Q9NV70 6.4473 EXOC1 SEC3 - 0 0 0 Co-IP Co-IP 0
Q9UBB9 5.9354 TFP11 TFIP11 STIP 0 0 0 Co-IP Co-IP 0
Q9Y6E2 7.6163 BZW2 HSPC028 - 0 0 0 Co-IP Co-IP 0
P11388 7.8618 TOP2A TOP2 - 0 0 0 Co-IP 0 Co-IP
P35659 8.1838 DEK - - 0 0 0 Co-IP 0 Co-IP
O43175 8.2946 SERA PHGDH PGDH3 0 0 0 0 Co-IP Co-IP
P27708 7.8531 PYR1 CAD - 0 0 0 0 Co-IP Co-IP
P30153 8.0529 2AAA PPP2R1A - 0 0 0 0 Co-IP Co-IP
P32189 7.9368 GLPK GK - 0 0 0 0 Co-IP Co-IP
P35232 8.8204 PHB - - 0 0 0 0 Co-IP Co-IP
P40763 7.9850 STAT3 APRF - 0 0 0 0 Co-IP Co-IP
P42285 7.3458 SK2L2 SKIV2L2 KIAA0052 0 0 0 0 Co-IP Co-IP
P42704 8.1207 LPPRC LRPPRC LRP130 0 0 0 0 Co-IP Co-IP
P50991 8.5139 TCPD CCT4 CCTD 0 0 0 0 Co-IP Co-IP
Q00610 8.2996 CLH1 CLTC CLH17 0 0 0 0 Co-IP Co-IP
Q9Y5B9 7.9425 SP16H SUPT16H FACT140 0 0 0 0 Co-IP Co-IP
Q08211 8.4041 DHX9 DDX9 - 0 0 0 0 Co-IP Co-IP
P13639 8.8879 EF2 EEF2 - 0 0 0 0 Co-IP Co-IP
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Figure 17: C/EBPβ Co-Immunoprecipitation from nuclear enriched SU-DHL-1 cell lysates revealing
multiple C/EBPβ interactors that were described before and/or detected by APS. Endogenous im-
munoprecipitations from nuclear enriched lysates of SU-DHL-1 cell line with an anti-C/EBPβ antibody
were analyzed by shotgun mass spectrometry (triplicates were used for label-free quantification,
missing values were imputated (vide Figure 14), significance level: FDR≤ 5 ). The x-axis shows the
t-test difference of the interactions of the anti-C/EBPβ IP samples (triplicates) versus bead control
(triplicates) and the y-axis presents the FDR in negative Log scale. C/EBPβ interactions with a FDR
≤ 5  are depicted as red dots. Previously published C/EBPβ interactions are depicted as green dots,
interactions found by APS as well as IP-MS are labeled by their protein name and depicted as yellow
dots, background binding proteins and contaminants binding to the bead control are depicted as grey
dots.
Extended bioinformatic analysis of the integrated APS and IP-MS data was carried out
to elucidate the range of functions that C/EBPβ protein interaction network is involved in.
The DAVID online tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009) was used to determine
the GO:terms and the functional domains with an exclusion threshold of Benjamini-Hochberg
≤ 5 . The Cytoscape software including the BisoGenet plugin (Martin et al., 2010; Shannon
et al., 2003), the CORUM database (Ruepp et al., 2008; 2010), the HIPPIE database (Schaefer
et al., 2011) and the STRING database (Jensen et al., 2009) were employed simultaneously
to unravel the functional complexes and networks C/EBPβ interacts with. The bioinformatic
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data analysis revealed a large variety of functional categories and numerous possible complexes
in which the acquired C/EBPβ interactors could be grouped, such as chromatin remodeling
and histone modifying complexes, as well as transcription factors and spliceosome components.
3.4 Proteomic analysis of leukemia cell lines
Despite the detection of a particular number of overlapping interactions the two detection
methods revealed numerous interactions of C/EBPβ that were only detected with either the
APS or the IP-MS technique. One reason could be the substantial difference in C/EBPβ protein
quantities itself of either the full-length C/EBPβ in the IP-MS or C/EBPβ peptides available
for interaction in APS. A cell specific minor expression pattern of C/EBPβ interaction partners
detected by APS but not by IP-MS could be another possible explanation for the difference
between the APS and IP-MS uncovered C/EBPβ interactors. In order to examine this theory
mass spectrometry proteomics and the Intensity-Based Absolute Quantification Index (iBAQ)
(Geiger et al., 2012; Schwanhäusser et al., 2011) were used for precise quantification of the
SU-DHL-1 proteome, representative for all used leukemia cell lines (in cooperation with
Günther Kahlert, MDC). Additionally, total C/EBPβ protein abundance was determined by
MS-SRM proteomics of U937 and SU-DHL-1 cell lysates. The MS-proteomic analysis revealed
that 85 of the IP-MS detected interacting proteins in SU-DHL-1 cells were also detected in
the SU-DHL-1 proteome by MS-iBAQ, whereas only ≈ 20.5 of all APS detected C/EBPβ
interaction partners were identified within the 4533 most abundant SU-DHL-1 proteins
(Figure 18). The remaining APS-derived C/EBPβ interaction partners (≈ 79, 5) were neither
detected in the SU-DHL-1 proteome nor identified as significant C/EBPβ interactors in the
SU-DHL-1 immunoprecipitations (Figure 18), suggesting absence or low expression in the
leukemia cell line, such as ZC3H3, MLL2, MEN1, NCOR2, KDM6B, L3MBT and p21/WAF1.
Thus, these interacting proteins were probably detected by APS due to the bulk amounts of
human proteins presented on the bacterially expressed APS macroarrays, although binding
in cells awaits further validation. The data suggest that the combinatory use of expression
independent in-vitro APS and endogenous IP-MS provides a powerful complementary tool to
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determine a broad overview of a protein interactome.
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Figure 18: The heatmap depicts all C/EBPβ interactions detected by all APS experiments, by IP-MS
from U937 and SU-DHL-1 (whole cell and nuclear enriched lysates) cells and the iBAQ quantification
of the SU-DHL-1 proteome. The proteomic expression levels in SU-DHL-1 cells of the depicted proteins
(first column from right) are presented as iBAQ intensity (grey = not detected, yellow = low, orange
= medium, red = high). The positive detection of interactions in the anti C/EBPβ IP-MS approaches
from U937 or SU-DHL-1 cells is marked in magenta (second and third column from right). Positive
detection of interaction in APS (first 5 columns on the left) is marked in green. Proteins, which were
not detected with one of the techniques, are marked in grey.
The number of C/EBPβ interactions detected in SU-DHL-1 cell lysates was larger
than those detected in U937, HL60, JEKO-1 and OPM2 cells. To determine the reason
of this difference the relative C/EBPβ protein abundance in SU-DHL-1 and U937 whole
cell lysates was analyzed by MS-SRM proteomics (in cooperation Günther Kahlert, MDC).
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SRM proteomics revealed an 18 times higher expression of C/EBPβ in the SU-DHL-1 cells
compared to U937 cells (Figure 19). The results suggest that the most likely cause for the
observed difference in interactions is the significantly higher expression of C/EBPβ in the
SU-DHL-1 compared to the U937 cell line. The minor abundance of C/EBPβ protein IP-bait
in U937 most probably leads to a shift of substantive C/EBPβ-protein interactions beneath
the detection limit of mass spectrometry. The same shift in C/EBPβ abundance could also
account for the reduced number of protein-protein interactions detected in the other analyzed
leukemia cell lines, but needs further experimental validation.
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Figure 19: Abundance of C/EBPβ protein in the tested lysates of U937 and SU-DHL-1 cells
determined by Selected Reaction Monitoring (SRM; Günther Kahlert, MDC). The x-axis depicts the
analyzed cell lines and the y-axis shows the C/EBPβ intensity normalized to Actin B. The barplot
shows an 18 times higher amount of C/EBPβ protein in SU-DHL-1 cell lysates (red) compared to
U937 cell lysates (yellow).
3.5 Integration of APS and MS-data reveals a wealth of novel
interaction partners of C/EBPβ
The C/EBPβ interaction data derived from APS and IP-MS approaches as well as the
iBAQ proteomics data was integrated and subjected to bioinformatic analysis (vide material
and methods section). The data integration of the direct and/or endogenous interactions of
C/EBPβ enabled the interpretation and evaluation of the detected protein-protein interactions
in a broader functional context and thereby the elucidation of potential novel roles and
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functions of the transcription factor C/EBPβ.
3.6 C/EBPβ interacts with proteins associated with metabolism
GO-term analysis of the protein interactions of C/EBPβ/ε revealed by APS and/or IP-MS
was performed with the DAVID online tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009). The
GO analysis characterized numerous interactors as members of the glucose, the lipid or the nu-
cleotide metabolism pathways. These results are in concordance with the proteomics results of
C/EBPβ infected C/EBPβ-/- MEF cells. C/EBPβ infection of C/EBPβ-/- MEF cells induced
differential expressions of proteins that could be grouped into the GO:terms GO:0055114
“oxidation-reduction process” and GO:0006091 “generation of precursor metabolites and
energy”. Several C/EBPβ/ε interactors from IP-MS and APS analysis are characterized by the
GO-term GO:0055114 as well (Figure 20). The interacting proteins classified by this GO:term
are ACADV (acyl-CoA-dehydrogenase), NDUA6 (NADH dehydrogenase (ubiquinone) 1 α
subcomplex subunit 6), NB5R3 (NADH cytochrome b5 reductase 3), CYC (Cytochrome C),
NNTM (nicotinamide nucleotide transhydrogenase) and QCR2 (Cytochrome b-c1 complex
subunit 2; part of the mitochondrial respiratory chain). Some of the interacting proteins could
additionally be grouped into the term GO:0006091 “generation of precursor metabolites and
energy”. C/EBPβ has been associated with glucose metabolism before (Arizmendi et al., 1999;
Liu et al., 1999). In accordance with this, interactors from APS and/or IP-MS approaches
could be characterized by the GO-term GO:0006006 “glucose metabolic process”. These
GO:term members are ATF3, ATF4, the Serine/threonine-protein phosphatase PP1-α (PP1A)
and the glycerol-3-phophate dehydrogenase (GPDA). GO:0006006 encompasses members of
the pentose phosphate pathway as well, namely the ribose 5-phosphate isomerase A (RPIA),
the phosphogluconate dehydrogenase (6PGD) and the glucose-6-phosphate-dehydrogenase
(G6PD), which interact with C/EBPβ (Figure 20). Additionally, GO:0006006 characterizes
the C/EBPβ interactors glycolysis/gluconeogenesis proteins ADHX (Alcohol-dehydrogenase
class 3), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase (PKM) and
enolase1 (ENOA) (Figure 20).
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Figure 20: Selected interactions of C/EBPβ/ε that could be grouped into metabolism associated
GO-terms like GO:0055114 “oxidation-reduction process”, GO:0006006 “glucose metabolic process”,
GO:0044242 “cellular lipid catabolic process” and GO:0009165 “nucleotide biosynthetic process” using
the DAVID online tool (DAVID.abcc.ncifcrf.gov; Huang et al., 2009). Direct interactions detected
by APS with peptides of the conserved regions of C/EBPβ/ε are depicted as green squares in the
heatmap. The legend below the heatmap illustrates the amino acid coverage of APS peptides of the
C/EBPβ/ε protein. Interactions detected by IP-MS (anti-C/EBPβ) from cell lysates of at least one of
the cell lines SU-DHL-1 (whole cell and/or nuclear enriched), U937, JEKO-1, OPM2 and HL60 are
depicted in blue. Grey squares indicate not detected interaction.
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Additionally, C/EBPβ/ε interactors from IP-MS and APS analysis could be grouped
into the GO-term GO:0044242 “cellular lipid catabolic process” like the lipoprotein lipase
(LIPL), the acyl-CoA-dehydrogenase (ACADV), the enoyl-CoA hydratase (ECHM) and the
3-hydroxyacyl-CoA-dehydrohgenase (ECHA) (Figure 20). Five interactors of C/EBPβ that
were revealed by IP-MS could be characterized by GO:0009165 “nucleotide biosynthetic
process”. These interactors are the purine metabolism associated PUR9, PUR2 and the
inosine-5’-monophosphate dehydrogenase 2 (IMDH2), as well as the pyrimidine metabolism
associated PYR1/CAD and the uridine 5’-monophosphate synthase (UMPS). In summary,
this data emphasizes the involvement of C/EBPβ in metabolism in concert with previous
studies (Arizmendi et al., 1999; Liu et al., 1999).
3.7 C/EBPβ interacts with proteins that regulate and partic-
ipate in the gene transcription machinery
C/EBPβ locates at the CCAAT-box sequence of its target gene promoters to initiate gene
transcription (Osada et al., 1996; Mahony et al., 2007, Nerlov et al., 1995). The here discussed
APS and IP-MS screening data encompasses yet unknown interactions with components of
the RNA-polymerase-II and III complexes. The screenings revealed a direct interaction of the
C/EBPβ TAD region with ERCC3 and the general transcription factor GTF2F1 (APS) as well
as GTF2B, GTF2H1 and GTF2H4 as endogenous interactions in the leukemic cell lines (IP-
MS) (Figure 21). The IP-MS approaches confirmed the known C/EBPβ interactor GTF3C1
(Steinberg et al., 2012) and unraveled unknown interactions with the RNA-Polymerase III
(RNA-POLIII) complex subunit POLR3C and POLR3E. The APS method detected GTF3A,
a further component of this complex. In concert with this the expression of all interacting
RNA-polymerase II and III complex proteins were detected in SU-DHL-1 cells by iBAQ,
except for GTF3 and TFIIS. Our laboratory revealed the interaction of the Mediator complex
component MED23 with the transactivation as well as the regulatory domain of C/EBPβ
recently (Kowenz-Leutz et al., 2010, Mo et al., 2004). The current APS approach identified
the Mediator complex member MED16 as direct interactor of the C/EBPβ TAD and MED15
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of the C/EBPβ RD. On top of that, IP-MS disclosed novel interactions of endogenous C/EBPβ
with the mediator complex components CDK19, MED30 and MED19 in U937 and MED16
in SU-DHL-1 (Figure 21).
3.8 C/EBPβ interacts with proteins regulating chromatin
structure and organization
The SWI/SNF complex component SNF5/SMARCB1/BAF47 was shown by our lab to
interact with the CR1/2 of C/EBPβ in a PTM dependent manner (Kowenz-Leutz et al.,
2010). This observation could be confirmed here by APS, which revealed interaction of
SNF5 with the C/EBPβ TAD peptides covering CR1-2 and CR3. Additionally, APS detected
interaction of the C/EBPβ TAD with BC11A and BC11B that were recently identified as
novel components of the SWI/SNF complex (Kadoch et al., 2013).
The IP-MS screenings identified interaction of C/EBPβ with the SWI/SNF component
MECP2. Interestingly, IP-MS also verified the recent reported interaction with the SWI/SNF
complex members BAF250 and BAF180/PB1 in U937 and SMC1A, SNF2H, BAF155 and
BRG1 in SU-DHL-1 (NE) (Steinberg et al., 2012; Figure 21). The expression of SMC1A,
SNF2H, BAF155 and BRG1 in SU-DHL-1 cells was verified by MS-iBAQ proteomics. Taken
together these results indicate the cooperation of C/EBPβ with the SWI/SNF complex in
leukemia cell lines and emphasizes the interaction of the SWI/SNF complex with the TAD
region of C/EBPβ, as suggested before (Kowenz-Leutz et al., 2010).
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Figure 21: Selected interactions of C/EBPβ/ε that could be grouped into functional
groups or published functional complexes using the CORUM database (http://mips.helmholtz-
muenchen.de/genre/proj/corum; Ruepp et al., 2008; 2010). Direct interactions detected by APS with
peptides of the conserved regions of C/EBPβ/ε are depicted as green squares in the heatmap. The
legend below the heatmap illustrates the amino acid coverage of APS peptides of the C/EBPβ/ε
protein. Interactions detected by IP-MS (anti-C/EBPβ) from cell lysates of at least one of the cell
lines SU-DHL-1 (whole cell and/or nuclear enriched), U937, JEKO-1, OPM2 and HL60 are depicted in
blue. Grey squares indicate not detected interaction. A) Selected interactions of C/EBPβ/ε detected
by APS and/or IP-MS that could be grouped into or associated with RNA polymerase, Mediator
complexes and SWI/SNF complex. B) Selected interactions of C/EBPβ/ε detected by APS and/or
IP-MS that could be grouped into or associated with the MLL1/2, NuRD, NCOR, PRC1 or LSD
complexes.
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3.9 C/EBPβ interacts with histone modifying proteins
This survey detected C/EBPβ to interact with epigenetic and histone modifying proteins
that participate in histone methyl- and acetyltransferase complexes as well as demethylase
and deacetylase complexes.
The APS approaches disclosed interactions of the C/EBPβ TAD with ASH2L and MCRS1 that
are understood to be components of the MLL1 histone methyltransferase complex. Moreover,
IP-MS detected endogenous C/EBPβ to interact with the proposed MLL1 complex members
PELP1 in SU-DHL-1 and RUVBL in JEKO-1 cells. The IP-MS data also revealed interaction
of C/EBPβ with the MLL2 methyltransferase complex component DPY30, while APS reports
the interaction of C/EBP TAD peptides with MEN1, ASH2L and MLL2 (also RD) (Figure
21). Furthermore, APS and IP-MS data reveal interactions of C/EBPβ with proteins of the
Jumonji- histone-demethylase family. The APS screening revealed a direct interaction of the
C/EBPβ CR1/2 region with the co-repressor KDM5C, known to demethylate the activating
H3K4me2/3 histone mark and the coactivator KDM6B known to demethylate the repressive
H3K27me2/3 signature (for overview see: Rotili and Mai, 2011; Cloos et al., 2008). IP-MS
revealed the interaction of the H3K9 demethylating coactivator KDM3B with endogenous
C/EBPβ in JEKO-1 and OPM2 cells.
This survey was able to identify C/EBPβ interaction with histone acetytransferases and
deacetylases. The interaction of C/EBPβ with components of the NuA4/Tip-HAT complex
like BRD8, RUVBL1 was revealed by IP-MS from JEKO-1 cells and APS added the complex
component MRGBP. The histone acetyltransferases (HAT) CBP and p300 are well-known
cooperation partners of C/EBPβ (Nerlov, 2004; Kovcs et al., 2003; Mink et al., 1996). The
interaction of CBP could be verified by the APS survey. In addition, a direct interaction of
C/EBPβ with TADA3 was detected by APS and IP-MS disclosed the TAF6L interaction in
SU-DHL-1 cells. These two proteins are putative components of the CBP/p300 cooperating
PCAF-HAT-complex (Cho et al., 1998; Korzus et al., 1998; Ogryzko et al., 1998; Vassilev
et al., 1998; Chen et al., 1997). These results suggest that the here identified epigenetic
modifiers could collaborate with C/EBPβ during target gene activation.
C/EBPβ is capable of both gene activation and repression (Descombes and Schibler,
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1991). APS and IP-MS experiments elucidated interaction with proteins associated with
negative gene regulation. IP-MS of HL60 cells revealed interaction of C/EBPβ with NOC2L,
a HAT inhibitor that was also shown to inhibit p300 mediated promoter acetylation of p53
target genes (Hublitz et al., 2005). The C/EBPβ TAD is published to interact with the co-
repressor NCOR2/SMRT as well as NCOR1 (Ki et al., 2005). Our APS approaches detected
an interaction of the C/EBPβ TAD with NCOR2 and the C/EBPβ RD peptide interacted
with the NCOR2 cooperator HDAC10 (Fischer et al., 2002; Figure 21). Additionally, the
APS approaches elucidated a direct interaction of the C/EBPβ TAD with TIF1B, SNF5,
SF3B3 and HDAC3 proposed components of the NCOR1-complex (Underhill et al., 2000).
The IP-MS data revealed LSD1 and RCOR (CoREST) as interaction partners of
endogenous C/EBPβ in U937 cells. APS data indicates a direct interaction of the CR1/2
peptide of C/EBPβ with the REST protein, which represses neural genes in non-neural
tissue in cooperation with RCOR (CoREST) and SIN3A (Grimes et al., 2000). Since the
LSD1-RCOR complex as well as NCOR1/2-complexes are known to recruit HDACs to gene
promoters (Lee et al., 2005; Metzger et al., 2005; Shi et al., 2005; Underhill et al., 2000; Yang
et al., 2006) we hypothesize that C/EBPβ could cooperate with those complexes to silence
target genes.
Intriguingly, this screening revealed interaction of C/EBPβ with the NuRD complex,
a complex that is depending on its subunits, associated with transcriptional activation or
repression and has been published to interact with C/EBPβ before (Günther et al., 2013;
Steinberg et al., 2012). IP-MS detected interaction of endogenous C/EBPβ with the Mi2-
NuRD complex components CHD4, MTA2 and MBD3 in SU-DHL-1 and GATAD2B in U937
cells. MBD3 was identified as direct C/EBPβ binder by the APS screening. Furthermore, APS
revealed interaction of the C/EBPβ CR3 peptide with the co-repressor protein TIF1B/TRIM28
known to recruit CHD3 to the NuRD-complex (Schultz et al., 2001; Figure 21).
Next to the interaction of C/EBPβ TAD peptides with transcriptional repressive
epigenetic modifiers APS revealed the interaction of the TAD with general transcriptional
repressors like the WD-repeat protein TLE2.
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3.10 C/EBPβ is cooperating with other transcription factors
C/EBPβ is known to associate and cooperate with other transcription factors like b-ZIP
proteins belonging to the ATF family (Podust et al., 2001; Shuman et al., 1997; Tsukada et
al., 1994; Vallejo et al., 1993). In SU-DHL-1 cells IP-MS verified the putative interaction of
C/EBPβ with ATF3 (Lee et al., 2010b). The data of the combined APS and IP-MS approach
revealed interaction of C/EBPβ with a multitude (>200) of zinc finger proteins containing
mostly the C2H2 or LIM-zinc finger domains as derived by Pfam/InterPro analysis (via
DAVID database, DAVID.abcc.ncifcrf.gov; Huang et al., 2009). The majority of zinc finger
transcription factors interacted with the N-terminus of C/EBPβ in the APS approaches, which
is in accordance to our previous results and suggest that C/EBPβ TAD plays an important
role in the recruitment of transcriptional regulatory factors (Kowenz-Leutz et al., 2010).
Interestingly, IP-MS from SU-DHL-1 cells detected interaction of STAT3 and ALK with
endogenous C/EBPβ. The interaction with the transcription factor STAT3 and the regulation
of C/EBPβ expression by STAT3 and the NPM-ALK-fusion kinase in the SU-DHL-1 cell
line were analyzed before (Anastasov et al., 2010; Piva et al., 2006; 2010). Additionally,
a high expression of C/EBPβ (Log10 of iBAQ intensity = 7.59), STAT3 (Log10 of iBAQ
intensity = 7.98), ALK (Log10 of iBAQ intensity = 7.87) and NPM (Log10 of iBAQ intensity
= 9.25) could be observed in SU-DHL-1 cells by MS-iBAQ proteomics. The expression of the
NPM-ALK fusion gene was confirmed by the cell line provider DSMZ. Therefore a certain
percentage of the by iBAQ detected ALK and NPM proteins should be present as fusion
kinases.
Furthermore, this survey revealed interaction of C/EBPβ with further transcription
factors like the direct interaction of the TAD (CR1/2) peptide with the eosinophil transcription
factor GATA1 in APS. C/EBPβ and GATA1 are thought to cooperatively regulate eosinophil
lineage genes like MBP (Yamaguchi et al., 1999). Additionally, APS detected interaction of
the C/EBPβ TAD with the transcription factors MAFB and MAFF that play important roles
during the development of various cells and tissues like uterus, blood cells, muscle, neurons
and brain.
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 73
RESULTS
3.11 C/EBPβ interacts with the NFκB pathway
C/EBPβ was shown to cooperate with NF-κB p50 in order to activate NF-κB target genes
and induce apoptosis (Dooher et al., 2011). Another study observed interaction of C/EBPβ
with NK-kB p65/RELA, resulting in the inhibition of TNF- induced phosphorylation of p65
and loss of the transactivation capability of p65 (Zwergal et al., 2006). The APS screenings
revealed RELA/p65/NFKB3 to interact directly with C/EBPβ. Moreover, IP-MS detected
the interaction of endogenous C/EBPβ with NFkB1/p50 and NKIP1 in U937 cells as well as
with further TNF-α/NF-κB-complex components and pathway members like SKP1, IKKA,
LRPPRC and TBK1 in SU-DHL-1 and IQGAP2 in HL60 cells.
3.12 C/EBPβ interacts with SUMO and ubiquitin ligases and
further factors associated with protein degradation
C/EBPβ was shown recently to interact with several components of protein ubiquitin ligase
complexes (Steinberg et al., 2012). The APS approaches of the C/EBPβ TAD revealed novel
interactions with proteins like Cullin1 (CUL1), ZNRF1 and TRIM37. Further ubiquitin
E3-ligases complex members interacted with endogenous C/EBPβ, like CUL5, HUWE1,
UBR4, HERC4 and TRIM21 in SU-DHL-1 cells, ZC3HC1 and TRIM21 in HL60 cells and
CUL3 in JEKO-1 cells. Endogenous C/EBPβ interacted with the ubiquitin E2-ligases UEV2
in HL60 cells and UBE2C in SU-DHL-1 cells, as detected by IP-MS.
Moreover, IP-MS detected the interaction of endogenous C/EBPβ with the SUMO1
protein (in HL60 and JEKO-1 cells), without distinguishing between covalent or non-covalent
SUMO1 interaction. Likewise, IP-MS revealed the interaction of C/EBPβ with the SUMO1-4
-E1 ligase UBA2 (in JEKO-1 and SU-DHL-1) and SUMO1-3 E1 ligase SAE1 (in SU-DHL-1).
The expression of ubiquitin or SUMO pathways associated interactors could be detected by
MS-iBAQ proteomics in SU-DHL-1 cells, except for TRIM21 (IP-MS), ZNRF1 (APS) and
TRIM37 (APS). The in this study observed interactions provide an interesting extension
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of previously reported modifications and interactions of C/EBPβ with SUMO proteins and
ligases (Berberich-Siebelt et al., 2006; Eaton et al., 2003; Kim et al., 2002).
3.13 C/EBPβ interacts with cell cycle regulators and other
proteins controlling proliferation
The APS and IP-MS interaction screenings elucidated prevalently novel interactions of
C/EBPβ with regulators of cell proliferation and cancer progression ranging from cell cycle
regulators to factors licensing and maintaining DNA replication. C/EBPβ is known to interact
with the cell cycle regulator protein Cyclin-D1 and to repress Cyclin-D1 target genes as well
(Lamb et al., 2003). In this screening the direct interaction with Cyclin-D1 could be verified
by APS. Notably, mass spectrometry neither detected interaction of Cyclin-D1 with C/EBPβ
nor the expression of Cyclin-D1 in the analyzed leukemia cell lines. Nevertheless, IP-MS
detected endogenous C/EBPβ to interact with the Cyclin-D associated CDK6, the anaphase
promoting complex subunit APC4, and CDK1, which promotes together with B-Cyclins the
G1-S phase transition. The data also reveals interaction of C/EBPβ with Cyclin-H that was
shown to regulate CDK7, a component of a complex that activates CDK1, CDK2, CDK4
and CDK6 as well as RNA polymerase II (Shiekhattar et al., 1995).
On top of that, IP-MS detected the C/EBPβ interaction with CDK6/Cyclin-D-complex
inhibitor p16-INK4a in SU-DHL-1 cells and APS revealed p21-WAF1, a Cyclin-D/CDK4
inhibitor and a p53 target gene, as a direct interaction partner of C/EBPβ.
C/EBPβ and ε peptides interacted with the tumor suppressor proteins RASSF1 and
RASSF2 that are also associated with negative cell cycle regulation according to GO-analysis
(see material and methods section). The mitotic checkpoint proteins BUB1B (in U937) and
BUB3 (in SU-DHL-1), as well as CK5P2/CDK5RAP2, a regulator of BUB1B transcription
(Zhang et al., 2009) and C/EBPβ target gene (Bonzheim et al., 2013), were detected by
IP-MS as novel interactors of C/EBPβ (Figure 22).
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3.14 C/EBPβ interacts with proteins organizing DNA repli-
cation and mitotic chromatin structure
The IP-MS and APS data revealed interactions of C/EBPβ with components that directly
facilitate, regulate and execute in DNA replication. The IP-MS screenings revealed the
interaction of endogenous C/EBPβ with PCNA in HL60, RFC1, TOP1, RPA1 and TOP2 in
SU-DHL-1 as well as TOP2 and RFC3 in U937 (Figure 22). Interestingly all six proteins
are known to form a functional complex with the DNA-polymerases during DNA replication
(Jiang et al., 2002; Coll et al., 1996). Additionally, APS data shows a direct interaction of the
TAD of C/EBPβ with CDT1 and MCM5, whereas MCM4 was detected by IP-MS in JEKO-1
cells (Figure 22). Those three proteins are components of the mini-chromosome maintenance
(MCM) complex, which facilitates the initiation of DNA replication and elongation in
eukaryotic cells (Ishimi et al., 1996). CDT1 is one of the factors that recruits the MCM
complex to the origins of replication on the DNA during the G1 phase of the cell cycle
(Bochman and Schwacha, 2009). Furthermore, APS detected interaction of C/EBPβ with the
polycomb group protein L3MBT, which is associated with MCM-mediated replication fork
progression and p53 target gene regulation.
The interaction screenings also unraveled interactions of C/EBPβ with proteins defining
mitotic chromatin structure like the centromere proteins that could be grouped into the
CEN-protein-complex. IP-MS detected endogenous C/EBPβ to interact with the by Obuse
and colleagues proposed CEN-complex members CENPM, NUP93, SUPT16H, HSPA5 and
HSP7C in SU-DHL-1 cells (Obuse et al., 2004). A direct interaction of the TAD with the
complex component HSP7C/HSPA8 was revealed by APS. Additionally, the kinetochore
proteins ZW10 and KNTC1/Rod interacted with endogenous C/EBPβ in SU-DHL-1 and APS
revealed the kinetochore associated kinesin KIF2C. Endogenous C/EBPβ co-precipitated from
SU-DHL-1 lysates the condensin-I and -II complex components NCAPD2, NCAPG, SMC2,
SMC4, CAPD3 and the before mentioned SWI/SNF complex and condensin component
SMC1A. In concert with these results MS-iBAQ proteomics detected the expression of all
centromeric complex components, except CENPM, in SU-DHL-1 cells.
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Figure 22: Selected interactions of C/EBPβ/ε detected by APS and/or IP-MS that could be
grouped into functional complexes or associated with DNA replication, kinetochor/centromer
functions and chromatin condensation using the CORUM database (http://mips.helmholtz-
muenchen.de/genre/proj/corum; Ruepp et al., 2008; 2010). Direct interactions detected by APS with
peptides of the conserved regions of C/EBPβ/ε are depicted as green squares in the heatmap. The
legend below the heatmap illustrates the amino acid coverage of APS peptides of the C/EBPβ/ε
protein. Interactions detected by IP-MS (anti-C/EBPβ) from cell lysates of at least one of the cell
lines SU-DHL-1 (whole cell and/or nuclear enriched), U937, JEKO-1, OPM2 and HL60 are depicted
in blue. Grey squares indicate not detected interaction.
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Utilizing IP-MS, novel interactions of C/EBPβ were detected with several nuclear
pore components in SU-DHL-1 cells. Some of these interacting proteins are known to have
additional functions in mitotic spindle and chromatin organization, namely RANBP2/NUP358,
NUP50 (both also in OPM2), NUP85, TPR, NUP160 and NUP210 (Figure 23). One of the
most significant interactions in SU-DHL-1, JEKO-1, OPM2 and U937 were the established
C/EBPβ export factor XPO1 (CRM1) (Buck et al., 2001) and its important cofactor RANBP3.
IP-MS from JEKO-1 cells revealed also the initial transport protein RAN. Moreover, the
GTPase activator RanGAP1, that converts Ran to the putatively inactive GDP-bound state,
as well as its interactor RANBP2/NUP358 were found to interact with endogenous C/EBPβ
in OPM2 and SU-DHL-1 cells. On top of this, IP-MS identified the export factors XPO2,
XPO5 and XPO6 (also in U937) as interactors of endogenous C/EBPβ in SU-DHL-1. Finally,
C/EBPβ interacted with the import factors IPO4 in HL60, with IPO12 in U937 and with
IPO9, TRN and the importin subunit-β (KPNB1) in SU-DHL-1. Eventually all the expression
of the interacting transport proteins, except for XPO6, were detected in the SU-DHL-1 cell
line using MS-iBAQ proteomics.
3.15 C/EBPβ interacts with proteins associated with DNA
repair and apoptosis
Interestingly, APS and IP-MS revealed the interaction of C/EBPβ with numerous proteins
associated with DNA repair mechanisms like Double-strand break (DSB) repair, non homol-
ogous end joining (NHEJ) or nucleotide excision repair (NER) (Figure 23). APS detected
the direct interaction of the C/EBPβ RD with the nucleotide excision repair (NER) pro-
tein RAD23A. IP-MS identified the interaction of endogenous C/EBPβ in SU-DHL-1 cells
with TELO2 (and in HL60 cells) and TTI1 (and in U937 cells), which are members of the
double-strand break repair triple-T (TTT) complex. The triple-T complex is considered to
regulate the stability of mitotic checkpoint kinase ATR, which itself interacts with C/EBPβ
in SU-DHL-1 cells (Hurov et al., 2010). Additionally, IP-MS revealed interaction of C/EBPβ
with FANCD2 in U937 and SU-DHL-1 cells. The FANCD2 protein, which was recently shown
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to interact with C/EBPδ is understood to have ATR target motifs and to be important for
the DNA damage response (DDR) (Andreassen et al., 2004; Matsuoka et al., 2007; Moldovan
and D’Andrea, 2009; Wang et al., 2010).
IP-MS detected the interactions of endogenous C/EBPβ with WRN in HL60 and PARP-
1, XRCC5 (also in JEKO-1 and OPM2) and XRCC6 (also in JEKO-1) in SU-DHL-1 cells
(NE) (Figure 23). The four proteins could be grouped into the Werner-syndrome complex,
a complex functioning in base excision repair (BER), non-homologous end joining (NHEJ)
and DNA replication (Li et al., 2004). Additionally, the Double-strand break (DSB) repair
BRCA1-complex member BRE (in JEKO-1), the DSB non-homologous end joining repair
protein NHEJ1 (in JEKO-1, U937 and SU-DHL-1) as well as the mismatch repair proteins
MLH1 (in SU-DHL-1) and MSH2 (in HL60) interacted with the endogenous C/EBPβ (Dong
et al., 2003).
C/EBPβ not only interacts with proliferation modulators. The here presented results
also features novel interactions of C/EBPβ with apoptosis associated factors. Endogenous
C/EBPβ interacted with the apoptosis regulators BAX, BID and Caspase 2 (CASP2). APS
experiments revealed direct interactions of the C/EBPβ TAD with the positive p53 regulator
ASPP2, CASP6, the TNFR1-apoptosis pathway member TRADD and the caspase independent
apoptosis regulator kinase PKM. On the other hand, APS detected the anti-apoptotic factor
MKL1, an inhibitor of TNF-induced caspases, and the negative ASPP2 regulator DDX42.
Finally, MS-iBAQ proteomics could detect the expression of all DDR associated C/EBPβ
interactors, except for UBA52, in SU-DHL-1 cells.
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Figure 23: Selected interactions of C/EBPβ/ε detected by APS and/or IP-MS that could
be grouped into functional complexes or associated with nuclear-cytoplasmic transport, DNA
damage response or DNA repair functions using the CORUM database (http://mips.helmholtz-
muenchen.de/genre/proj/corum; Ruepp et al., 2008; 2010). Direct interactions of peptides covering
the conserved regions of C/EBPβ/ε, which were detected by APS are depicted as green squares in the
heatmap. The legend below the heatmap illustrates the amino acid coverage of APS peptides of the
C/EBPβ/ε protein. Interactions detected by IP-MS (anti-C/EBPβ) from cell lysates of at least one of
the cell lines SU-DHL-1 (whole cell and/or nuclear enriched), U937, JEKO-1, OPM2 and HL60 are
depicted in blue. Grey squares indicate not detected interaction.
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3.16 RNA binding and processing proteins interact with C/EBPβ
Intriguingly, the APS and the endogenous IP-MS screenings unraveled C/EBPβ to be associ-
ated with a significant number of RNA binding proteins like components of the spliceosome,
RNA processing, RNA transportation and RNA degradation associated proteins (Figure 24
and 25, Table S1). This is intriguing, as recent studies reported of the interaction of C/EBPα
and C/EBPβ with RNA binding proteins and Spliceosome components (Siersbaek et al.,
2014; Giambruno et al., 2013). Some of those interactions were verified by this survey (vide
Table S1). Pfam and InterPro analysis revealed that numerous proteins, which were found to
interact with C/EBPβ in this study, possess RNA binding motifs like the RBD/RRM or the
DEAD/DEAH box (RNA) helicase domain (via DAVID database, DAVID.abcc.ncifcrf.gov;
Huang et al., 2009).
PF00271:Helicase C
PF00076:RRM
PF00076:RBD
PF02985:HEAT
PF00270:DEAD
0 5 10 15
IP-MS
PF00076:RRM
PF00076:RBD
PF01352:KRAB
APS
Number of proteins
20
0 10 20 30
Figure 24: Illustrated is a selection of the most abundant RNA binding domains of C/EBPβ/ε inter-
acting proteins that were found by APS and/or IP-MS (vide Supplemental Table S1). The NIH DAVID
resource was used to determine PFAM domains, Benjamini-Hochberg ≤ 5  (DAVID.abcc.ncifcrf.gov;
Huang et al., 2009). Depicted are the total numbers of proteins carrying the named RNA-binding
domains that interacted with C/EBPβ/ε in APS and/or IP-MS.
Data analysis of the IP-MS/APS-data with either the UniProt or the GeneOntol-
ogy online resources indicates RNA binding and modifying functions for more than ninety
C/EBPβ/ε interacting proteins (Figure 24 and 25). A large number of those C/EBP inter-
acting proteins are components of the spliceosome or RNA helicases like CIRBP, DHX15/9,
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LSM2/6/7, PPIL1, RBM15/22/25, SNRPF, SF3B3, SKIV2L2, BCAS2, SRSF1, SRSF2/5/7
XAB2, TFIP11 and THOC5 (Jurica et al., 2002; Zhou et al., 2002; Figure 24 and 25). The
interacting proteins CDC5L, SRSF2, SRSF1, ILF2, SPF27, PP1A and GCN1L could be
grouped into the Spliceosome associated CDC5L-protein complex, known to promote mRNA
splicing (Ajuh et al., 2000). Moreover, the RNA splicing proteins RALY, HNRPU, HNRPM,
ROA3, ROA1, HNRPC and HNRPK that could be grouped into the C complex of the
spliceosome (Jurica et al., 2002) were mostly simultaneously detected by APS and IP-MS
from SU-DHL-1 cells (Figure 25). Eventually, MS-iBAQ proteomics revealed the expression
of all spliceosome components that were detected to interact with C/EBP peptides and
endogenous C/EBPβ, except for CIRBP, RALY, SRSF4, SRSF10 and DDX5.
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Figure 25: IP-MS and APS revealed interaction of C/EBPβ with various RNA binding and processing
proteins that could be grouped into the Spliceosome, the Splice-CDC5L- and the Splice-C-complex
using the CORUM database (http://mips.helmholtz-muenchen.de/genre/proj/corum; Ruepp et al.,
2008; 2010). Further RNA associated proteins are grouped according to their RNA binding or helicase
domains or their association with RNA transport as derived by GO analysis (NIH DAVID resource)
and UniProt (vide material and methods section). The color of the nodes indicates the detection
method: lime green nodes depict proteins that were detected by APS, turquois nodes indicate proteins
that were detected with IP-MS and yellow nodes indicate detection with both methods. The grey
edges were determined with the Cytoscape BisoGenet tool (Martin et al., 2010; Shannon et al., 2003)
and depict previously reported interactions. The blue colored edges indicate interactions with C/EBPβ
that were detected in this survey.
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C/EBPβ was also observed in this study to interact with family members of the
eukaryotic translation initiation factors. Subunits of the eIF-3 translation initiation complex
were detected by IP-MS, like eIF-3A and eIF-3M in SU-DHL-1 cells and APS detected
eIF-3D to directly interact with the C/EBPβ RD. The eIF-3 complex initiates the ribosome
60S-subunit dissociation and facilitates thereby the binding of eIF-4 proteins that guide the
mRNA to the 40S-ribosome (Bommer et al., 1991; Hinnebusch, 2006). Additionally, IP-MS
detected interactions with the eIF-4 complex subunits eIF-4A1, eIF-4A3 in SU-DHL-1 and
EIF4B in JEKO-1 and APS revealed eIF-4H to interact with the C/EBPβ RD (Richter et al.,
1999; Rogers et al., 2001). C/EBPβ also interacted in this survey with translation elongation
factors. The APS and/or IP-MS experiments detected EEF1A1 (in SU-DHL-1 and also by
APS), EEF2 (in SU-DHL-1), EEF1G (in JEKO-1, HL60 and SU-DHL-1), EEF1B2 (JEKO-1
and SU-DHL-1), EEF1D (JEKO-1 and SU-DHL-1) as interaction partners of C/EBPβ.
Noteworthy, the APS screenings also revealed C/EBPβ and ε to interact directly
with the RNA binding proteins ELAVL-1/3/4 (HuR, HuC, HuD). ELAV-like proteins were
until now only known to regulate C/EBPβ expression via influencing mRNA stability and
degradation upon binding (Basu et al., 2011). Intriguingly, recent data describes the NPM-
ALK-fusion kinase to enhance ELAVL-1/HuR-interaction with the C/EBPβ mRNA in ALCL
cells (Bergalet et al., 2011).
3.17 CEBPβ is phosphorylated and interacts with kinases in
leukemia / lymphoma cell lines
C/EBPβ is abundantly modified after translation. The phosphorylation of the regulatory
domain by the Ras/MAPK signaling pathway associated receptor tyrosine kinase ERK1/2
was proposed to induce a conformational change enabling the interaction with transcriptional
activators like the Mediator- and the SWI/SNF-complex (Kowenz-Leutz and Leutz, 1999; Mo
et al., 2004; Sato et al., 2004). Notably, the IP-MS analysis of HL60 cells revealed C/EBPβ
to interact with the ERK2 kinase.
Moreover, the MAPK downstream kinase RSK2 was shown before to interact with
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C/EBPβ and phosphorylate Ser217 (mouse; Ser105 rat), causing an increased DNA binding
ability and homodimerization (Lee et al., 2010a; Hanlon et al., 2001). Intriguingly, the
IP-MS results revealed the interaction of endogenous C/EBPβ with RSK2 in SU-DHL-1 cells.
C/EBPβ is known to be phosphorylated by the cycle kinases CDK1 und CDK2 (Shuman et
al., 2004) and as mentioned before IP-MS detected an interaction with the CDK1 and CDK6
kinases.
Altogether, the interaction data might suggest a potentially phosphorylated and ac-
tivated state of C/EBPβ in the analyzed leukemia cell lines, although this will have to be
experimentally verified.
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The C/EBPβ protein regulates differentiation, proliferation and survival in numerous tissues
and cell types. To understand how C/EBPβ executes this diversity of functions as a pioneering
transcription factor and participates in numerous biological processes it is important to
determine its complete interactome. Here, we applied comprehensive array peptide screening
(APS) and immune-precipitation mass-spectrometry (IP-MS) abetted by MS proteomics to
unveil C/EBPβ protein-protein interactions and potential C/EBPβ regulated proteins. The
APS approaches encompassed the screening of human protein expression libraries with various
synthetic peptides derived from the trans-activating and regulatory regions of C/EBPβ and ε.
The data derived by APS was integrated with data form IP-MS of endogenous C/EBPβ from
various leukemia cell lines. The data confirmed known interactions and revealed a plenitude of
novel C/EBPβ interactors that could function as components in protein complexes associated
with the regulation of gene transcription, chromatin remodeling and histone modification.
Other potential complexes that interacted with C/EBPβ play a part in DNA replication
and cell cycle regulation, DNA-repair/DDR, nuclear transport, osteogenesis and myeloid
differentiation. The involvement of C/EBPβ in energy metabolics was validated by the in this
survey obtained interaction and proteomics data. In addition, components of the spliceosome
and RNA-processing proteins were detected, suggesting novel functions of C/EBPβ. In
conclusion, the data presented largely expands previous knowledge and discloses entirely
novel areas of influence of C/EBPβ.
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Figure 26: Selection of protein-protein interactions (nodes) of C/EBPβ that were detected in
this survey by APS and/or IP-MS are visualized with Cytoscape (vide Table S1). The Cytoscape
BisoGenet tool (Martin et al., 2010; Shannon et al., 2003) was used to determine previously reported
protein-protein interactions (edges) between the protein nodes. Protein complex and/or functional
group membership of nodes are depicted by colors and was determined by the CORUM database
(http://mips.helmholtz-muenchen.de/genre/proj/corum; Ruepp et al., 2008; 2010), the Cytoscape
BisoGenet plugin and the UniProt database.
4.1 Combinatory use of APS and IP-MS
In order to unravel a most detailed view of the functional network of C/EBPβ we applied two
different screening methods to detect protein-protein interactions of the transcription factor.
First we employed the array peptide screening (APS) that was recently developed by our
group (Pless et al., 2011). The usage of short peptides in APS enabled the mapping of protein
interactions to certain C/EBPβ domains that are conserved within the family of C/EBP
transcription factors. But due to the usage of brief peptide sequences the APS technique
is less practical for the detection of protein-interactions that require larger interaction or
recognition motifs or rely on multiple contact sites. A suitable complement to this is the
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immunoprecipitation of endogenous full length C/EBPβ followed by mass spectrometry
measurements as it was employed in this survey. Furthermore, the APS technique enables
especially the identification of direct protein interactions as a consequence of the absence of
cellular cofactors and protein complexes, which naturally encompass numerous proteins in the
cellular context. On the other hand the detection of protein interactions with APS depending
on cofactors or a complex environment is therefore unfortunately unfeasible. Nevertheless,
a further advantage of the APS technique is the possibility of simultaneous discovery of
the utmost possible protein-protein interactions of a protein as the bacterial expression of
human proteins on the array overcomes cell type specific protein expression or the fluctuating
cellular abundance of proteins. This is underlined in this survey by the MS-iBAQ analysis
of SU-DHL-1 cells, which revealed on one side that 85 of the IP-MS identified C/EBPβ
interactions were also detectable analyzing the SU-DHL-1 proteome by MS-iBAQ proteomics.
However, hardly ≈ 20  of the proteins that interacted with C/EBPβ in the APS approaches
were detected among the most abundant proteins of the SU-DHL-1 cell proteome (Figure
16). This observation could be one of the explanations for the considerable difference in
detected C/EBPβ interactors by the endogenous IP-MS approaches and the APS technique.
In conclusion, the amount of data obtained in this survey underlines the advantage of a
combinatory employment of the expression independent in-vitro APS and endogenous IP-MS
technique to unravel C/EBPβ protein interaction network. This is especially supported by
the fact that significant numbers of known C/EBPβ interactors could be validated in by
survey (Figure 15, Table S1).
A further point of discussion is the difference of C/EBPβ protein interactions that
were detected by endogenous IP-MS in the different leukemia cell lines. The detection of
peptides by mass spectrometry heavily relies on the amount of each individual protein per
sample and the ionization properties of the measured peptides during electrospray ionization.
Protein interactors of C/EBPβ that are low abundant in a cell type, or generate poorly
ionizing peptides can fall below the detection limit of mass spectrometry. Therefore, cell
type specific protein expression differences between the five analyzed leukemia cell lines could
account for the variation of identified C/EBPβ interactions. In concert with this is the cell
type specific abundance of the C/EBPβ IP-bait protein itself providing a rational for the
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 87
DISCUSSION
differential amount of detected interactions as suggested by the 18 times higher abundance
of C/EBPβ protein in the SU-DHL-1 cells compared to U937 cells as determined by SRM
proteomics (Figure 17). On top of that, the type of label-free IP-MS survey selected to
discover C/EBPβ interactors based on a t-test only acknowledges proteins that were detected
at least twice (for nuclear extract IPs) or three times (for whole cell lysate IPs) in either the
IP-C/EBPβ or the bead control group. Under these statistical conditions minor changes in
protein abundance are a criterion for exclusion. In summary, the here-itemized reasons can
account for the differences between the protein-interactions detected for C/EBPβ by IP-MS
in this study. Nevertheless, the analysis of protein-protein interactions in leukemia cell lines
facilitated a crucial insight into potential cancer relevant interactions of C/EBPβ and may
provide a starting point for future studies.
4.2 C/EBPβ interacts with epigenetic regulators of gene tran-
scription
The transcription factor C/EBPβ binds the CCAAT-box sequence of the promoters of its
target genes (Osada et al., 1996; Mahony et al., 2007, Nerlov et al., 1995). Transcription
factors initiate gene transcription by recruiting cofactors and the polymerase complex to
the transcriptional start side. The interaction of C/EBPβ with the transcription activating
Mediator complex as well as the RNA-polymerase II and III complexes was described recently
(Steinberg et al., 2012; Kowenz-Leutz et al., 2010, Mo et al., 2004). Intriguingly, this study
was able to add a substantial number of protein components from both, the Mediator and
the RNA polymerase II/III complexes to the list of C/EBPβ interaction partners. The
cooperation between C/EBPβ and the Mediator and RNA polymerase complexes is most
probably essential to transcriptional activation of C/EBPβ target genes, as suggested by
others (Kowenz-Leutz et al., 2010, Mo et al., 2004).
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4.2.1 Transcriptional activating histone methyltransfereases and
demethylases
Gene transcription critically relies on the accessibility of DNA by the transcription machinery.
The compaction status of the DNA can be modulated by posttranslational modifications of
the histone tails (Luger et al., 1997; Kornberg and Thomas, 19974; Kornberg, 1974). Histone
tail modifications are understood to provide a "histone code" determining a transcriptionally
active or repressive state of gene promoters (for overview see: Strahl and Allis, 2000). The
histone code attracts the chromatin remodeling and polymerase complexes or heterochromatin
binding proteins (Dou et al., 2005; Hughes et al., 2004). Transcriptionally active promoters
are characterized by methylation of the histone H3 at lysine 4 (H3K4) or lysine acetylation
of several histone subunits. The removal of Histone H3K9 and H3K27 as well as the
establishment of H3K4 methylation and histone tail acetylation is essential for the initiation
of gene transcription (Jenuwein, 2001; Strahl and Allis, 2000; Turner, 2000). The methylation
of lysines or arginines of histone tails is carried out by histone-methyltransferases and the
acetylations of histones by histone acteyltransferases (HATs). A wealth of those proteins that
either establish or read histone modifications are considered as cooperators of transcription
factors or polymerases during transcriptional regulation (for overview see: Miller et al., 2009;
Cheung et al., 2000; Jenuwein, 2001; Turner, 2000).
This study observed interaction of C/EBPβ with components of the MLL1 and MLL2
histone H4K4 methyltransferase complex. The histone methyltransferases of the MLL-family
predominantly activate HOX gene promoters. Additionally, they are recognized to impact
the transcription of non-HOX genes by methylation of histone H3K4 as well. On top of
that, C/EBPβ was discovered to interact with the transcriptional co-activators KDM6B and
KDM3B in this survey. These two demethylases are known to remove the repressive histone
H3K9 and H3K27 methylation marks. All together the cooperation of C/EBPβ with the
mentioned activating histone methyltransferases and demethylases probably aids C/EBPβ
during the activation of its target genes.
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4.2.2 Transcriptional repressive histone deacetylases and his-
tone demethylases
The removal of Histone H3K4 methylation and histone tail acetylations is essential for the
initiation of gene repression. The subsequent establishment of histone H3K9 and H3K27
methylation characterizes silent promoters. Several studies revealed that C/EBPβ regu-
lates gene repression (Ki et al., 2005; Descombes and Schibler, 1991). The here presented
data unravels C/EBPβ involvement in the downregulation of various proteins and shows
the interplay of C/EBPβ with protein complex components associated with negative gene
regulation. In the APS approaches the C/EBPβ CR1-2 interacted with the co-repressor
KDM5C. KDM5C is a putative H3K4me2/3 demethylase. The IP-MS data also revealed
LSD1 and RCOR (CoREST) as interaction partners of endogenous C/EBPβ in U937 cells.
LSD1 is known to remove the activating histone tail methylation of H3K4 as well as the
repressive methylation of H3K9 and was also suggested to form a transcriptional repressive
complex with RCOR (Yang et al., 2006). Interestingly, APS showed a direct interaction of
the CR1/2 domains of C/EBPβ with the REST protein, which represses neural genes in
non-neural tissue in cooperation with CoREST and SIN3A (Grimes et al., 2000). C/EBPβ
interacted also with members of the repressive NCOR1/2 complexes. As the LSD1-RCOR
complex as well as NCOR1/2-complexes are known to recruit HDACs to gene promoters (Lee
et al., 2005; Metzger et al., 2005; Shi et al., 2005; Underhill et al., 2000) it is possible that
C/EBPβ cooperates with these complexes to silence target genes. Additionally, APS revealed
the direct interaction of KDM5C, NCOR- and CoREST-complex components exclusively with
the TAD of C/EBPβ underlining the importance of this C/EBPβ domain for gene repressive
functions.
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4.3 C/EBPβ interacts with proteins regulating chromatin
structure
An open chromatin structure facilitates the access of the transcription machinery to gene
promoters and is thereby essential for successful activation of gene expression. Chromatin
remodeling complexes modulate the chromatin structure by shuffling histones along the DNA
in an ATP dependent fashion. The opening of chromatin around gene promoters facilitates
the binding of the RNA-polymerases and Mediator complexes that initiate transcription
(Ryme et al., 2009; Nie et al., 2000). Chromatin remodeling complexes can be categorized
into the SWI/SNF, ISWI, NURD/Mi-2/CHD and INO80 families and consist of numerous,
highly conserved, subunits including a characteristic ATPase II helicase-related subunit (Tang
et al., 2010; Singleton and Wigley, 2002). The human SWI/SNF family consists of the two
subfamilies of BAF and PBAF complexes. The BAF and PBAF complexes are discriminated
by their different components containing either the ATPase hBRM (BAF) or BRG1 (BAF /
PBAF), the DNA binding protein BAF250 (BAF) or BAF200 (PBAF) and the bromodomain
protein BAF180 (PBAF), whereas the core components BAF45, BAF47, BAF53, BAF57,
BAF60, BAF155, BAF170 and β-Actin are shared by these complexes (Tang et al., 2010;
Mohrmann and Verrijzer, 2005).
Several SWI/SNF complex components were previously found to interact with C/EBPβ
target gene promoters and are putatively essential for successful target gene activation pre-
dominantly by interaction with the LAP* specific CR1 region (Kowenz-Leutz and Leutz,
1999; Steinberg et al., 2012). Intriguingly, the interaction of the SWI/SNF complex with the
CR1/2 of C/EBPβ is regulated by posttranslational modifications (PTMs) of C/EBPβ. A
methylation at the Arg3 (R3) position of the C/EBPβ CR1 region by the arginine methyl-
transferase PRMT4/CARM1 abrogates the interaction with the SWI/SNF and Mediator
complex. The phosphorylation of the C/EBPβ RD region by the Ras/MAPK-pathway
prohibits the methylation of the R3 residue by PRMT4/CARM1 and thereby facilitates
the interaction of C/EBPβ with the SWI/SNF and Mediator complexes and subsequent
target gene activation (Kowenz-Leutz et al., 2010). Further studies showed that a functional
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SWI/SNF complex (Vradii et al., 2005) as well as its interaction with C/EBPβ TAD are
essential for the differentiation of myeloid progenitor cells and transdifferentiation of B-cell
progenitors into the granulocytic lineage (Stoilova et al., 2013). This study verified known and
revealed novel interactions of SWI/SNF complex members with C/EBPβ by IP-MS and APS.
The interactions with the recently reported C/EBPβ interactors BAF250 and BAF180/PB1
(Steinberg et al., 2012) were detected by IP-MS in the U937 lymphoma cell line. In SU-
DHL-1 cells the interaction of endogenous C/EBPβ with the SWI/SNF components MECP2,
SMC1A, SNF2H, BAF155 and BRG1 was discovered. Moreover, APS identified SNF5 as
direct interactor of the C/EBPβ TAD. Those findings strongly emphasize C/EBPβ functional
association with the SWI/SNF complex, which could assist the C/EBPβ transcription factor
during target gene activation as suggested before (Stoilova et al., 2013; Kowenz-Leutz et al.,
2010; Kowenz-Leutz and Leutz, 1999).
Additionally, the proteomic screening of C/EBPβ infected C/EBPβ-/- MEF cells
revealed a significant up-regulation of the two SWI/SNF family members Baf180 and Smarcd1
(Figure 6 and Figure S1) after over-expression of both C/EBPβ LAP* and LAP isoforms.
This suggests a connection between the expression levels of C/EBPβ LAP*/LAP isoforms
and the availability of SWI/SNF complex components as C/EBPβ interaction partners.
C/EBPβ can be manipulated by several PTMs such as phosphorylation or methylation
of the regulatory domain (RD). PTMs of the RD, positively or negatively influence the
protein-protein interactions of the TAD and by that impact C/EBPβ gene regulating function
(Kowenz-Leutz et al., 1994; Williams et al., 1995 Nakajima et al., 1993; Figure 4). The
MAPK-downstream kinase RSK2 was shown to phosphorylate C/EBPβ on Ser105 (in rat;
Thr217 in mouse) increasing DNA binding and homodimerization properties of C/EBPβ (Lee
et al., 2010a; Hanlon et al., 2001; Buck et al., 1999). C/EBPβ is activated by phosphorylation
of the RD by the MAPK-pathway kinases ERK1/2 prohibiting the repressive methylation of
C/EBPβ K39 by the lysine-methyltransferase G9a (Pless et al., 2008). This phosphorylation
is accompanied by a conformational change of C/EBPβ enabling the interaction with the
transcriptional activating Mediator- and the SWI/SNF-complexes (Mo et al., 2004; Sato
et al., 2004; Kowenz-Leutz and Leutz, 1999). Monocytic differentiation of the investigated
lymphoma cell lines HL60 and U937 can be triggered by the MAPK-pathway activator
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12-O-Tetradecanoylphorbol-13-acetate (PMA/TPA). The monocytic differentiation of these
lymphoma cell lines by PMA/TPA is C/EBPβ dependent (Chen et al., 1996; Ji and Studzinski,
2004). These combined facts emphasize the here observed interactions of C/EBPβ with the
SWI/SNF and Mediator complex (in SU-DHL-1 and U937) as well as with the kinases ERK2
(in HL60) and RSK2 (in SU-DHL-1), indicating a transcriptionally activate state of C/EBPβ
in the examined leukemia cell lines.
The IP-MS survey of C/EBPβ protein partners in SU-DHL-1 and U937 cells revealed
several kinases. The kinases encompass three MAP-kinases and one MAPK activator. It
is possible to group these kinases applying the GO-term "GO:0006468 protein amino acid
phosphorylation". These findings extend C/EBPβ own regulatory network and demonstrate
C/EBPβ interplay with cellular signaling pathways and protein complexes in the analyzed
lymphoma cell lines.
The observed protein interactions of C/EBPβ with factors regulating chromatin struc-
ture during mitosis, cell cycle and DNA replication described in this survey are most likely to
expand the known protein interaction pattern of C/EBPβ significantly and suggest potential
novel functions of C/EBPβ.
4.4 C/EBPβ interacts with cell cycle regulators as well as with
centromere and kinetochore proteins
In the course of the cell cycle DNA is duplicated and sister chromatids are separated. The
prophase marks the onset of mitosis during which chromosomes condensate. The prophase is
followed by the prometaphase. The main characteristic of the prometaphase is the breakdown
of the nuclear envelope and the attachment of the microtubules to the kinetochores of the
compacted chromosomes (Marston and Amon, 2004; Nigg, 2001).
The organization, structure and compact state of mitotic chromosomes and the tran-
scriptionally silenced heterochromatin intrinsically rely on condensin proteins contained in
the condensin-I and -II complexes (Hirano, 2006; Ono et al., 2004; 2003; Losada and Hirano,
2001; Schmiesing et al., 2000). In this study the interaction of endogenous C/EBPβ with
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six condensin-I and -II complex components was revealed by IP-MS in SU-DHL-1 cells. The
condensin II complex is located in the nucleus during inter- and prophase and interacts with
chromatin. In contrast to the condensing II complex the condensin I complex is cytoplasmatic
and its interaction with chromatin is only possible after nuclear envelope breakdown during
mitosis (Hirota et al., 2004; Ono et al., 2004). Interestingly, the condensin complex I was
suggested to have additional functions during interphase where it interacts with PARP-1
and XRCC1 and translocates with those factors to DNA damage sites (Heale et al., 2006).
Moreover, the condensin I complex members NCAPD2 and SMC1A were shown to be targets
of the DNA damage ATR kinase (Matsuoka et al., 2007). NCAPD2 and SMC1A are novel
protein partners of C/EBPβ revealed by this study.
The kinetochore is the structural component that mediates cytoskeletal interaction
with the chromosomal DNA enabling the separation of sister chromatids during mitosis. This
process is controlled by the spindle assembly checkpoint (SAC). The SAC prevents aneuploidy
by delaying the mitotic progress until all kinetochores are attached to microtubules and
subsequently initiates the separation of the sister chromatids during anaphase (Marston and
Amon, 2004; Nigg, 2001). MAD2 is one of the proteins that regulates the SAC by inhibiting
the anaphase-promoting complex/cyclosome (APC/C) until all kinetochores are attached
(Logarinho et al., 2008; Sudakin et al., 2001; Tang et al., 2001; 2004). The kinetochores are
formed at the centromeric region of chromosomes and are primarily characterized by the
incorporation of the histone 3 specimen Centromere Protein A (CENP-A). CENP-A is essential
for kinetochore formation. The centromeric DNA sequence consists of a large assemblage
of 171-bp tandem α-satellite repeats that are recognized by the DNA-binding Centromeric
Protein B (CENP-B). The incorporation of CENP-B at the centromeric α-satellite repeats of
DNA is understood to foster centromere formation and recognition (Allshire and Karpen,
2008; Carroll and Straight, 2006; Westhorpe and Straight, 2013). Previous research reports
up to eight repeats of consensus C/EBP binding sites in mouse centromeric α-satellite DNA
and intriguingly C/EBPβ was shown to co-localize with murine centromeric α-satellite DNA
and the centromeric protein CEBP-B during adipocyte differentiation (Tang et al., 2003;
Tang and Lane, 1999). A survey of the centromeric proteins by the Yoda group suggested a
large protein complex important for the alignment and segregation of chromosomes (Izuta
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 94
DISCUSSION
et al., 2006; Obuse et al., 2004). The Yoda group performed anti-CENP-A chromatin
immunoprecipitations obtaining the interphase centromere complex (ICEN). In our study
IP-MS detected endogenous C/EBPβ to interact with six proteins that are proposed members
of the ICEN. Among these proteins was the PANE1/CENP-M protein, a protein that probably
aids CENP-A during kinetochore assembly.
The recruitment of cytoskeletal components to the kinetochore is essential for correct
chromosomal segregation during mitosis (Cleveland et al., 2003; Williams et al., 2003). During
this process the bridging proteins zeste white 10 (ZW10) and rough deal (hRod/KNTC1)
form a functional complex and link the microtubule motor protein dynein to the kineto-
chores facilitating segregation of the sister chromatids (Scaërou et al., 2001; Williams et
al., 2003). The ZW10/hRod complex was suggested to exert a dual regulatory role during
mitotic microtubule attachment to the kinetochore. The ZW10/hRod complex helps in the
context of the SAC to delay anaphase by recruiting the Mad1-Mad2 heterodimer complex
to unattached kinetochores and is required for the release of the heterodimer complex after
correct microtubule attachment as well (Kops et al., 2005). In this study the IP-MS analysis
of the SU-DHL-1 cell line uncovered the interaction of both proteins ZW10 and hRod/KNTC1
with endogenous C/EBPβ. Summed up, these findings suggest a possible involvement of
C/EBPβ in mitotic chromatin organization and chromosome condensation.
C/EBPβ was also detected to interact with five nuclear pore complex components
that are thought to play additional roles after mitotic nuclear envelope breakdown (NEBD)
by regulating mitotic progress as well as functionality of the kinetochore and spindle mi-
crotubules (Sood and Brickner, 2014; Bukata et al., 2013; Drechsler and McAinsh, 2012;
Dawlaty et al., 2008; Joseph et al., 2004; 2002; Salina et al., 2003). Additionally, the TPR
(Megator) nucleoporin interacted with C/EBPβ in SU-DHL-1 cells. Besides TPR’s function
as nuclear pore component it is associated with the mitotic spindle elongation and the spindle
assembly checkpoint (SAC) response as well. A study of the Maiato group reported a mitotic
co-localization of Tpr with the nuclear pore until the late prometaphase during mitosis.
Afterwards, Tpr partially localizes at the mitotic spindle followed by a re-localization to
the reassembled nuclear membrane throughout the telophase. The authors suggested a task
of Tpr during the spindle assembly checkpoint (SAC), similar to the previously mentioned
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ZW10/hRod complex (Lince-Faria et al., 2009).
In addition to this, IP-MS data revealed the interaction of endogenous C/EBPβ with
the nucleoporin NUP85 in SU-DHL-1 cells. NUP85 was described previously as an essential
component of the Nup107-160 nucleoporin complex. The Nup107-160 complex was proposed
to regulate mitotic kinetochore and spindle assembly and additionally shows similar behavior
upon unattached kinetochores such as the SAC regulator Mad2 (Orjalo et al., 2006; Zuccolo
et al., 2007). Furthermore, C/EBPβ interacted with the nucleoprotein and SUMOylase
RANBP2 (NUP358) in SU-DHL-1 cells. The nuclear pore complex member RANBP2 is
considered to play two different roles during interphase and mitosis. During interphase
RANBP2 binds to RanGAP1, effectively regulating protein import and throughout mitosis
both proteins translocate to kinetochores and spindle microtubules. RanBP2 was suggested
to be essential for localization of RanGAP1, Mad1/2 and CENP-E/F during mitosis and
for the interaction of mitotic microtubules with kinetochores (Joseph et al., 2002; 2004;
Salina et al., 2003). The SUMOylase ability of RanBP2 probably plays an important role in
mitotic chromosome segregation. In the study of Dawlaty et al. RanBP2 aided chromosome
separation by SUMOylation of Topoisomerase II-α (TOP2A) during mitosis, which facilitated
the translocation of TOP2A to centromeres where it untangles sister chromatids and prevents
chromosome bridging and missegregation (Dawlaty et al., 2008). Notably, the here-described
IP-MS approaches identified RANBP2 and TOP2A as interaction partners of the endogenous
C/EBPβ in U937 and SU-DHL-1 cells. Additionally, APS verified TOP2B as a direct interactor
of the C/EBPβ TAD. Altogether, these observations further strengthen the possibility that
C/EBPβ could have unexplored functions during mitotic chromatin organization.
In agreement with this theory our study also reported interactions of the endogenous
C/EBPβ with the WD40-repeat protein BUB3 and the serine/threonine-protein kinase
BUBR1, two essential SAC regulators. BUBR1 is understood to supervise the CENP-
E mediated kinetochore attachment to microtubules during mitosis (Chan et al., 1999).
Furthermore, BUB3 and BUBR1 form a functional mitotic checkpoint complex (MCC) with
further checkpoint proteins like MAD2 (Sudakin et al., 2001). Additionally, this survey
detected an C/EBPβ interaction with CK5P2/CDK5RAP2, a regulator of BUB1B and MAD2
transcription (Zhang et al., 2009). Finally, APS experiments revealed interaction of C/EBPβ
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RD with the mRNA transport protein RAE1, which shares high sequence similarity with the
before discussed SAC protein BUB3 and supposedly has similar functions during SAC and
accurate chromosome segregation (Babu et al., 2003).
These findings further expand the functional network of C/EBPβ suggesting a role in
the regulation of chromatin structure throughout the cell cycle, during DNA replication and
in mitotic regulation in accordance with previous results (Tang and Lane, 1999; Tang et al.,
2003).
4.5 C/EBPβ interacts with proteins controlling DNA damage
response and apoptosis
DNA damage, insufficient attachment of microtubules to the kinetochores or retarded chro-
matid segregation during mitosis induce cell cycle arrest and lead in case of an irreparable
damage to apoptosis. This study revealed C/EBPβ to interact not only with proteins regulat-
ing mitotic chromatin organization and cell cycle arrest but also DNA damage response and
apoptosis induction.
DNA damage response (DDR) summarizes mechanisms recognizing and repairing DNA
lesions like double- or single-strand breaks, nucleotide excision or mismatch repair (Lord and
Ashworth, 2012). As a result of the DDR the arrest of the cell cycle or apoptosis is initiated.
The triple-T (TTT) complex is one of the DDR complexes activated by UV or ionizing
radiation (IR) induced double strand breaks. Its components TTI1, TTI2 and TELO2 were
indicated to play a crucial role during DDR by regulating the stability of the checkpoint
kinases ATM/ATR (Hurov et al., 2010). Intriguingly, this study revealed the interaction of
C/EBPβ with two TTT-complex members as well as the ATR kinase in SU-DHL-1 cells.
The Werner syndrome protein (WRN) possesses helicase and exonuclease function
and participates in several DNA repair mechanisms. These repair mechanisms range from
base excision repair (BER) and non-homologous end joining (NHEJ) to the untangling of
loops, Holliday junctions or replication forks during DNA replication and other interfering
DNA secondary structures (Rossi et al., 2010). WRN is the central component of the WRN-
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DNA repair complex that encompasses also the DNA helicases XRCC5 (Ku80), XRCC6
(Ku70) as well as the ADP-ribosyltransferase PARP-1 (Li and Comai, 2001; Li et al., 2004).
Our experiments revealed the interaction of C/EBPβ with all components of this complex
either in the SU-DHL-1 (some in parallel also in OPM2 and/or JEKO-1 cells) or in the
HL60 cell line. Moreover, the WRN protein was suggested to interact with ATR and to be
posttranslationally regulated by this checkpoint kinase as well (Pichierri et al., 2011; Rossi
et al., 2010), highlighting the close connection of these two C/EBPβ partners detected by
IP-MS. In summary, the interaction data collected in this survey suggests a yet undescribed
role of C/EBPβ in different DNA damage response pathways; however, further research is
necessary to substantiate this theory.
DNA interstrand cross-links (ICLs) induced by toxic substances lead to the activation
of the S-phase checkpoint and the inhibition of DNA replication and gene transcription
(Noll et al., 2006). ICLs induce two DNA repair pathways, both regulated by the mitotic
checkpoint kinase ATR. Noteworthy, IP-MS not only identified ATR but also FANCD2 as a
C/EBPβ interaction partner in SU-DHL-1 cells. FANCD2 is part of the FACD protein family
and putatively regulates the repair of ICLs (Pichierri and Rosselli, 2004) and DNA double
strand breaks (Nakanishi et al., 2005). FANCD2 was revealed to have ATR target motifs
(Matsuoka et al., 2007) and on top of that ATR is known to phosphorylate FANCD2. ATR is
stated to be required for FANCD2 monoubiqutitinylation leading to FANCD2 translocation
to DNA damage foci during the DDR (Moldovan and D’Andrea, 2009; Andreassen et al.,
2004). Moreover, FANCD2 was recently shown to interact with C/EBPδ, which facilitates
its nuclear import by IPO4 upon DNA damage (Wang et al., 2010). This study identified
IPO4, FANCD2 and ATR as C/EBPβ interaction partners in leukemia cell lines leading to
assumption that C/EBPβ could play a similar role in the DNA damage response as C/EBPδ
does.
Several studies suggest that C/EBPβ impacts apoptosis and cellular survival. The
phosphorylation of C/EBPβ Thr217 by RSK2 facilitates C/EBPβ interaction with the
Caspases 1 and 8 (Buck et al., 2001). C/EBPβ interaction with the Caspases 1 and 8 inhibits
the cleavage of both these caspases and the subsequent apoptosis of hepatic stellate cells.
Another study suggested that C/EBPβ represses p53 and p18Arf, prohibiting apoptosis and
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promoting cell survival and tumorigenesis after DNA damage in skin cells (Ewing et al.,
2008). Supporting these previous observations, the data of this study revealed C/EBPβ to
interact with apoptosis regulators like BAX, BID, TRADD, PKM, Caspase 2 and 6 and the
caspase independent apoptosis regulator kinase PKM.
4.6 C/EBPβ interacts with nucleoplasmic transport factors
The nuclear export protein XPO1 (CRM1) mediates C/EBPβ nuclear export in a phosphory-
lation dependent manner, regulated by the MAPK-pathway (Buck et al., 2001). One of the
most significant interactions in all leukemia IP-MS experiments is the export factor XPO1
(CRM1) and its important co-factor RANBP3 (Lindsay et al., 2001). Furthermore, the Ran
GTPase activator RanGAP1, known to convert Ran to the putatively inactive GDP-bound
state, was found to interact with C/EBPβ in the SU-DHL-1 cell line. The protein RANBP2
(NUP358) is a known interaction partner of the sumoylated RanGAP1 (Lee et al., 1998;
Mahajan et al., 1997). As discussed before RANBP2 and RanGAP1 interact with C/EBPβ in
the SU-DHL-1 cells. Furthermore, this survey detected endogenous C/EBPβ to interact with
three nuclear exportins and five importins. The proteomics of C/EBPβ infected C/EBPβ-/-
MEF cells revealed several protein transport factors to be upregulated after LAP* and LAP
expression. In conclusion, the detected importins could aid the translocation of C/EBPβ into
the nucleus and thereby foster C/EBPβ target gene regulation. Finally, the here presented
data adds several potential transport factors to the already known proteins mediating C/EBPβ
nucleoplasmic transport, although this theory will have to be experimentally verified.
Additionally, this study detected the interaction of C/EBPβ with five components of the
nuclear pore important for the nucleoplasmic transport. Of these nuclear pore components
RANBP2, TPR, NUP85 and the mRNA transport protein RAE1 are suggested to play an
additional role in the kinetochore and spindle attachment during mitosis, as discussed before
(Lince-Faria et al., 2009; Dawlaty et al., 2008; Zuccolo et al., 2007; Orjalo et al., 2006; Joseph
et al., 2002; 2004; Salina et al., 2003).
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4.7 Involvement of C/EBPβ in lipid, amino acid and glucose
metabolism
C/EBPβ has been implicated to play an important role in hepatic energy metabolism including
gluconeogenesis and lipid metabolism. C/EBPβ binds to the promoters of genes encoding
the tyrosine aminotransferase, the acetyl-CoA carboxylase, albumin and phoenolpyruvate
carboxy-kinase (PEPCK) (Arizmendi et al., 1999). The C/EBPβ transcript expression itself
and C/EBPβ binding to promoters of gluconeogenesis genes is regulated by insulin and
glucocorticoids (Duong et al., 2002; Ghosh et al., 2001; Guo et al., 2001; Yamada et al., 1999).
Moreover, C/EBPβ serine-phosphorylation in response to cyclic adenosine monophosphate
(cAMP) regulates the expression of the acetyl-CoA carboxylase gene (Tae et al., 1995).
Surveys of C/EBPβ knockout mice describe two possible phenotypes of mice concerning their
energy metabolism. The first phenotype is lethal only 2 hours after birth as 50 of C/EBPβ
-/- mice are unable to maintain normal blood glucose levels. During the research on a second
reported phenotype the group of J.E. Friedman observed that the viable adult C/EBPβ -/-
mice show hypoglycemia and lower hepatic glucose production after several hours of fasting,
probably due to decreased liver gluconeogenesis. Additionally, the study described a decreased
release of free fatty acids from adipose tissues and reduced levels of β-hydroxybutyrate due
to the knockout of C/EBPβ (Liu et al., 1999). The C/EBPβ knockout not only influences
carbohydrate and lipid metabolism but also impacts amino acid metabolism. Croniger et
al. observed increased levels of ammonia/urea/nitrogen, ornithine and glutamine in the
blood of adult C/EBPβ -/- mice after several hours of fasting (Croniger et al., 2001). As
a reason the authors suggested an impaired hepatic urea cycle as C/EBPβ is known to
induce transcription of the arginase gene in a glucocorticoid dependent manner. Arginase is
a pivotal urea cycle enzyme. In accordance with this the here presented IP-MS interaction
screenings from leukemia cell lines revealed interactors involved in glucose, nucleotide and
amino acid metabolism and in energy transfer. Furthermore, numerous C/EBPβ interactors
involved in energy transfer, glucose and lipid metabolism were revealed by APS. These results
underline the advantage of the APS screening, as several of the APS derived interactors are
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predominantly expressed in liver, spleen, intestine or adipose tissue.
The interaction data is augmented by the results of the proteomics analysis of the
C/EBPβ knockout MEF cells that were retrovirally infected with constructs containing
the C/EBPβ LAP* or LAP isoforms. The functional GO analysis of the proteins that
were at least 2 fold upregulated by infection with the LAP* and/or the LAP constructs
returned GO-terms like "GO:0055114 oxidation reduction" and "GO:0006091 generation of
precursor metabolites and energy". These two GO-terms comprise proteins mainly involved in
carbohydrate, fatty acid and amino acid metabolism. Remarkably, these upregulated proteins
also encompass several of C/EBPβ protein-interaction partners revealed by this survey. In
summary, the results of this study expand the knowledge of C/EBPβ contribution to cellular
energy, nucleotide and amino acid metabolism maintenance.
A comprehensive C/EBPβ interactome - PhD thesis - Julia Wiebke Böhm 101
DISCUSSION
Concluding remarks and future directions
The transcription factor C/EBPβ is associated with tumorigenesis, the regulation of tumor
cell proliferation, metastasis and tumor survival as well as senescence and apoptosis (Gutsch
et al., 2011; Pal et al., 2009; Piva et al., 2006; Luedde et al., 2004; Robinson et al., 1998;
Seagroves et al., 1998). The protein-interaction data of C/EBPβ revealed by this study
expands the knowledge of its cellular cooperation network and offers interesting new fields
for future research on the diverse functions of C/EBPβ.
APS and IP-MS interaction screenings disclosed C/EBPβ interplay with numerous
RNA binding proteins, associated with RNA metabolism and splicing. The data of this
survey is in concert with recent reports, which presented the interaction of C/EBPα and β
with Spliceosome components and RNA binding proteins using shotgun proteomics (Siersbaek
et al., 2014; Giambruno et al., 2013). This study verifies some of the previously reported
interactions and extends the number of C/EBPβ partners involved in RNA processing notably,
revealing numerous of them as direct interaction partners (vide Table S1). Prospective
investigations are required to elucidate C/EBPβ functional relationship with these RNA
binding and processing proteins in a cellular context.
The C/EBPβ protein-protein-interaction network (Table S1) and the protein abundance
alteration triggered by C/EBPβ expression (Figure 6; Figure S1) investigated in this study
substantiates the established functional role of C/EBPβ as a regulator of metabolic pathways.
Moreover, the obtained data identifies C/EBPβ involvement in the alteration of the protein
abundance of several SWI/SNF complex and MAPK pathway components. This is intriguing,
as several of these proteins belong to a collection of putative and novel C/EBPβ interaction
partners (Figure 21; Kowenz-Leutz et al., 2010 and 1999). Future research will have to
disclose the relationship between the proteins that were upregulated by C/EBPβ expression
and the proteins that are C/EBPβ interaction partners.
C/EBPβ fosters the proliferation and the survival of anaplastic large cell lymphoma
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(Anastasov et al., 2010; Piva et al., 2006 and 2010; Quintanilla-Martinez et al., 2006). The
collection of protein-protein interaction data put forth by this survey emphasizes the role of
C/EBPβ in ALCL tumorigenicity by disclosing numerous novel C/EBPβ interaction partners
responsible for executing diverse cellular functions. C/EBPβ was unveiled to interact with
HuR, ALK and STAT3 in SU-DHL-1 cells by IP-MS or by APS, whereas up until now these
proteins were only known to act as regulators of C/EBPβ mRNA expression in SU-DHL-1
cells (Bergalet et al., 2011; Piva et al., 2006 and 2010; Quintanilla-Martinez et al., 2006).
A recent study reported numerous potential target genes of C/EBPβ in SU-DHL-1 cells
(Bonzheim et al., 2013). Several of the in this survey reported interaction partners of C/EBPβ
in SU-DHL-1 are regulators of gene expression and potentially aid C/EBPβ during target
gene regulation.
Interestingly, the proliferation of SU-DHL-1 cells partly relies on the activating C/EBPβ
Thr235 phosphorylation by the MAPK pathway kinase ERK1/2 (Anastasov et al., 2010). In
addition to this, the data of this study further emphasizes the multifaceted association of
C/EBPβ with the MAPK/ERK1/2 pathway and other kinase pathways suggesting potential
therapeutic targets for leukemia like ALCL. This is underlined by recent studies reporting of
the beneficial effects of a pharmaceutical therapy combining established ALCL therapeutics
with inhibitors of the MAPK/ERK1/2- pathway in ALCL (Georgakis et al., 2006; Ito et al.,
2010).
In this study the C/EBPβ protein interaction network of several distinct leukemia
types was investigated. This C/EBPβ interaction network provides a solid basis for future
research, for example by therapeutically targeting C/EBPβ interaction partners in leukemias
and other cancer types, as C/EBPβ is also associated with aggressive types of breast tumors
and high-grade colorectal cancers (Van de Vijver et al., 2002; Zahnow, 2009; Rask et al.,
2000).
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ABBREVIATIONS
ABBREVIATIONS
aa amino acid
ala/A Alanine
ALCL Anaplastic large cell lymphoma
AML Acute myeloid leukemia
APS array peptide screening
arg/R Arginine
bZIP basic leucine zipper domain
cAMP cyclic adenosine monophosphate
C/EBP CCAAT/enhancer-binding protein
C2H2 protein domain, Cys2-His2
CR conserved region
Cys/C Cysteine
DBD DNA binding domain
ddH2O double deionized water
DDR DNA damage response
DEAD symbolizing amino acid sequence asp-glu-ala-asp
DEAH symbolizing amino acid sequence asp-glu-ala-his
DMEM Dulbecco’s modified Eagle’s medium
DNA desoxyribonucleic acid
DSB double strand break
EDTA ethylenediaminetetraacetic acid
EGTA ethylene glycol tetraacetic acid
FCS Fetal Bovine Serum
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ABBREVIATIONS
g gram
GO:term gene ontology term
H3 histone H3
H4 histone H4
HAT histone acetyltransferase
HDAC histone deacetylase
iBAQ Intensity-Based Absolute Quantification
ICL (DNA) interstrand cross-links
IP immunoprecipitation
IP-MS immunoprecipitation followed by mass spectrometry analysis
IR ionizing radiation
l liter
LCR low complexity region
LIM protein domain named after proteins Lin11, Isl-1 and Mec-3
lys/K Lysine
M molar
µ micro
MCC mitotic checkpoint complex
me methylation
Min minute
MEF mouse embryonic fibroblasts
MIEG MSCV-IRES-EGFP retroviral vector
MM Multiple myeloma
MSCV Murine Stem Cell Virus
MS mass spectrometry
NEB nuclear envelope breakdown
NE(L) nuclear enriched lysates
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ABBREVIATIONS
NHEJ non-homologous end joining
PBS phosphate buffered saline
pH potentia Hydrogenii
PMA phorbol 12-myristate 13-acetate
PMSF Phenylmethylsulfonylfluorid
PTM posttranslational modification
RBD RNA binding domain
RD regulatory domain
RNA ribonucleic acid
RRM RNA recognition motif
r.p.m. revolutions per minute
RPMI Roswell Park Memorial Institute
RT room temperature (25 ℃)
SAC spindle assembly checkpoint
SDS Sodium dodecyl sulfate
sec second
ser/S Serine
SRM selected reaction monitoring
SUMO small ubiquitin-like modifier
TAD transactivation domain
TF transcription factor
thr/T Threonine
TPA 12-O-Tetradecanoylphorbol-13-acetate
Tris tris(hydroxymethyl)aminomethane
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Rpl11
Cab45
Pygb
Tpm3
D8Ertd738e
Impa3
Egap
Naa15
mCG_67985
Tmco1
Snx5
Cars
Mapre1
Mlycd
Kiaa1291
Myg1
Utp11l
Sec24d
Cdk4
Rps10
Pak1
Frap
Aak1
Slc25a1
Sec61a
Cast
mCG_11651
Rab1
Kiaa0152
Pon2
Psmc5
Pdia5
Polr2d
Snrnp70
Eif5
Itpr3
Ndufa4
Eif3k
Eps8
Ddx17
Pfn2
Arfgef2
Sec23
Abcf2
Ilk
Plbd2
Nckap1
Tpm4
Coq9
Bag3
Smap1
Psmd6
Nuc
Ube4b
Ktn1
Smt3c
Nol1
Pgm2
Ilkap
Tubb4
G2an
Kbp
Kiaa0891
Rab5b
Uap1l1
Fkbp60
Pdgfrb
Fis1
Cycs
D14Ucla2
Afg3l2
Csl
Gsto1
Cisd1
Rab14
Erlin2
Eif2b2
Efhd2
Nmral1
Faf1
Bsg
Hmgts
Itgb1
Cpsf100^
Rheb
D11Ertd619e
Sod2
Prm3
Eif3j
Xpot
Tceb1
Db83
RP23−216M21.1−001
Hcp70.1
Kiaa1612
Ezr
Face1
Btf3
Ap2b1
Alg11
Calr
Kiaa0992
Cs
Golgb1
Bat2d
H2−Ke2
Mrps10
Ttf2
Gtf2f2
Alg5
Vps29
Cyp10l
Mrpl1
Wdr36
Cttn
Risc
mCG_5895
Rab18
Map4
Top2
Dcp1a
Hmox2
Pah
Txndc17
Dysf
Mhr23b
Nomo1
Hmgcl
Surf6
Mrc2
Anx8
Api5
Abcc1
Immt
Thumpd1
Pgp
Prep
Kiaa1499
Ccdc39
Dhm1
Mrpl22
Sec24a
RP23−188H3.2−004
Gna−rs1
Gmfb
Csda
Otub1
Fubp3
Akr7a5
RP23−356J7.1−003
Terf2
Ubch10
Pitpnb
Impa1
Usp24
Kiaa2024
A2mr
Tnpo2
Ppih
Pdcd5
Hisppd1
Htf9a
Rdx
Fkbp23
Parp1
Gapex5
Kiaa0268
Ergic53
mCG_121767
Fkbp38
Craf
Col6a3
Abca4
Supt5h
Arht1
Cul4a
Bms1
Srprb
Edf1
Acadl
Caprin1
Cdk5
Pdha1
Arhgdia
Rexo2
Slc1a5
Pgd
Prdx5
Apip
Vmn1r18
Letm1
Ankrd46
Rock2
Nup107
Rap2b
Kif2
Prpsap1
Arsdr1
Dal1
Orc3
Esl1
Arid1a
Rps27
B4galt1
Marcksl1
Pcmt1
Ppp1r7
Tmod3
mCG_4072
P4ha1
Bcar1
Ndufs4
Larp4
Ikbip
Smc1a
Akr1b1
Ppp2r2a
Csl4
Parn
Tbl3
Ubin
Skiv2l2
Dnttip2
Spg21
Rpl35
Map2k1
Capc
Txn
Abp1
Ddx19b
Tal
Lin7c
Armc1
Mapre2
Clic4
Loh11cr2a
Hsp84b
Cstf2
Dck
Gyg
Dlat
Npc1
Gins4
Bcat1
Mpdz
Eftud1
Ctdspl2
Tfrc
Ca13
Brwd2
Ppm1b
Trrap
Atp6s14
Tbc1d1
Mrps7
Lrp
Epb4.1l2
Myo1b
Ubap2l
Jip4
Fsc2
AA536749
Fam115c
Safb
Crept
Aof2
Acsl4
Dek
Baz1b
Lamb−2
Ddx23
Kif5b
Ap3b1
Flot2
Mak16
mCG_23557
Emk
Ythdf3
Dctn3
Ndrp
Ndufs3
Nampt
Hibadh
Kras
Vcam1
Ppid
Bag1
Hmbs
Hexc
Sgpl1
Fth
3930401K13Rik
Rap1gds1
Nup88
Adnp
Lsm4
Alcam
Lzic
Dnajc7
Csrp2
Gga2
Cul3
Ddx20
Edc4
Rpl36a
Kiaa0398
Crtap
Prune
Sh3bgrl
Ppp6c
Hrs
Ubc12
mCG_19062
Rbm7
D10Ertd749e
Ctnnbl1
Supv3l1
Apbb1ip
Cpla2
Ki−67
Cbx3
Tbca
Eea1
Stk10
Lrpap1
Inpp5e
Mxra7
Aat2
Prpf3
Nup98
Svil
Mov10
Cyp20a1
Ctsa
Nhlrc2
Atp6c
Camk2d
Syap1
Sec23ip
Polr2b
Pad1
Gpsn2
Decr1
Mtap1b
Uap1
Dpm1
Ralb
Gars
Carm1
Denr
Cops2
Mp68
Pacsin2
Top1
Recc1
Mta1
Tmem214
Agpat4
Hrp12
Ftsj3
Cdc123
Sec23b
Nenf
Polr3b
Cip4
Steap2
Jak1
Tars
Nsf
H2afy2
Mcb1
Nip7
Prpf6
Kiaa1715
Pmm2
Pfkp
Rpa2
Itgav
Dhx29
Grb2
Aldh1l2
mCG_7369
Nup133
Gdap3
Tomm70a
Rnh1
Impdh1
Nol14
Appils
Agfg1
Ddx24
Rab12
Man1a2
Ppil1
Hexb
AF013969
D11Ertd603e
Cox7c
Rsl24d1
Uqcrc1
Fundc2
Ubxd2
Skp1
Bet3
Nub1
Mbtps1
Map1lc3a
Cai
Gorab
Dhodh
Glo1
D15Ertd682e
Flot1
Exoc5
Cpk
Ctpct
Kif22
Dimt1
Wdr26
Kiaa0460
Enah
Lgals3
Clip2
Armet
Canp1
Hibch
Herc4
Ndap7
Kiaa0991
Tfb1m
Acadvl
Snap47
Ltv1
Strn
Agm1
Es10
Gmppa
Col6a2
Rpp40
Fyttd1
Commd8
Gclm
Napg
Dnajc8
Ndufb3
Mvk
Pcnp
Kiaa1113
Nipp1
Aimp1
Ndufv2
Nedd8
Mcca
Eif2ak2
Mrps22
Cope
Psme1
Jnkk1
Txln
Pofut2
Crsp3
Mct4
Cmya3
Cd34
Cpt2
Rbm12
Ll5b
Reps1
mCG_22253
Hmg2a
Psmb2
Commd2
Epdr1
Rock1
mCG_16488
centb2
Scp2
Dhfr
Dnajc3
Spr
Ddx54
Hrb2
Golim4
Nvl
Gk
JsdX
Capa6
Met
Hmox1
Ift20
D16Bwg1547e
Fen1
Clp
Nif3l1
Dnajb11
Rrm2
Echs1
Pcyt2
Arl2bp
Pap
Gdi1
Emb
Ankmy2
Hmgcr
Pfdn1
Sbf1
Cpo
Chaf1b
Mrps9
C330027C09Rik
Tubb6
Fbx4
Ehd2
G7b
Glrx
Cul1
Thy28
Bccip
Gstm5
Hr21
Mrpp1
Por
Kiaa0162
Dp1
Pdhb
Gc1
Ppil2
Ppp4
Calna
Lamb−1
Fam107b
Bre1a
Myo9b
BC032265
Uso1
Bicd2
Ppt
Dock1
Ivd
Pfdn3
D14Ertd500e
P4ha2
Gne
Sbdn
Dfrp1
Mrpl46
BC035947
RP23−26L6.8−002
Tegt
Dlc2
Dbt
DXImx38e
Dnajc1
Src
Ncam
Brox
Cast2
Ddx36
Rabip4
Serpinb1
Smt3h1
Ercc6l
Golph3
Scyl1
Gemin4
Commd7
Atpi
Kiaa1090
Acot2
Abcc4
Macf1
Kiaa1230
Whip
2900010J23Rik
Bap29
Kiaa0776
Pafah1b2
Erk2
Plod2
Gpc4
Garp45
Eps15
Pafah1b3
Gmppb
Mki67ip
Nup121
Kiaa1429
Prim2
Cd97
Mrpl20
Nbn
Tial1
Plod
Pycr1
Sfrs1
Ccdc22
Cpt1
Rcd1
Ddx41
Rap1b
Prc1
Dleu8
Bup
Pra
Heatr2
D8Ertd233e
Dlgh4
Snap29
Vps36
Actp
Itm2b
mCG_7289
Efha1
Cyld
Phf5a
Epn2
Uba6
Dhx37
D12Ertd771e
Impact
Tubgcp6
Mrps15
Hsp25
mCG_5513
Pitpn
Cobll1
Frp
RP23−193A16.5−001
Pbk
Cep290
Llph
Farp1
Sec22b
Col5a1
Tsfm
Prkar2b
Met
Hk2
Tbce
Sqrdl
Jnk2
Ctdp1
Abtap
Tgm2
Kpna4
Cnb
Pc
Baf190a
Pin1
Snx4
Samm50
Snag1
Myo18a
Fam61a
Gm111
Exoc3
Osmr
Dlc1
Taf15
Peci
Cd14
Cbr
Dcakd
Ccdc109a
Mrpl11
Nxf7
Cdc73
Pdcl3
Apeh
Spak
Bpnt1
Mrpl27
Ccdc58
Doc1
Acsl1
mCG_15924
Cit
Med8
Smndc1
Nt5c3
Cytsa
Polr1a
Creb1
Noc4l
Iqgap3
Ifi204
Ehbp1
Bag2
Hbp
Trip11
mCG_122520
Pkd2
Cdc27
Safb2
Ppwd1
Atp5j
Dhrs7
Nudt5
Ash2l
Erg9
Nudt16l1
Caip150
D14Ertd231e
Gm10126
Gtf3c4
RP23−19L12.1−003
E2f4
Rbbp5
Kif2c
Itfg3
Bcdin3
Eif1
mKIAA0118
Ppm1f
Cebpb
Fkbp10
Ggps1
Ncube1
mKIAA4216
Gltp
Cul2
Cd109
Fkbp13
Kcc1
mCG_6742
Mesd
Morc3
Cand2
Prpf38a
Ttc27
Amsh
Gbp2
Tsg118
FAM120A
Cvak104
Yif1b
Baf180
Ccdc139
mCG_15724
Nid2
Eif1ax
Kiaa1040
RP23−76M15.2−001
Fam125a
Tex10
Sdc4
Pdgfra
Golga2
Aktip
Farp2
Phkb
Mfn1
Pdrg
Pip4k2a
Bpag1
Ly75
Tmx1
Ifi205
Xdh
Ltb4dh
Sccpdh
Trim47
Arhgef2
Sdccag1
Golph3l
Casp12
Pcbp4
Akr1cl2
Palm2
Rrp1b
Fox2
Ftsjd2
Gm7293
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-
-
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-
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Supplemental Figure S1: Caption vide next page.
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Supplemental Figure S1: The heatmap on page 123 depicts all proteins detected in the pro-
teomics experiment with C/EBPβ-/- MEF cells infected with the retroviral vectors carrying either
C/EBPβ LAP*, LAP or a control vector. The first two columns of the heatmap show the Log2 fold
change of the detected proteins (MS analysis by Günther Kahlert, MDC) from the cells infected with
C/EBPβ ("LAP*" and "LAP") constructs versus cells infected with the control construct ("control").
Signals with a Log2 fold change ≥ 1 or ≤ −1 were considered as significant. Proteins that were detected
with a significant Log2 fold change of ≤ −1 after C/EBPβ infection compared to the control vector are
depicted with a red scale. Proteins detected with a Log2 fold change of ≥ 1 after C/EBPβ infection
compared to the control vector are depicted with a green scale. Protein signals with an insignificant
Log2 fold change are depicted with a grey scale. The third column of the heatmap depicts the Log2
fold change of the cells infected with the C/EBPβ LAP isoform ("LAP") versus the cells infected with
the LAP* isoform ("LAP*"). Proteins that were detected with a significant log2 fold change of ≥ 1
after LAP infection compared to the LAP* isoform are depicted with a yellow scale. Proteins detected
with a Log2 fold change of ≤ −1) after LAP* infection are depicted with a blue scale. Protein signals
with an insignificant Log2 fold change are depicted with a grey scale.
Supplemental Table S1: The table on the following pages (pages 125-137) itemizes the protein-
interactions of C/EBPβ that were detected in the analyzed leukemia cell lines by IP-MS and by
APS as well as the log10 of iBAQ intensity from iBAQ quantification of SU-DHL-1 cells (column 3).
Immunoprecipitations of endogenous C/EBPβ (with an anti-C/EBPβ antibody) from whole cell lysates
of U937, JEKO-1, HL60 and SU-DHL-1 and from nuclear enriched lysates of OPM2 and SU-DHL-1
cells (colunm 7-12) were prepared as triplicates and were analyzed by shotgun mass spectrometry
(Günther Kahlert, MDC) using a label-free quantification approach (Hubner and Mann, 2011; vide
material and methods section). The APS was performed by hybridization of C/EBPβ peptides
covering the conserved regions of C/EBPβ and ε (CR1-7; comprising the transactivation domain
(TAD) and regulatory domain (RD), but not the basic zipper domain (bZIP)) to UniPEx-peptide
macroarrays (colunm 13-17) . Peptides of murine C/EBPβ TAD (CR1-2, aa1-41), (CR3, aa49-72),
and murine C/EBPβ RD (N-terminal part of CR7, aa153-173), (mixture of CR4-5, aa79-111; CR 6-7,
aa128-172; CR 7 aa152-196), and murine C/EBPε TAD (CR2-4, aa1-61) were used for APS (vide
Material and methods section).
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UniProt 
AC
RefSeq ID 
UniPEx-
library Name
HL60 
[whole 
cell 
lysate]
JEKO-1 
[whole 
cell 
lysate]
OPM2 
[nuclear 
enriched 
lysate]
U937 
[whole 
cell 
lysate]
SU-DHL-1 
[ whole 
cell lysate]
SU-DHL-1 
[nuclear 
enriched 
lysate]
C/EBP  
aa1-41 
[CR1-2]
C/EBP  
aa1-62 
[CR2-4] 
C/EBP  
aa49-72 
[CR3]
C/EBP  
aa153-
173 
[CR7]
C/EBP  
aa79-196 
[CR4-7]
P17676 - 7.5900 CEBPB TCF5 - Co-IP Co-IP Co-IP Co-IP Co-IP Co-IP 0 0 0 0 0
Q9H0C8 - 7.1884 ILKAP - - Co-IP Co-IP Co-IP Co-IP Co-IP Co-IP 0 0 0 0 0
O14980 - 8.0217 XPO1 CRM1 - 0 Co-IP Co-IP Co-IP Co-IP Co-IP 0 0 0 0 0
P13010 - 8.6857 XRCC5 G22P2 - 0 Co-IP Co-IP 0 Co-IP Co-IP 0 0 0 0 0
Q92733 - 6.8760 PRCC TPRC - 0 0 Co-IP 0 Co-IP Co-IP 0 0 0 0 0
P26641 - 8.6992 EF1G EEF1G - Co-IP Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0
E9PRY8 - 8.1325 E9PRY8 EEF1D - 0 Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0
P12956 - 8.8269 XRCC6 G22P1 - 0 Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0
P78527 - 8.0827 PRKDC HYRC - 0 Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0
O43175 - 8.2946 SERA PHGDH PGDH3 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P27708 - 7.8531 PYR1 CAD - 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P30153 - 8.0529 2AAA PPP2R1A - 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P32189 - 7.9368 GLPK GK - 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P35232 - 8.8204 PHB - - 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P40763 - 7.9850 STAT3 APRF - 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P42285 - 7.3458 SK2L2 SKIV2L2 KIAA0052 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P42704 - 8.1207 LPPRC LRPPRC LRP130 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P50991 - 8.5139 TCPD CCT4 CCTD 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
Q00610 - 8.2996 CLH1 CLTC CLH17 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
Q9Y5B9 - 7.9425 SP16H SUPT16H FACT140 0 0 0 0 Co-IP Co-IP 0 0 0 0 0
P11388 - 7.8618 TOP2A TOP2 - 0 0 0 Co-IP 0 Co-IP 0 0 0 0 0
P35659 - 8.1838 DEK - - 0 0 0 Co-IP 0 Co-IP 0 0 0 0 0
O43823 - 6.9873 AKAP8 AKAP95 - 0 Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0
P0C0L5 - - CO4B - - 0 Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0
Q7LBC6 - 6.6277 KDM3B JMJD1B - 0 Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0
P19338 - 8.8166 NUCL NCL - 0 0 Co-IP 0 0 Co-IP 0 0 0 0 0
P42166 - 7.9299 LAP2A TMPO LAP2 0 0 Co-IP 0 0 Co-IP 0 0 0 0 0
P49792 - 6.8798 RBP2 RANBP2 NUP358 0 0 Co-IP 0 0 Co-IP 0 0 0 0 0
Q9UKX7 - 7.0178 NUP50 NPAP60L - 0 0 Co-IP 0 0 Co-IP 0 0 0 0 0
O00299 - 8.8855 CLIC1 - G6 0 Co-IP 0 0 0 Co-IP 0 0 0 0 0
P12268 - 8.6713 IMDH2 IMPDH2 IMPD2 0 Co-IP 0 0 0 Co-IP 0 0 0 0 0
P22102 - 8.1383 PUR2 GART PGFT 0 Co-IP 0 0 0 Co-IP 0 0 0 0 0
P62195 - 8.1190 PRS8 PSMC5 SUG1 0 Co-IP 0 0 0 Co-IP 0 0 0 0 0
Q13200 - 8.0567 PSMD2 TRAP2 - 0 Co-IP 0 0 0 Co-IP 0 0 0 0 0
O95347 - 7.5986 SMC2 CAPE - Co-IP 0 0 0 0 Co-IP 0 0 0 0 0
Q9UJZ1 - 8.3277 STML2 STOML2 SLP2 Co-IP 0 0 0 0 Co-IP 0 0 0 0 0
Q9H6Z4 - 7.3333 RANB3 RANBP3 - Co-IP Co-IP Co-IP Co-IP Co-IP 0 0 0 0 0 0
P62244 - 8.9113 RS15A RPS15A - Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9H8S9 - 7.4340 MOB1A C2orf6 - Co-IP 0 0 Co-IP Co-IP 0 0 0 0 0 0
P80303 - 7.4130 NUCB2 NEFA - Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q9BUL8 - 7.5315 PDC10 PDCD10 CCM3 Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q9NSP4 - - CENPM C22orf18 - Co-IP Co-IP 0 0 Co-IP 0 0 0 0 0 0
P11172 - 7.5503 UMPS - - Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
P19474 - - RO52 TRIM21 RNF81 Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
P55060 - 8.2769 XPO2 CSE1L CAS Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
Q8TCG1 - 6.5320 CIP2A KIAA1524 - Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
Q99623 - 8.6230 PHB2 BAP - Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
Q9Y4R8 - 6.3775 TELO2 KIAA0683 - Co-IP 0 0 0 Co-IP 0 0 0 0 0 0
B4DLZ8 - - B4DLZ8 - - Co-IP 0 0 Co-IP 0 0 0 0 0 0 0
Q8N392 - - RHG18 - - Co-IP 0 0 Co-IP 0 0 0 0 0 0 0
Q96AX1 - 5.0024 VP33A VPS33A - Co-IP 0 0 Co-IP 0 0 0 0 0 0 0
Q9UK61 - 5.9612 F208A FAM208A C3orf63 Co-IP 0 0 Co-IP 0 0 0 0 0 0 0
P62805 - 10.1851 H4 HIST1H4A H4/A Co-IP 0 Co-IP 0 0 0 0 0 0 0 0
B8ZZN6 - 7.8841 B8ZZN6 SUMO1 - Co-IP Co-IP 0 0 0 0 0 0 0 0 0
Q96N11 - 5.6972 CG026 C7orf26 - Co-IP Co-IP 0 0 0 0 0 0 0 0 0
Q9H9Q4 - 5.9103 NHEJ1 XLF - 0 Co-IP 0 Co-IP Co-IP 0 0 0 0 0 0
B7Z5E3 - - B7Z5E3 - - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
D3DUS9 - - D3DUS9 DNM1L - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
O60711 - 6.7463 LPXN LDLP - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
O95684 - 7.1031 FR1OP FOP - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P04406 - 9.5663 G3P GAPDH GAPD 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P07737 - 9.1337 PROF1 PFN1 - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P24534 - 8.2158 EF1B EEF1B2 EEF1B 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P41250 - 8.3967 SYG GARS - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P49720 - 8.5113 PSB3 PSMB3 - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P62306 - 8.7701 RUXF SNRPF PBSCF 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
P62937 - 9.3061 PPIA CYPA - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q86UY3 - - Q86UY3 - - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q96JB2 - 6.1842 COG3 SEC34 - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q9UBT2 - 7.9537 SAE2 UBA2 - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
Q9UQ13 - 5.8638 SHOC2 KIAA0862 - 0 Co-IP 0 0 Co-IP 0 0 0 0 0 0
A6NHB5 - 5.0052 A6NHB5 - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
B5M451 - - B5M451 - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
D3DPG0 - - D3DPG0 - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
P42694 - - HELZ - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
P53990 - 6.7855 IST1 - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
Q5JTZ9 - 5.7636 SYAM - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
Q7Z351 - - Q7Z351 - - 0 Co-IP 0 Co-IP 0 0 0 0 0 0 0
P46060 - 7.5258 RAGP1 RANGAP1 KIAA1835 0 0 Co-IP 0 Co-IP 0 0 0 0 0 0
Q12905 - 8.6838 ILF2 NF45 - 0 0 Co-IP 0 Co-IP 0 0 0 0 0 0
Q9NYL4 - 7.8137 FKB11 FKBP11 FKBP19 0 0 Co-IP 0 Co-IP 0 0 0 0 0 0
O43156 - 6.9478 TTI1 - - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
P33121 - - ACSL1 FACL1 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
P46459 - 7.3631 NSF - - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
P55160 - 6.3735 NCKPL NCKAP1L HEM1 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q13724 - 7.4045 MOGS GCS1 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q5VYK3 - - ECM29 KIAA0368 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q96ER3 - 6.9216 SAAL1 - - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q96QU8 - - XPO6 KIAA0370 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9BVI4 - 7.0331 NOC4L - - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9BXW9 - 6.4636 FACD2 FANCD2 FACD 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
IP-MS APS
Synonyms
iBAQ 
[log10 of 
iBAQ 
intensity] 
SU-DHL-1
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UniProt 
AC
RefSeq ID 
UniPEx-
library Name
HL60 
[whole 
cell 
lysate]
JEKO-1 
[whole 
cell 
lysate]
OPM2 
[nuclear 
enriched 
lysate]
U937 
[whole 
cell 
lysate]
SU-DHL-1 
[ whole 
cell lysate]
SU-DHL-1 
[nuclear 
enriched 
lysate]
C/EBP  
aa1-41 
[CR1-2]
C/EBP  
aa1-62 
[CR2-4] 
C/EBP  
aa49-72 
[CR3]
C/EBP  
aa153-
173 
[CR7]
C/EBP  
aa79-196 
[CR4-7]
IP-MS APS
Synonyms
Q9BZZ5 - 7.7939 API5 MIG8 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9NV70 - 6.4473 EXOC1 SEC3 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9UBB9 - 5.9354 TFP11 TFIP11 STIP 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
Q9Y6E2 - 7.6163 BZW2 HSPC028 - 0 0 0 Co-IP Co-IP 0 0 0 0 0 0
P26640 - - SYVC VARS G7A 0 Co-IP 0 0 Co-IP Co-IP direct interact. 0 0 0 0
Q08211 AK226102 8.4041 DHX9 DDX9 - 0 0 0 0 Co-IP Co-IP direct interact. direct interact. direct interact. direct interact. direct interact.
P52272 NM_005968 8.5349 HNRPM HNRNPM - 0 0 Co-IP 0 0 Co-IP direct interact. 0 direct interact. 0 0
P13639 NM_001961 8.8879 EF2 EEF2 - 0 0 0 0 Co-IP Co-IP 0 0 direct interact. 0 0
P04843 NM_002950 8.3652 RPN1 - - 0 0 Co-IP 0 0 Co-IP 0 0 direct interact. 0 0
Q3KQU3 AB033013 6.0916 MA7D1 MAP7D1 KIAA1187 Co-IP 0 0 0 0 0 0 direct interact. direct interact. 0 0
Q8TB61 NM_178148 6.7538 S35B2 SLC35B2 PAPST1 Co-IP 0 0 0 0 0 0 0 direct interact. 0 0
B4DG73 - - B4DG73 - - Co-IP 0 0 0 0 0 0 0 0 0 0
B4DGT3 - - B4DGT3 - - Co-IP 0 0 0 0 0 0 0 0 0 0
B4DR61 - 7.2195 B4DR61 - - Co-IP 0 0 0 0 0 0 0 0 0 0
B7Z3B7 - - B7Z3B7 - - Co-IP 0 0 0 0 0 0 0 0 0 0
O00541 - 7.4675 PESC PES1 - Co-IP 0 0 0 0 0 0 0 0 0 0
O14949 - 7.5219 QCR8 UQCRQ - Co-IP 0 0 0 0 0 0 0 0 0 0
O75190 - - DNJB6 - - Co-IP 0 0 0 0 0 0 0 0 0 0
O75306 - 7.3115 NDUS2 NDUFS2 - Co-IP 0 0 0 0 0 0 0 0 0 0
O94927 - 6.1444 HAUS5 - - Co-IP 0 0 0 0 0 0 0 0 0 0
P00367 - 8.6122 DHE3 GLUD1 GLUD Co-IP 0 0 0 0 0 0 0 0 0 0
P05107 - - ITB2 ITGB2 CD18 Co-IP 0 0 0 0 0 0 0 0 0 0
P0C0S8 - - H2A1 H2AFP - Co-IP 0 0 0 0 0 0 0 0 0 0
P10606 - 7.4973 COX5B - - Co-IP 0 0 0 0 0 0 0 0 0 0
P11279 - 7.5957 LAMP1 - - Co-IP 0 0 0 0 0 0 0 0 0 0
P12004 - 8.0876 PCNA - - Co-IP 0 0 0 0 0 0 0 0 0 0
P28482 - 7.5406 MK01 MAPK1 ERK2 Co-IP 0 0 0 0 0 0 0 0 0 0
P32780 - 6.3460 TF2H1 GTF2H1 - Co-IP 0 0 0 0 0 0 0 0 0 0
P43246 - 7.5119 MSH2 - - Co-IP 0 0 0 0 0 0 0 0 0 0
P48378 - - RFX2 - - Co-IP 0 0 0 0 0 0 0 0 0 0
P51809 - - VAMP7 SYBL1 - Co-IP 0 0 0 0 0 0 0 0 0 0
P62277 - 8.9080 RS13 RPS13 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q02978 - 7.5380 M2OM SLC25A11 SLC20A4 Co-IP 0 0 0 0 0 0 0 0 0 0
Q07812 - 7.8180 BAX BCL2L4 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q13576 - - IQGA2 IQGAP2 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q14191 - 5.7970 WRN RECQ3 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q14739 - 7.6779 LBR - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q15080 - - NCF4 SH3PXD4 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q15819 - 7.7901 UB2V2 UBE2V2 MMS2 Co-IP 0 0 0 0 0 0 0 0 0 0
Q15907 - 8.1941 RB11B RAB11B YPT3 Co-IP 0 0 0 0 0 0 0 0 0 0
Q27J81 - 5.3039 INF2 C14orf151 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q546F9 - - Q546F9 - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q5BJF2 - - TMM97 TMEM97 MAC30 Co-IP 0 0 0 0 0 0 0 0 0 0
Q5JTV8 - 7.8452 TOIP1 TOR1AIP1 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q6B6N3 - - Q6B6N3 - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q6P9B9 - 6.2978 INT5 INTS5 KIAA1698 Co-IP 0 0 0 0 0 0 0 0 0 0
Q6UW68 - 7.0464 TM205 TMEM205 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q7RTS9 - 6.0730 DYM - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q86TP1 - 6.4830 PRUNE - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q86VR2 - 7.1670 F134C FAM134C - Co-IP 0 0 0 0 0 0 0 0 0 0
Q86WB0 - 6.4909 NIPA ZC3HC1 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q8NEM7 - - SP20H - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q8TDZ2 - - MICA1 MICAL1 MICAL Co-IP 0 0 0 0 0 0 0 0 0 0
Q8TEX9 - 7.4716 IPO4 IMP4B - Co-IP 0 0 0 0 0 0 0 0 0 0
Q969X0 - - RIPL2 RILPL2 RLP2 Co-IP 0 0 0 0 0 0 0 0 0 0
Q96AN2 - 6.8618 Q96AN2 NRF1 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q96DZ1 - 6.0765 ERLEC ERLEC1 C2orf30 Co-IP 0 0 0 0 0 0 0 0 0 0
Q96HY6 - 7.1156 DDRGK DDRGK1 C20orf116 Co-IP 0 0 0 0 0 0 0 0 0 0
Q9BTC0 - 6.2940 DIDO1 C20orf158 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9H836 - - Q9H836 - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9H9B4 - 8.2961 SFXN1 - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9NRK6 - 6.3375 ABCBA ABCB10 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9NRP0 - 7.1681 OSTC DC2 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9NV66 - 6.1987 TYW1 RSAFD1 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9UKE5 - - TNIK - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y228 - - T3JAM TRAF3IP3 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y277 - - VDAC3 - - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y282 - - ERGI3 ERGIC3 C20orf47 Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y3Q3 - - TMED3 C15orf22 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y3T9 - 7.2186 NOC2L NIR - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y4P3 - 6.7928 TBL2 WBSCR13 - Co-IP 0 0 0 0 0 0 0 0 0 0
Q9Y5Y5 - 5.9031 PEX16 - - Co-IP 0 0 0 0 0 0 0 0 0 0
P06733 AL833741 9.3449 ENOA ENO1 ENO1L1 0 Co-IP 0 0 0 0 direct interact. 0 direct interact. 0 0
P29558 NM_016839 6.9589 RBMS1 C2orf12 - 0 Co-IP 0 0 0 0 direct interact. 0 direct interact. 0 0
P23588 NM_001417 - IF4B - - 0 Co-IP 0 0 0 0 0 0 direct interact. 0 0
Q9NY61 NM_012138 7.7516 AATF CHE1 - 0 Co-IP 0 0 0 0 0 0 0 direct interact. 0
A8MQB6 - - A8MQB6 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
B3KSH1 - 8.3032 B3KSH1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
B3V096 - - B3V096 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
B4DF70 - - B4DF70 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
B5MDF5 - 9.0468 B5MDF5 RAN - 0 Co-IP 0 0 0 0 0 0 0 0 0
O15145 - 7.8994 ARPC3 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
O43681 - 7.7166 ASNA - - 0 Co-IP 0 0 0 0 0 0 0 0 0
O75431 - 7.5319 MTX2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
O75531 - 8.4100 BAF - - 0 Co-IP 0 0 0 0 0 0 0 0 0
O94925 - 7.0974 GLSK - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P00491 - 8.5555 PNPH - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P00558 - 8.9335 PGK1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P04075 - 9.1471 ALDOA - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P04083 - 8.7710 ANXA1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P06737 - 8.3841 PYGL - - 0 Co-IP 0 0 0 0 0 0 0 0 0
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P06744 - 8.9083 G6PI - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P07195 - 8.9149 LDHB - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P08243 - 7.7987 ASNS - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P08865 - 8.7790 RSSA RPSA - 0 Co-IP 0 0 0 0 0 0 0 0 0
P15311 - 7.6361 EZRI - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P15408 - 7.2466 FOSL2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P18583 - 7.0724 SON - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P18669 - 8.9269 PGAM1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P25786 - 8.3825 PSA1 PSMA1 - 0 Co-IP 0 0 0 0 0 0 0 0 0
P30419 - 8.1241 NMT1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P30740 - 8.8102 ILEU - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P33991 - 7.7942 MCM4 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P35244 - 7.8212 RFA3  RPA3 - 0 Co-IP 0 0 0 0 0 0 0 0 0
P49588 - 7.8792 SYAC - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P50579 - 7.3099 MAP2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P52209 - 8.2765 6PGD - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P55010 - 7.9429 IF5 eIF5 - 0 Co-IP 0 0 0 0 0 0 0 0 0
P55786 - 8.0811 PSA - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P83436 - 6.0419 COG7 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P99999 - 8.9317 CYC - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q01105 - 8.4653 SET - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q06830 - 8.8777 PRDX1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q07617 - - SPAG1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q08J23 - 7.8352 NSUN2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q13144 - 7.1162 EI2BE - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q13618 - 7.1829 CUL3 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q14746 - 6.0859 COG2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q15102 - 8.5729 PA1B3 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q15181 - 8.6352 IPYR - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q16401 - 7.5026 PSMD5 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q32Q12 - 8.8573 Q32Q12 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q3B7T1 - - EDRF1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q59GX2 - - Q59GX2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q6ICB0 - - DESI1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q6KC79 - 5.7978 NIPBL - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q70UQ0 - 7.0012 IKIP - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q71RC2 - 6.2261 LARP4 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q7Z2W7 - - TRPM8 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q7Z7G8 - - VP13B - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8IU60 - - DCP2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8IY67 - 6.1188 RAVR1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8N6G5 - 6.3463 CGAT2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8NBS9 - 7.8742 TXND5 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8NI22 - 7.0737 MCFD2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q8WXH0 - 5.2997 SYNE2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9BS26 - 7.6013 ERP44 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9BVA0 - - KTNB1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9BZF1 - 6.7799 OSBL8 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9H0E9 - - BRD8 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9H0S4 - 7.4640 DDX47 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9H270 - 6.2231 VPS11 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9H2K8 - 6.0370 TAOK3 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9NR12 - 7.0860 PDLI7 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9NVU0 - 5.8427 RPC5 POLR3E - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9NXR7 - 7.2440 BRE - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9NXW1 - - Q9NXW1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9P2G1 - - AKIB1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9UI10 - 7.2696 EI2BD - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9UIA0 - - CYH4 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9UJX5 - - APC4 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9UQ80 - 8.6168 PA2G4 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9Y265 - 8.4005 RUVB1 RUVBL1 - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9Y2R4 - 7.1330 DDX52 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9Y333 - 8.2776 LSM2 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
Q9Y3D6 - 7.7176 FIS1 - - 0 Co-IP 0 0 0 0 0 0 0 0 0
P33176 NM_004521 7.4971 KINH KIF5B KNS 0 0 0 0 0 Co-IP direct interact. direct interact. 0 direct interact. 0
P62987 NM_001033930 - RL40 UBA52 UBCEP2 0 0 0 0 0 Co-IP direct interact. direct interact. 0 direct interact. 0
P61978 NM_002140 8.5239 HNRPK HNRNPK - 0 0 0 0 0 Co-IP direct interact. 0 direct interact. direct interact. 0
P35579 NM_002473 7.9494 MYH9 - - 0 0 0 0 0 Co-IP direct interact. 0 0 direct interact. direct interact.
P07910 BC103758 8.8378 HNRPC HNRNPC - 0 0 0 0 0 Co-IP direct interact. 0 0 direct interact. 0
P27635 NM_006013 8.9099 RL10 RPL10 - 0 0 0 0 0 Co-IP direct interact. 0 0 direct interact. 0
P18847 NM_001040619 - ATF3 - - 0 0 0 0 0 Co-IP direct interact. 0 0 0 0
P21333 X53416 7.9224 FLNA FLN - 0 0 0 0 0 Co-IP direct interact. 0 0 0 0
P30626 NM_003130 8.7059 SORCN SRI - 0 0 0 0 0 Co-IP direct interact. 0 0 0 0
Q8TEM1 NM_024923 7.4334 PO210 NUP210 KIAA0906 0 0 0 0 0 Co-IP direct interact. 0 0 0 0
Q00839 NM_031844 8.6520 HNRPU HNRNPU - 0 0 0 0 0 Co-IP 0 direct interact. direct interact. direct interact. 0
P09651 NM_031157 9.2385 ROA1 HNRPA1 - 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
P11021 NM_005347 8.9411 GRP78 HSPA5 - 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
P11142 NM_006597 9.0335 HSP7C HSPA8 HSC70 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
P21796 AK122953 8.7486 VDAC1 VDAC - 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
P30101 NM_005313 8.8459 PDIA3 ERP57 - 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
Q14152 NM_003750 7.7567 EIF3A EIF3S10 - 0 0 0 0 0 Co-IP 0 0 direct interact. 0 0
Q13151 NM_006805 8.4866 ROA0 HNRNPA0 HNRPA0 0 0 0 0 0 Co-IP 0 0 0 direct interact. 0
A8MXP9 - 8.3681 A8MXP9 MATR3 - 0 0 0 0 0 Co-IP 0 0 0 0 0
B3KTC7 - 7.2817 B3KTC7 MRE11A - 0 0 0 0 0 Co-IP 0 0 0 0 0
E7ENR4 - - E7ENR4 HK1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
F5H2F4 - 6.3998 F5H2F4 MTHFD1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
G8JLB6 - 8.3817 G8JLB6 HNRNPH1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
H3BLZ8 - - H3BLZ8 DDX17 - 0 0 0 0 0 Co-IP 0 0 0 0 0
H3BPE7 - 8.1516 H3BPE7 FUS - 0 0 0 0 0 Co-IP 0 0 0 0 0
J3KPX7 - - J3KPX7 PHB2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
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J3KQ73 - 7.8794 J3KQ73 FKBP8 - 0 0 0 0 0 Co-IP 0 0 0 0 0
J9JID7 - 7.6930 J9JID7 LMNB2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
M0R0R2 - - M0R0R2 RPS5 - 0 0 0 0 0 Co-IP 0 0 0 0 0
O00567 - 8.2986 NOP56 NOL5A - 0 0 0 0 0 Co-IP 0 0 0 0 0
O00571 - 8.1034 DDX3X DBX - 0 0 0 0 0 Co-IP 0 0 0 0 0
O14776 - 7.5497 TCRG1 TCERG1 CA150 0 0 0 0 0 Co-IP 0 0 0 0 0
O43684 - 7.7139 BUB3 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
O60264 - 7.5611 SMCA5 SMARCA5 SNF2H 0 0 0 0 0 Co-IP 0 0 0 0 0
O75400 - 7.4539 PR40A FBP11 - 0 0 0 0 0 Co-IP 0 0 0 0 0
O75475 - 7.6965 PSIP1 DFS70 - 0 0 0 0 0 Co-IP 0 0 0 0 0
O75533 - 8.0133 SF3B1 SAP155 - 0 0 0 0 0 Co-IP 0 0 0 0 0
O75643 - 7.7762 U520 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
O94776 - 7.2959 MTA2 MTA1L1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
O94906 - 7.1980 PRP6 PRPF6 C20orf14 0 0 0 0 0 Co-IP 0 0 0 0 0
P02786 - 8.3614 TFR1 TFRC - 0 0 0 0 0 Co-IP 0 0 0 0 0
P05114 - 7.9492 HMGN1 HMG14 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P05141 - 8.6246 ADT2 SLC25A5 ANT2 0 0 0 0 0 Co-IP 0 0 0 0 0
P05455 - 8.3147 LA SSB - 0 0 0 0 0 Co-IP 0 0 0 0 0
P06576 - 8.7587 ATPB ATP5B ATPMB 0 0 0 0 0 Co-IP 0 0 0 0 0
P07814 - 7.8517 SYEP EPRS GLNS 0 0 0 0 0 Co-IP 0 0 0 0 0
P08107 - 9.1218 HSP71 HSPA1A HSPA1 0 0 0 0 0 Co-IP 0 0 0 0 0
P08621 - 8.2245 RU17 RNPU1Z - 0 0 0 0 0 Co-IP 0 0 0 0 0
P09429 - 8.9782 HMGB1 HMG1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P09661 - 8.2094 RU2A SNRPA1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P09874 - 8.3864 PARP1 ADPRT - 0 0 0 0 0 Co-IP 0 0 0 0 0
P10809 - 9.2729 CH60 HSPD1 HSP60 0 0 0 0 0 Co-IP 0 0 0 0 0
P11387 - 8.2252 TOP1 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
P12270 - 7.5366 TPR  Megator - 0 0 0 0 0 Co-IP 0 0 0 0 0
P14625 - 8.6960 ENPL GRP94 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P14866 - 8.8144 HNRPL HNRNPL - 0 0 0 0 0 Co-IP 0 0 0 0 0
P16220 - 7.2644 CREB1 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
P17844 - - DDX5 G17P1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P17987 - 8.4731 TCPA TCP1 CCT1 0 0 0 0 0 Co-IP 0 0 0 0 0
P18754 - 7.7185 RCC1 CHC1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P20700 - 8.5378 LMNB1 LMN2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P22695 - 8.1384 QCR2 UQCRC2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P23193 - 8.2005 TCEA1 GTF2S - 0 0 0 0 0 Co-IP 0 0 0 0 0
P24539 - 8.0119 AT5F1 ATP5F1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P31939 - 8.5118 PUR9 ATIC PURH 0 0 0 0 0 Co-IP 0 0 0 0 0
P35251 - 6.7624 RFC1 RFC140 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P38159 - 8.2315 RBMX HNRPG - 0 0 0 0 0 Co-IP 0 0 0 0 0
P38646 - 8.8713 GRP75 HSPA9 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P38919 - 8.2801 IF4A3 EIF4A3 DDX48 0 0 0 0 0 Co-IP 0 0 0 0 0
P39687 - 8.5587 AN32A ANP32A C15orf1 0 0 0 0 0 Co-IP 0 0 0 0 0
P40939 - 8.0267 ECHA HADHA HADH 0 0 0 0 0 Co-IP 0 0 0 0 0
P42167 - 7.6168 LAP2B TMPO LAP2 0 0 0 0 0 Co-IP 0 0 0 0 0
P45880 - 8.5352 VDAC2 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
P46013 - 6.8371 KI67 MKI67 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P48643 - 8.5240 TCPE CCT5 CCTE 0 0 0 0 0 Co-IP 0 0 0 0 0
P49368 - 8.5472 TCPG CCT3 CCTG 0 0 0 0 0 Co-IP 0 0 0 0 0
P50990 - 8.7306 TCPQ CCT8 C21orf112 0 0 0 0 0 Co-IP 0 0 0 0 0
P51148 - 8.4868 RAB5C RABL - 0 0 0 0 0 Co-IP 0 0 0 0 0
P51572 - 7.8745 BAP31 BCAP31 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P51608 - 6.8308 MECP2 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
P51991 - 8.4869 ROA3 HNRNPA3 HNRPA3 0 0 0 0 0 Co-IP 0 0 0 0 0
P60468 - 7.8280 SC61B SEC61B - 0 0 0 0 0 Co-IP 0 0 0 0 0
P60842 - 8.8379 IF4A1 EIF4A1 DDX2A 0 0 0 0 0 Co-IP 0 0 0 0 0
P61221 - 7.9643 ABCE1 RLI - 0 0 0 0 0 Co-IP 0 0 0 0 0
P61981 - 8.5366 1433G YWHA - 0 0 0 0 0 Co-IP 0 0 0 0 0
P62081 - 9.0781 RS7 RPS7 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P62263 - 9.1293 RS14 RPS14 PRO2640 0 0 0 0 0 Co-IP 0 0 0 0 0
P78371 - 8.6480 TCPB CCT2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
P84103 - 8.6480 SRSF3 SFRS3 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q01780 - 7.0423 EXOSX EXOSC10 PMSCL 0 0 0 0 0 Co-IP 0 0 0 0 0
Q13423 - 7.2995 NNTM NNT - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q13950 - - RUNX2 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q14204 - 7.7668 DYHC1 DYNC1H1 DHC1 0 0 0 0 0 Co-IP 0 0 0 0 0
Q14683 - 6.9590 SMC1A DXS423E - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q14839 - 7.5089 CHD4 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q14974 - 8.6996 IMB1 KPNB1 NTF97 0 0 0 0 0 Co-IP 0 0 0 0 0
Q15149 - 7.1737 PLEC PLEC1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q15365 - 8.3672 PCBP1 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q15459 - 7.7969 SF3A1 SAP114 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q16649 - 6.8000 NFIL3 E4BP4 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q16666 - 8.0618 IF16 IFI16 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q16891 - 7.8753 MIC60 IMMT HMP 0 0 0 0 0 Co-IP 0 0 0 0 0
Q5UIP0 - 6.6469 RIF1 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q6P2Q9 - 7.6838 PRP8 PRPF8 PRPC8 0 0 0 0 0 Co-IP 0 0 0 0 0
Q7L014 - 7.6680 DDX46 KIAA0801 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q8N163 - 7.5161 CCAR2 DBC1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q8N1F7 - 7.5658 NUP93 KIAA0095 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q8N5K1 - 7.7667 CISD2 CDGSH2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q92522 - 7.9290 H1X H1FX - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q92922 - 6.9859 SMRC1 SMARCC1 BAF155 0 0 0 0 0 Co-IP 0 0 0 0 0
Q92945 - 8.0816 FUBP2 KHSRP - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q92973 - 7.7489 TNPO1 KPNB2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q99459 - 7.5146 CDC5L KIAA0432 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9BQG0 - 7.5587 MBB1A MYBBP1A P160 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9H3N1 - 8.2156 TMX1 TMX - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9HBD4 - 6.9299 Q9HBD4 SMARCA4 BRG1 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9NR30 - 8.4495 DDX21 - - 0 0 0 0 0 Co-IP 0 0 0 0 0
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Q9UBE0 - 8.0953 SAE1 AOS1 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9UKM9 - - RALY HNRPCL2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9UM73 - 7.8718 ALK - - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9Y2X3 - 8.1875 NOP58 NOL5 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9Y383 - 7.7274 LC7L2 LUC7L2 - 0 0 0 0 0 Co-IP 0 0 0 0 0
Q9Y678 NM_016128 7.8706 COPG1 COPG - 0 0 0 0 Co-IP 0 direct interact. 0 direct interact. 0 0
O95983 NM_003926 6.5042 MBD3 - - 0 0 0 0 Co-IP 0 direct interact. 0 0 direct interact. 0
P68104 - 9.2142 EF1A1 EEF1A1 EEF1A 0 0 0 0 Co-IP 0 direct interact. 0 0 0 0
Q92556 AL136787 7.0135 ELMO1 KIAA0281 - 0 0 0 0 Co-IP 0 direct interact. 0 0 0 0
Q9Y2X0 AF106934 5.9797 MED16 DRIP92 - 0 0 0 0 Co-IP 0 direct interact. 0 0 0 0
Q14008 NM_001008938 7.1800 CKAP5 KIAA0097 - 0 0 0 0 Co-IP 0 0 direct interact. 0 0 0
Q92616 NM_006836 7.5075 GCN1L GCN1L1 KIAA0219 0 0 0 0 Co-IP 0 0 direct interact. 0 0 0
P22670 NM_002918 6.8528 RFX1 - - 0 0 0 0 Co-IP 0 0 0 direct interact. 0 0
Q5GLZ8 NM_022079 6.7220 HERC4 KIAA1593 - 0 0 0 0 Co-IP 0 0 0 direct interact. 0 0
A5YKK6 - 6.9198 CNOT1 CDC39 - 0 0 0 0 Co-IP 0 0 0 0 0 0
A8K0K1 - - A8K0K1 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
A8K8W9 - - A8K8W9 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B3KT11 - - B3KT11 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DEA8 - - B4DEA8 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DJ38 - - B4DJ38 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DJV9 - - B4DJV9 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DLV7 - - B4DLV7 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DQX2 - - B4DQX2 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DSU8 - - B4DSU8 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DTS2 - - B4DTS2 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DU42 - - B4DU42 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B4DZ73 - - B4DZ73 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
B7Z7L3 - - B7Z7L3 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
C9J4C3 - - C9J4C3 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
C9JI13 - - C9JI13 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
C9JI70 - - C9JI70 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
O00178 - 7.1738 GTPB1 GTPBP1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O00762 - 6.5299 UBE2C UBCH10 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O14893 - - GEMI2 GEMIN2 SIP1 0 0 0 0 Co-IP 0 0 0 0 0 0
O14981 - 5.8696 BTAF1 TAF172 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O15111 - 6.2621 IKKA CHUK - 0 0 0 0 Co-IP 0 0 0 0 0 0
O15260 - 8.4156 SURF4 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
O43143 - 8.1480 DHX15 DBP1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O43264 - 6.8555 ZW10 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
O43615 - 7.6814 TIM44 TIMM44 MIMT44 0 0 0 0 Co-IP 0 0 0 0 0 0
O43929 - - ORC4 ORC4L - 0 0 0 0 Co-IP 0 0 0 0 0 0
O60443 - 7.3314 DFNA5 ICERE1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O60613 - 7.0594 41897 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
O60749 - 7.4188 SNX2 TRG9 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O75494 - 7.9445 SRS10 SRSF10 FUSIP1 0 0 0 0 Co-IP 0 0 0 0 0 0
O75955 - 8.2233 FLOT1 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
O95372 - - LYPA2 LYPLA2 APT2 0 0 0 0 Co-IP 0 0 0 0 0 0
O95487 - - SC24B SEC24B - 0 0 0 0 Co-IP 0 0 0 0 0 0
O96005 - 7.3051 CLPT1 CLPTM1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
O96008 - 8.4218 TOM40 TOMM40 C19orf1 0 0 0 0 Co-IP 0 0 0 0 0 0
P05388 - 8.8975 RLA0 RPLP0 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P0CB44 - - SKA2L - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P11177 - 7.9089 ODPB PHE1B - 0 0 0 0 Co-IP 0 0 0 0 0 0
P23258 - 7.3651 TBG1 TUBG1 TUBG 0 0 0 0 Co-IP 0 0 0 0 0 0
P26196 - 7.8555 DDX6 HLR2 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P27694 - 7.7242 RFA1 RPA1 REPA1 0 0 0 0 Co-IP 0 0 0 0 0 0
P40616 - 7.4741 ARL1 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P40692 - 5.8790 MLH1 COCA2 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P42345 - 6.0189 MTOR FRAP - 0 0 0 0 Co-IP 0 0 0 0 0 0
P42695 - 6.1419 CNDD3 NCAPD3 CAPD3 0 0 0 0 Co-IP 0 0 0 0 0 0
P42771 - 7.3792 CD2A1 p16 CDKN2A 0 0 0 0 Co-IP 0 0 0 0 0 0
P43490 - 9.1935 NAMPT PBEF - 0 0 0 0 Co-IP 0 0 0 0 0 0
P49411 - 8.4337 EFTU TUFM - 0 0 0 0 Co-IP 0 0 0 0 0 0
P49643 - 7.3657 PRI2 PRIM2 PRIM2A 0 0 0 0 Co-IP 0 0 0 0 0 0
P49756 - 7.5260 RBM25 RNPC7 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P50748 - 5.8816 KNTC1 KIAA0166 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P51571 - 7.7945 SSRD SSR4 TRAPD 0 0 0 0 Co-IP 0 0 0 0 0 0
P51812 - 7.8994 KS6A3 RPS6KA3 ISPK1 0 0 0 0 Co-IP 0 0 0 0 0 0
P51946 - - CCNH - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P53396 - 8.4787 ACLY - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P53621 - 7.7538 COPA - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P54886 - 7.7946 P5CS ALDH18A1 GSAS 0 0 0 0 Co-IP 0 0 0 0 0 0
P55957 - 7.8724 BID - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P61019 - 7.7870 RAB2A RAB2 - 0 0 0 0 Co-IP 0 0 0 0 0 0
P61106 - 7.8971 RAB14 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P62140 - 7.0172 PP1B PPP1CB - 0 0 0 0 Co-IP 0 0 0 0 0 0
P62312 - 7.9051 LSM6 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
P63208 - 7.5148 SKP1 EMC19 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q00534 - 7.8883 CDK6 CDKN6 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q07960 - 7.2411 RHG01 ARHGAP1 CDC42GAP 0 0 0 0 Co-IP 0 0 0 0 0 0
Q12769 - 6.9414 NU160 NUP160 KIAA0197 0 0 0 0 Co-IP 0 0 0 0 0 0
Q12789 - 5.9314 TF3C1 GTF3C1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q13535 - 5.7407 ATR FRP1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q13868 - 7.1850 EXOS2 EXOSC2 RRP4 0 0 0 0 Co-IP 0 0 0 0 0 0
Q14166 - 7.5434 TTL12 TTLL12 KIAA0153 0 0 0 0 Co-IP 0 0 0 0 0 0
Q14254 - - FLOT2 ESA1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q14674 - - ESPL1 ESP1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q14697 - 8.3607 GANAB G2AN - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q15021 - 7.2261 CND1 NCAPD2 CAPD2 0 0 0 0 Co-IP 0 0 0 0 0 0
Q15126 - 7.3335 PMVK PMKI - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q15645 - 7.5911 PCH2 TRIP13 - 0 0 0 0 Co-IP 0 0 0 0 0 0
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Q5HY81 - - Q5HY81 UBL4A - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q5T4S7 - 6.9405 UBR4 KIAA0462 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q5VIR6 - 6.6225 VPS53 PP13624 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q66K14 - - TBC9B TBC1D9B KIAA0676 0 0 0 0 Co-IP 0 0 0 0 0 0
Q6YN16 - 7.0345 HSDL2 C9orf99 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7KZF4 - 7.9211 SND1 TDRD11 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7L2H7 - 8.1415 EIF3M HFLB5 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7Z3E5 - 5.5983 ARMC9 KIAA1868 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7Z4H7 - 6.3597 HAUS6 DGT6 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7Z6Z7 - 7.2223 HUWE1 KIAA0312 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q7Z7F5 - - Q7Z7F5 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8IU81 - 6.7595 I2BP1 IRF2BP1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8IZL8 - - PELP1 HMX3 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8N0X7 - 6.6067 SPG20 KIAA0610 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8N3C0 - 5.9154 ASCC3 HELIC1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8N3D4 - 5.3977 EH1L1 EHBP1L1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8TE02 - 6.3345 ELP5 C17orf81 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8WTW3 - 5.9911 COG1 KIAA1381 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q8WUX9 - 6.6172 CHMP7 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q92575 - 6.9097 UBXN4 KIAA0242 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q92608 - 7.0604 DOCK2 KIAA0209 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q92759 - 6.7907 TF2H4 GTF2H4 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q93008 - 6.6307 USP9X DFFRX - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q93034 - 6.8595 CUL5 VACM1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q93100 - 5.8963 KPBB PHKB - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96BY7 - - ATG2B C14orf103 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96H20 - 7.0328 SNF8 EAP30 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96JG6 - 6.2632 CC132 CCDC132 KIAA1861 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96KA5 - 7.2258 CLP1L CLPTM1L CRR9 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96P70 - 7.5440 IPO9 IMP9 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q96SN8 - - CK5P2 CEP215 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q99832 - 8.5071 TCPH CCT7 CCTH 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9BPX3 - 7.2037 CND3 NCAPG CAPG 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9BSJ8 - 7.3817 ESYT1 FAM62A - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9BTX7 - 6.2348 TTPAL C20orf121 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9BUQ0 - - Q9BUQ0 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9BW27 - 7.1505 NUP85 NUP75 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9C005 - 8.2500 DPY30 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9H0W8 - 6.3226 SMG9 C19orf61 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9H269 - 6.3655 VPS16 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9H4A6 - 6.7172 GOLP3 GOLPH3 GPP34 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9H4E7 - - DEFI6 DEF6 IBP 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9H9A6 - 7.0926 LRC40 LRRC40 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9HAU5 - 6.4215 RENT2 UPF2 KIAA1408 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9HAV4 - 7.4547 XPO5 KIAA1291 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9HCU5 - 7.0744 PREB SEC12 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9NQC7 - - CYLD CYLD1 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9NTJ3 - 7.3118 SMC4 CAPC - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9NVI1 - 6.7026 FANCI KIAA1794 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9P2A4 - 6.9038 ABI3 NESH - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UBB4 - 7.1520 ATX10 ATXN10 SCA10 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UBD5 - 6.8643 ORC3 LATHEO - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UBF2 - 7.2423 COPG2 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UHD2 - 6.7905 TBK1 NAK - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UI12 - 6.8282 VATH ATP6V1H - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UJY4 - 5.7374 GGA2 KIAA1080 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UKZ1 - 6.4089 CNO11 CNOT11 C2orf29 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UNQ2 - 7.7014 DIM1 DIMT1 DIMT1L 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9UNY4 - - TTF2 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9Y3I1 - 6.5433 FBX7 FBXO7 - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9Y5X2 - 6.3875 SNX8 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9Y679 - 6.7884 AUP1 - - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q9Y6J9 - 5.6499 TAF6L PAF65A - 0 0 0 0 Co-IP 0 0 0 0 0 0
Q99536 NM_006373 8.1292 VAT1 - - 0 0 0 Co-IP 0 0 0 0 direct interact. 0 0
P35268 NM_000983 8.9112 RL22 RPL22 - 0 0 0 Co-IP 0 0 0 0 0 direct interact. 0
A0JLT2 - 6.1788 MED19 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
A4D1P6 - - WDR91 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
A6NNN6 - - A6NNN6 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
A8K2S4 - - A8K2S4 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B4DMN1 - - B4DMN1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B4DN86 - - B4DN86 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B4DR52 - 9.5559 B4DR52 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B4DRD7 - - B4DRD7 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B4E1T5 - - B4E1T5 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B7Z2R8 - - B7Z2R8 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B8ZZ87 - 7.0705 B8ZZ87 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
B9EIQ6 - - B9EIQ6 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
C9JDG0 - - C9JDG0 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
O14497 - 6.0197 ARI1A BAF250 ARID1A 0 0 0 Co-IP 0 0 0 0 0 0 0
O15014 - - ZN609 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
O60341 - 6.7713 KDM1A LSD1 - 0 0 0 Co-IP 0 0 0 0 0 0 0
O60566 - - BUB1B  BUBR1 - 0 0 0 Co-IP 0 0 0 0 0 0 0
O60645 - 6.2066 EXOC3 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
O95163 - 7.0360 ELP1 IKBKAP - 0 0 0 Co-IP 0 0 0 0 0 0 0
P06493 - 7.4226 CDK1 CDC2 - 0 0 0 Co-IP 0 0 0 0 0 0 0
P07355 - 8.5841 ANXA2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P08574 - 7.9485 CY1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P09132 - 6.9514 SRP19 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P0C0S5 - 8.9918 H2AZ - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P17029 - 5.7225 ZKSC1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P19838 - 6.3254 NFKB1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
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P20292 - 7.7305 AL5AP - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P27986 - - P85A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P30050 - 8.6834 RL12 RPL12 - 0 0 0 Co-IP 0 0 0 0 0 0 0
P37108 - 8.8960 SRP14 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P39880 - 5.5297 CUX1  CUTL1 - 0 0 0 Co-IP 0 0 0 0 0 0 0
P40938 - 7.1797 RFC3 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P42575 - - CASP2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P46783 - 8.5852 RS10 RPS10 - 0 0 0 Co-IP 0 0 0 0 0 0 0
P48047 - 8.2477 ATPO - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P62266 - 8.3081 RS23 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
P62851 - 8.8036 RS25 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q00403 - 6.8163 TF2B GTF2B TFIIB 0 0 0 Co-IP 0 0 0 0 0 0 0
Q08050 - - FOXM1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q08AM6 - 6.5511 VAC14 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q12851 - - M4K2 MAP4K2  M2K4 0 0 0 Co-IP 0 0 0 0 0 0 0
Q14318 - - FKBP8 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q14C86 - 6.3308 GAPD1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q15013 - - MD2BP - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q15058 - - KIF14 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q15631 - 8.1004 TSN - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q15788 - - NCOA1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q2TB18 - - ASTE1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q32NF0 - - Q32NF0 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q5TA45 - - INT11 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q5W0V3 - - F16B1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q63HN8 - 6.3871 RN213 RNF213 - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q658Y4 - 6.1181 F91A1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q659A1 - - ICE2 NARG2 - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q6FI13 - 8.3413 H2A2A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q6P1X5 - 5.2037 TAF2  TFIID - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q7Z6I6 - 5.7853 RHG30 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q7Z7H5 - 7.0363 TMED4 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q86U86 - 6.3430 PB1 BAF180 - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q86US8 - - EST1A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q86WJ1 - 6.3051 CHD1L - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8IUD2 - 5.5241 RB6I2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8IWR0 - - Z3H7A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8N442 - 5.7559 GUF1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8TAF3 - - WDR48 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8WUF5 - 5.7487 IASPP - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8WWN8 - - ARAP3 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q8WXI9 - 6.4019 P66B GATAD2B - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q92688 - 8.2484 AN32B - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q969U7 - 7.1002 PSMG2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96D71 - 6.3771 REPS1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96FJ2 - 7.4893 DYL2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96HR3 - - MED30 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96Q15 - - SMG1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96QG7 - - MTMR9 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q99856 - 7.0662 ARI3A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9BUI4 - 6.3430 RPC3 POLR3C - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9BWU1 - 5.5598 CDK19 CDC2L6 - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9H583 - 7.6247 HEAT1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9H5X1 - 6.9063 FA96A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9NRG7 - 5.7589 D39U1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9NVI7 - 7.2418 ATD3A - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9NVP1 - 8.0194 DDX18 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9NZ45 - 7.8771 CISD1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UBP0 - 5.7916 SPAST - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UBQ0 - 7.5689 VPS29 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UH65 - - SWP70 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UK45 - 7.2428 LSM7 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UKL0 - - RCOR1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9ULJ3 - 5.7651 ZBT21 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UNX4 - 7.2388 WDR3 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9UPW5 - 6.2017 CBPC1 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9Y2H2 - 5.6213 SAC2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9Y5L0 - 7.1374 TNPO3 IPO12 - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9Y6C9 - 8.0461 MTCH2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q9Y6M1 - - IF2B2 - - 0 0 0 Co-IP 0 0 0 0 0 0 0
Q96PK6 BC000488 7.8405 RBM14 SIP - 0 0 Co-IP 0 0 0 direct interact. 0 direct interact. 0 0
C9JYP6 - - C9JYP6 - - 0 0 Co-IP 0 0 0 0 0 0 0 0
E7ENU4 - 7.2887 E7ENU4 ADAR - 0 0 Co-IP 0 0 0 0 0 0 0 0
P10412 - 8.3776 H14 H1F4 - 0 0 Co-IP 0 0 0 0 0 0 0 0
P10515 - 7.4802 ODP2 DLAT DLTA 0 0 Co-IP 0 0 0 0 0 0 0 0
P16401 - 9.2269 H15 H1F5 - 0 0 Co-IP 0 0 0 0 0 0 0 0
P18621 - 8.7622 RL17 RPL17 - 0 0 Co-IP 0 0 0 0 0 0 0 0
P42677 - 8.3097 RS27 RPS27 MPS1 0 0 Co-IP 0 0 0 0 0 0 0 0
P49207 - 8.5371 RL34 RPL34 - 0 0 Co-IP 0 0 0 0 0 0 0 0
P62424 - 8.9776 RL7A RPL7A SURF-3 0 0 Co-IP 0 0 0 0 0 0 0 0
Q02878 - 8.9842 RL6 RPL6 TXREB1 0 0 Co-IP 0 0 0 0 0 0 0 0
Q86UE4 - 7.4200 LYRIC MTDH AEG1 0 0 Co-IP 0 0 0 0 0 0 0 0
Q96KC8 - 5.5509 DNJC1 DNAJC1 HTJ1 0 0 Co-IP 0 0 0 0 0 0 0 0
Q99417 - 7.5967 MYCBP AMY1 - 0 0 Co-IP 0 0 0 0 0 0 0 0
Q6PKG0 NM_033551 7.3704 LARP1 KIAA0731 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. direct interact. 0
Q86XP3 NM_007372 6.9329 DDX42 - - 0 0 0 0 0 0 direct interact. direct interact. direct interact. direct interact. 0
Q96S94 NM_001039577 - CCNL2 SB138 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. direct interact. 0
Q9NSD4 NM_001080485 - ZN275 ZNF275 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. direct interact. 0
O60765 NM_005649 - Z354A ZNF354A EZNF 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 direct interact.
Q5M8T3 BC087840 - Q5M8T3 HES5 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 direct interact.
P81877 NM_012446 - SSBP2 SSDP2 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 0
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Q14576 NM_001420 - ELAV3 ELAVL3 HUC 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 0
Q15388 NM_014765 7.6932 TOM20 TOMM20 KIAA0016 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 0
Q86XZ4 NM_023071 - SPAS2 SPATS2 SCR59 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 0
Q9H0M5 AK126871 - ZN700 ZNF700 - 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0 0
O14640 NM_004421 - DVL1 - - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. direct interact.
P52824 BC063801 - DGKQ DAGK4 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. direct interact.
Q92793 NM_004380 5.3233 CBP CREBBP - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. direct interact.
Q9BT23 NM_030576 - LIMD2 SB143 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. direct interact.
O14686 NM_003482 - KMT2D MLL2 ALR 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
O94910 NM_001008701 - LPHN1 - - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
P10588 BC002669 - NR2F6 EAR2 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
P43699 NM_003317 - NKX21 NKX201 NKX2A 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
P78543 NM_006763 - BTG2 PC3 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q13835 NM_000299 - PKP1 - - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q1KMD3 DQ470474 7.3715 HNRL2 HNRPUL2 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q6DD87 BC077728 - ZN787 ZNF787 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q8NDT2 NM_013286 5.6036 RB15B RBM15B OTT3 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q8TBZ5 NM_033210 - ZN502 ZNF502 - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q96MS0 AY509035 - ROBO3 - - 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
Q9UL40 NM_012279 - ZN346 ZNF346 JAZ 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact. 0
P62979 BE875057 9.0349 RS27A - - 0 0 0 0 0 0 direct interact. direct interact. 0 0 direct interact.
Q00604 X65724 - NDP EVR2 - 0 0 0 0 0 0 direct interact. direct interact. 0 0 direct interact.
B2R4W8 AK054921 - B2R4W8 - - 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
P69905 BQ709225 8.6265 HBA HBA1 HBA2 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q01844 BX648769 7.4015 EWS EWSR1 - 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q15717 NM_001419 - ELAV1 ELAVL1 HUR 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q7L190 NM_018189 - DPPA4 - - 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q8N9T8 NM_023008 6.3754 KRI1 - - 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q99729 NM_031266 - ROAA HNRNPAB ABBP1 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q9UK76 BC039343 7.6306 HN1 ARM2 - 0 0 0 0 0 0 direct interact. direct interact. 0 0 0
Q14011 AK095781 - CIRBP - - 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact. direct interact.
B3KPK9 AK056467 - B3KPK9 - - 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact. 0
P79522 NM_025263 6.3581 PRR3 CAT56 - 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact. 0
Q8NEZ9 AK090484 - Q8NEZ9 FLJ00406 - 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact. 0
Q92614 D86970 - MY18A MYO18A KIAA0216 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact. 0
P61204 NM_001659 - ARF3 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 direct interact.
B3KTY1 NM_138356 - B3KTY1 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
B3KY12 AK128438 - B3KY12 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
D6W5D9 NM_022893 - D6W5D9 BCL11A - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
O14979 NM_031372 8.0489 HNRDL HNRPDL JKTBP 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
O43776 NM_004539 7.5364 SYNC NARS - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
P49247 NM_144563 7.3865 RPIA RPI - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
P62136 AK098311 8.3001 PP1A PPP1CA PPP1A 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q06945 NM_003107 - SOX4 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q12824 NM_003073 - SNF5 SMARCB1 BAF47 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q15059 NM_007371 5.6380 BRD3 KIAA0043 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q15784 NM_006160 - NDF2 NEUROD2 BHLHA1 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q2QGD7 NM_001040653 - ZXDC ZXDL - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q6ZS47 AK127739 - Q6ZS47 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q8IZ52 AB095813 - CHSS2 CHPF CSS2 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q8NF73 AK090406 - Q8NF73 FLJ00296 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q92576 BX648268 5.5810 PHF3 KIAA0244 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q92913 BC012347 - FGF13 FHF2 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q969T9 NM_012478 - WBP2 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q96G74 NM_017602 - OTUD5 - - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q96JB5 AF217982 - CK5P3 CDK5RAP3 IC53 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9H813 AK001736 - TM206 TMEM206 C1orf75 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9H8M2 BC007217 - BRD9 UNQ3040 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9NW64 AL136933 6.3840 RBM22 ZC3H16 - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9NWF9 NM_207111 - RN216 RNF216 TRIAD3 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9UBG0 NM_006039 5.3243 MRC2 CLEC13E - 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9UBL0 NM_016300 - ARP21 ARPP21 TARPP 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9UL33 AK126779 - TPC2L TRAPPC2L HSPC126 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q9Y508 NM_018683 - RN114 RNF114 ZNF228 0 0 0 0 0 0 direct interact. 0 direct interact. 0 0
Q59F65 AB209596 - Q59F65 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact..5 0
O00468 AB191264 5.4766 AGRIN AGRN - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O14730 NM_003831 - RIOK3 SUDD - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O14978 NM_005741 - ZN263 ZNF263 FPM315 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O15428 U82382 - PINL PIN1L - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O43159 AB007869 6.5605 RRP8 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O75325 AF030435 - LRRN2 GAC1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
O95248 BC087612 - MTMR5 SBF1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
P01137 X02812 - TGFB1 TGFB - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
P25774 NM_004079 - CATS CTSS - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
P29590 NM_033238 5.3306 PML MYL - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
P51911 BC036307 - CNN1 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
P56270 NM_001042539 - MAZ ZNF801 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q04206 BC110830 6.5697 TF65 RELA NFKB3 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q06587 BC002922 5.9522 RING1 RNF1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q13685 NM_001087 - AAMP - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q14160 NM_182706 6.1380 SCRIB CRIB1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q14584 AB095928 - ZN266 ZNF266 KIAA2007 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q15560 AK226140 - TCEA2 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q25QX8 AB065282 - Q25QX8 TIPUH1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q3T8J9 AY335491 - GON4L GON4 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q499Z4 BC035140 - ZN672 ZNF672 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q4LE74 AB209997 - Q4LE74 MYO9B - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q59F37 AB209624 - Q59F37 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q59FF1 AB209509 - Q59FF1 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q59FY8 AB209321 - Q59FY8 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q59H57 AB208902 - Q59H57 - - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
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Q5SWA1 BC065280 - PR15B PPP1R15B - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q5T9A4 AB033099 6.2726 ATD3B ATAD3B KIAA1273 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q6P597 BC073841 - KLC3 KLC2 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q6P6B7 BC067892 - ANR16 ANKRD16 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q8IWT6 NM_019594 - LRC8A LRRC8A KIAA1437 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q8N3V7 AB028952 6.4326 SYNPO KIAA1029 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q8WW22 NM_018602 6.7323 DNJA4 DNAJA4 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q969Z0 AB023165 7.1716 TBRG4 CPR2 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q96B54 NM_182498 - ZN428 ZNF428 C19orf37 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q99661 NM_006845 7.1920 KIF2C KNSL6 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q99941 NM_004381 - ATF6B CREBL1 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9BZR9 NM_030912 - TRIM8 GERP - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9C0C2 NM_033396 5.4274 TB182 TNKS1BP1 KIAA1741 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9NV56 NM_018270 6.7385 MRGBP C20orf20 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9UIS9 NM_015846 - MBD1 CXXC3 - 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9Y468 AB014581 - LMBL1 L3MBTL1 KIAA0681 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q9Y5S2 AF128625 - MRCKB CDC42BPB KIAA1124 0 0 0 0 0 0 direct interact. 0 0 direct interact. 0
Q0664 BC018898 - - - - 0 0 0 0 0 0 direct interact. 0 0 0 direct interact.
Q15773 BM919311 - MLF2 - - 0 0 0 0 0 0 direct interact. 0 0 0 direct interact.
Q9P253 AL713725 6.2793 VPS18 KIAA1475 - 0 0 0 0 0 0 direct interact. 0 0 0 direct interact.
A6NDC7 AK092882 - A6NDC7 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KNA8 AK024202 - B3KNA8 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KNS9 AK054888 - B3KNS9 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KQ39 AK057302 - B3KQ39 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KQE6 AK074821 - B3KQE6 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KR73 AK091118 - B3KR73 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KSB0 AK093216 - B3KSB0 NCBP2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KUN3 AK097610 - B3KUN3 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KW85 AK124526 - B3KW85 BCAR1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KWB2 AK124709 - B3KWB2 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B3KWN0 AK125379 - B3KWN0 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
B5B2S0 NM_004555 - B5B2S0 NFATC3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
D9ZGF1 NM_006079 - D9ZGF1 CITED2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O00255 NM_130803 - MEN1 - SCG2 0 0 0 0 0 0 direct interact. 0 0 0 0
O00622 Y11307 - CYR61 CCN1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O14492 NM_020979 - SH2B2 APS - 0 0 0 0 0 0 direct interact. 0 0 0 0
O14986 BC030587 - PI51B PIP5K1B STM7 0 0 0 0 0 0 direct interact. 0 0 0 0
O15054 NM_001080424 - KDM6B JMJD3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O15209 NM_005453 - ZBT22 ZBTB22 BING1 0 0 0 0 0 0 direct interact. 0 0 0 0
O15230 NM_005560 - LAMA5 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
O15379 AF005482 6.0241 HDAC3 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
O43474 NM_004235 - KLF4 EZF - 0 0 0 0 0 0 direct interact. 0 0 0 0
O43768 NM_207043 - ENSA - - 0 0 0 0 0 0 direct interact. 0 0 0 0
O60499 BQ057394 6.5230 STX10 SYN10 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O60547 AK130651 6.8815 GMDS - - 0 0 0 0 0 0 direct interact. 0 0 0 0
O60828 BM909365 6.7803 PQBP1 NPW38 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O75110 NM_006045 - ATP9A ATPIIA - 0 0 0 0 0 0 direct interact. 0 0 0 0
O75509 AB209394 - TNR21 TNFRSF21 DR6 0 0 0 0 0 0 direct interact. 0 0 0 0
O75832 NM_002814 7.1072 PSD10 PSMD10 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O76003 AK021926 8.0572 GLRX3 PICOT - 0 0 0 0 0 0 direct interact. 0 0 0 0
O94941 NM_014948 - RNF37 UBOX5 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O94972 NM_015294 - TRI37 TRIM37 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O94985 AB020718 - CSTN1 CLSTN1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O95125 NM_003455 - ZN202 ZNF202 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O95376 NM_006321 - ARI2 ARIH2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
O95793 NM_017453 7.4571 STAU1 STAU - 0 0 0 0 0 0 direct interact. 0 0 0 0
P00387 NM_007326 7.8604 NB5R3 CYB5R3 DIA1 0 0 0 0 0 0 direct interact. 0 0 0 0
P01023 CR749334 - A2MG A2M CPAMD5 0 0 0 0 0 0 direct interact. 0 0 0 0
P02461 NM_000090 - CO3A1 COL3A1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P02749 BC026283 - APOH B2G1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P02768 AF130077 - ALBU ALB GIG20 0 0 0 0 0 0 direct interact. 0 0 0 0
P04049 NM_002880 - RAF1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P07858 NM_147780 7.9285 CATB CTSB CPSB 0 0 0 0 0 0 direct interact. 0 0 0 0
P07996 NM_003246 - TSP1 THBS1 TSP 0 0 0 0 0 0 direct interact. 0 0 0 0
P08047 NM_138473 - SP1 TSFP1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P08253 NM_004530 - MMP2 CLG4A - 0 0 0 0 0 0 direct interact. 0 0 0 0
P14649 BQ673169 5.9642 MYL6B MLC1SA - 0 0 0 0 0 0 direct interact. 0 0 0 0
P14921 NM_005238 - ETS1 EWSR2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P15976 NM_002049 - GATA1 ERYF1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P17026 NM_006963 6.3086 ZNF22 KOX15 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P18848 NM_001675 - ATF4 CREB2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P21695 NM_005276 - GPDA GPD1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P24593 NM_000599 - IBP5 IGFBP5 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P25791 NM_005574 - RBTN2 LMO2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P26378 BC036071 - ELAV4 ELAVL4 HUD 0 0 0 0 0 0 direct interact. 0 0 0 0
P27918 AK122955 - PROP CFP PFC 0 0 0 0 0 0 direct interact. 0 0 0 0
P29279 NM_001901 - CTGF CCN2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P29597 NM_003331 - TYK2 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P30040 NM_006817 8.2806 ERP29 C12orf8 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P35080 BC043646 - PROF2 PFN2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P35269 NM_002096 7.4058 T2FA GTF2F1 RAP74 0 0 0 0 0 0 direct interact. 0 0 0 0
P35442 NM_003247 - TSP2 THBS2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P38936 NM_078467 - CDN1A p21 CDKN1A 0 0 0 0 0 0 direct interact. 0 0 0 0
P40855 NM_002857 6.8640 PEX19 HK33 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P41221 NM_003392 - WNT5A - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P41229 NM_004187 - KDM5C JARID1C - 0 0 0 0 0 0 direct interact. 0 0 0 0
P51523 BC036656 - ZNF84 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P51693 NM_001024807 - APLP1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P52737 AK123008 - ZN136 ZNF136 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P53804 D84294 - TTC3 DCRR1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
P54105 NM_001293 7.5603 ICLN CLNS1A CLCI 0 0 0 0 0 0 direct interact. 0 0 0 0
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P61968 NM_006769 - LMO4 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
P62841 BM923584 - RS15 RPS15 RIG 0 0 0 0 0 0 direct interact. 0 0 0 0
P68133 BC012597 - ACTS ACTA1 ACTA 0 0 0 0 0 0 direct interact. 0 0 0 0
P98175 NM_005676 6.6396 RBM10 DXS8237E - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q04725 NM_003260 - TLE2 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q05923 L11329 - DUS2 DUSP2 PAC1 0 0 0 0 0 0 direct interact. 0 0 0 0
Q06889 NM_004430 - EGR3 PILOT - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q13127 NM_005612 - REST NRSF - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q13616 NM_003592 6.9944 CUL1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q13625 NM_005426 - ASPP2 TP53BP2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q13642 AK122708 - FHL1 SLIM1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q13751 NM_001025598 - LAMB3 LAMNB1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q14201 BC011957 - BTG3 ANA - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q14C66 NM_001109 - Q14C66 ADAM8 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q14CW9 NM_020218 - AT7L3 ATXN7L3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q15070 BX248001 - OXA1L - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q15334 NM_004140 - L2GL1 LLGL1 DLG4 0 0 0 0 0 0 direct interact. 0 0 0 0
Q15393 D13642 8.0127 SF3B3 KIAA0017 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q15628 AK090673 6.9764 TRADD - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q15935 BC043354 - ZNF77 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q16881 NM_003330 7.9267 TRXR1 TXNRD1 GRIM12 0 0 0 0 0 0 direct interact. 0 0 0 0
Q2TAZ0 BC110650 - ATG2A KIAA0404 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q2YDX2 NM_014643 - Q2YDX2 ZNF516 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q32P51 AK126454 - RA1L2 HNRNPA1L - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q3KQV3 NM_175872 - ZN792 ZNF792 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q3V5L5 AB235153 - MGT5B MGAT5B KIAA2008 0 0 0 0 0 0 direct interact. 0 0 0 0
Q3ZCU9 BC039299 - Q3ZCU9 STIP1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q4VBQ6 NM_016162 - Q4VBQ6 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q53EL4 AK223625 - Q53EL4 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q59F46 AB209615 - Q59F46 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q59FM7 AB209433 - Q59FM7 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q59FW3 AB209346 - Q59FW3 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q59HB4 AB208845 - Q59HB4 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q5MNZ6 NM_019613 - WIPI3 WDR45B WDR45L 0 0 0 0 0 0 direct interact. 0 0 0 0
Q5TGY3 NM_001029882 - AHDC1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q5VUD6 AF318355 - FA69B FAM69B C9orf136 0 0 0 0 0 0 direct interact. 0 0 0 0
Q63HK3 CA434734 - ZKSC2 ZKSCAN2 ZNF694 0 0 0 0 0 0 direct interact. 0 0 0 0
Q676U5 NM_030803 - A16L1 ATG16L1 APG16L 0 0 0 0 0 0 direct interact. 0 0 0 0
Q69YH5 NM_152562 5.7600 CDCA2 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6NTE8 BX537968 - CE045 C5orf45 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6P0P0 NM_052897 - Q6P0P0 MBD6 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6P4A8 NM_024829 - PLBL1 PLBD1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6ZN04 AK131424 - MEX3B KIAA2009 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6ZNI9 AK131106 - Q6ZNI9 FLJ00395 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q6ZQU7 AK128712 - Q6ZQU7 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q7Z5J4 NM_030665 - RAI1 KIAA1820 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q7Z7K2 AK131441 - ZN467 ZNF467 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q86V38 BC051795 - Q86V38 ATN1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q86WZ6 BC047570 - ZN227 ZNF227 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q86YR5 AL117478 - GPSM1 AGS3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IVM0 AJ557013 6.1927 CCD50 CCDC50 C3orf6 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IWC1 AL832120 - MA7D3 MAP7D3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IWT3 CR749511 - CUL9 H7AP1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IXK2 NM_024642 - GLT12 GALNT12 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IXR4 BC039496 - Q8IXR4 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IXW5 AK023212 - RPAP2 C1orf82 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IY17 BC050553 6.1829 PLPL6 PNPLA6 NTE 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8IYI8 AK095252 - ZN440 ZNF440 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8N1G0 AB037862 - ZN687 ZNF687 KIAA1441 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8N3F0 NM_152793 - MTURN C7orf41 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8N567 AL512712 - ZCHC9 ZCCHC9 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8NB37 NM_182612 - PDDC1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8ND25 NM_032268 - ZNRF1 NIN283 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8NDP4 AL833935 - ZN439 ZNF439 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8NE65 BC034499 - ZN738 ZNF738 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8NEB1 NM_033141 - Q8NEB1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8TAP4 NM_018640 - LMO3 RBTN3 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8TAS9 BC025971 - Q8TAS9 C7orf50 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8TEK3 AB058717 - DOT1L KIAA1814 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q8WYH8 NM_032329 - ING5 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q969K4 AF447886 - ABTB1 BPOZ - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96BJ3 BC015535 - AIDA C1orf80 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96C19 NM_024329 7.5948 EFHD2 SWS1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96EP1 BC012072 - CHFR RNF196 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96GP6 NM_153334 - SREC2 SCARF2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96HZ4 AK075040 - HES6 BHLHB41 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96JF6 AB058774 - ZN594 ZNF594 KIAA1871 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96JW5 AK027837 - Q96JW5 BZW2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96K62 NM_032792 - ZBT45 ZBTB45 ZNF499 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96MT1 BC042684 - RN145 RNF145 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96NM4 AK055135 - TOX2 C20orf100 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96PE2 NM_014786 - ARHGH KIAA0337 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96RP9 AF309777 7.4132 EFGM GFM1 EFG 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96ST2 AK027561 6.6758 IWS1 IWS1L - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q96T37 BC042587 6.4774 RBM15 OTT - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q99439 NM_004368 - CNN2 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q99543 NM_014377 7.0904 DNJC2 DNAJC2
MPHOSPH1
1 0 0 0 0 0 0 direct interact. 0 0 0 0
Q99750 CR594049 - MDFI - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9BWG4 NM_033044 - SSBP4 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9BWG6 AK056322 - SCNM1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9C0K0 NM_138576 - BC11B BCL11B CTIP2 0 0 0 0 0 0 direct interact. 0 0 0 0
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Q9H211 AB053172 - CDT1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9H3P2 AK126056 7.0487 NELFA WHSC2 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9H4M3 CR749368 - FBX44 FBXO44 FBG3 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9HBE1 NM_014323 - PATZ1 PATZ - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9HCS7 AK074035 7.0928 SYF1 XAB2 HCNP 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9NR46 AL832592 - SHLB2 SH3GLB2 KIAA1848 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9NSK0 AK055293 5.5281 KLC4 KNSL8 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9NSV7 AL137714 - Q9NSV7
DKFZp434K
1323 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9NUL5 AK096142 - CS066 C19orf66 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9NYZ3 NM_016426 - GTSE1 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9P0J7 NM_020122 - KCMF1 FIGC - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9P219 NM_001080414 - DAPLE CCDC88C - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UBL3 BC015936 6.9553 ASH2L ASH2L1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UBQ7 AK024386 7.6289 GRHPR GLXR - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UHF1 AK091964 - EGFL7 MEGF7 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UHY1 AK122664 6.9663 NRBP NRBP1 BCON3 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UJ88 Y12395 6.2046 Q9UJ88 IFRD2 hCG 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9UNE7 NM_005861 6.4561 CHIP STUB1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y3C6 AY359032 7.2984 PPIL1 CYPL1 - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y3X0 AL050284 6.6634 CCDC9 - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y534 NM_014460 - CSDC2 PIPPIN - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y5A6 NM_145914 - ZSC21 ZSCAN21 ZFP38 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y5Q3 NM_005461 - MAFB KRML - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y6J0 AB002328 - CABIN CABIN1 KIAA0330 0 0 0 0 0 0 direct interact. 0 0 0 0
Q9Y6R7 NM_003890 - FCGBP - - 0 0 0 0 0 0 direct interact. 0 0 0 0
Q7Z5L9 NM_182972 6.3165 I2BP2 IRF2BP2 - 0 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0
Q9P2K9 NM_020780 - PTHD2 PTCHD2 DISP3 0 0 0 0 0 0 0 direct interact. direct interact. direct interact. 0
P13196 NM_000688 6.8970 HEM1 - - 0 0 0 0 0 0 0 direct interact. direct interact. 0 direct interact.
P17038 NM_003423 - ZNF43 KOX27 - 0 0 0 0 0 0 0 direct interact. direct interact. 0 0
Q6NYC5 NM_002374 - Q6NYC5 - - 0 0 0 0 0 0 0 direct interact. direct interact. 0 0
O95613 NM_006031 - PCNT PCNT2 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact.
Q9NS23 NM_170714 - RASF1 RASSF1 RDA32 0 0 0 0 0 0 0 direct interact. 0 direct interact. direct interact.
O60331 NM_012398 - PI51C PIP5K1C KIAA0589 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
P15621 NM_016264 - ZNF44 GIOT2 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
P17480 NM_001076683 7.4080 UBF1 UBTF UBF 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
P30405 NM_005729 7.8572 PPIF CYP3 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
P52756 AB208813 6.0664 RBM5 H37 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q16478 NM_002088 - GRIK5 GRIK2 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q59GA1 AB209208 - Q59GA1 - - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q59H49 AB208910 - Q59H49 - - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q7L945 BC098416 - ZN627 ZNF627 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q8IUX7 NM_001129 - AEBP1 ACLP - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q92879 AB210019 - CELF1 BRUNOL2 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q969V6 BC115039 5.5105 MKL1 KIAA1438 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q96CW1 NM_004068 7.2405 AP2M1 CLAPM1 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q96PV7 AB067518 - F193B FAM193B KIAA1931 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q9BV10 NM_024105 - ALG12 PP14673 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q9NQV8 NM_020226 - PRDM8 PFM5 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q9NUD5 BC069238 - ZCHC3 ZCCHC3 C20orf99 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q9NW07 NM_018083 - ZN358 ZNF358 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
Q9UBN1 NM_014405 - CCG4 CACNG4 - 0 0 0 0 0 0 0 direct interact. 0 direct interact. 0
P56556 NM_002490 7.0935 NDUA6 - - 0 0 0 0 0 0 0 direct interact. 0 0 direct interact.
P61353 BF219474 9.0689 RL27 - - 0 0 0 0 0 0 0 direct interact. 0 0 direct interact.
Q15697 NM_003450 - ZN174 ZNF174 ZSCAN8 0 0 0 0 0 0 0 direct interact. 0 0 direct interact.
Q6PJ21 BC041897 - SPSB3 C16orf31 - 0 0 0 0 0 0 0 direct interact. 0 0 direct interact.
Q96G42 BC009980 - KLD7B - - 0 0 0 0 0 0 0 direct interact. 0 0 direct interact.
- XR_019643 - - - - 0 0 0 0 0 0 0 direct interact. 0 0 0
O15169 AB208876 - AXIN1 AXIN - 0 0 0 0 0 0 0 direct interact. 0 0 0
P05412 NM_002228 6.6522 JUN  AP-1 - 0 0 0 0 0 0 0 direct interact. 0 0 0
P30084 NM_004092 7.4695 ECHM - - 0 0 0 0 0 0 0 direct interact. 0 0 0
P49674 NM_152221 - KC1E - - 0 0 0 0 0 0 0 direct interact. 0 0 0
P49748 NM_000018 7.4713 ACADV ACADVL VLCAD 0 0 0 0 0 0 0 direct interact. 0 0 0
P50749 AY154470 - RASF2 RASSF2 KIAA0168 0 0 0 0 0 0 0 direct interact. 0 0 0
Q15025 NM_006058 - TNIP1 KIAA0113 - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q4V348 NM_001032297 - Z658B ZNF658B - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q76LX8 AB069698 - ATS13 C9orf8 - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q8TF20 NM_133474 - ZN721 - - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q8WTV1 NM_138350 - THAP3 - - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q96EZ8 NM_006337 - MCRS1 INO80Q - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q96JG8 NM_001098800 - MAGD4 MAGED4 KIAA1859 0 0 0 0 0 0 0 direct interact. 0 0 0
Q9BU23 BC014652 - LMF2 TMEM112B - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q9NV79 AB028973 - PCMD2 PCMTD2 C20orf36 0 0 0 0 0 0 0 direct interact. 0 0 0
Q9P1Y5 NM_001080429 - CAMP3 CAMSAP3 KIAA1543 0 0 0 0 0 0 0 direct interact. 0 0 0
Q9UK11 BC022466 - ZN223 ZNF223 - 0 0 0 0 0 0 0 direct interact. 0 0 0
Q9ULX9 NM_001161572-4 6.4362 MAFF - - 0 0 0 0 0 0 0 direct interact. 0 0 0
O00459 NM_005027 - P85B PIK3R2 - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
P08247 BC064550 - SYPH SYP - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
P51674 NM_201591 - GPM6A M6A - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
P98161 NM_001009944 - PKD1 - - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
Q01814 AB210008 - AT2B2 ATP2B2 PMCA2 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
Q8IWZ8 AY072916 6.3029 SUGP1 SF4 - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
Q8IZD0 AK094209 - SAM14 SAMD14 - 0 0 0 0 0 0 0 0 direct interact. direct interact. 0
P48509 AK130369 - CD151 - - 0 0 0 0 0 0 0 0 direct interact. 0 direct interact.
P62993 NM_002086 7.4483 GRB2 ASH - 0 0 0 0 0 0 0 0 direct interact. 0 direct interact.
Q68CR1 BC060867 - SE1L3 - - 0 0 0 0 0 0 0 0 direct interact. 0 direct interact.
A0AUZ9 NM_152519 - KAL1L - - 0 0 0 0 0 0 0 0 direct interact. 0 0
A6NHR9 NM_015295 7.0601 SMHD1 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
A8KAG1 NM_182679 - A8KAG1 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
AK226126 - - - - - 0 0 0 0 0 0 0 0 direct interact. 0 0
B3KXJ0 NM_006158 - B3KXJ0 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
B9A6J5 NM_015705 - B9A6J5 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
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E9KL44 NM_000182 - E9KL44 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
O14683 BC045666 - P5I11 TP53I11 PIG11 0 0 0 0 0 0 0 0 direct interact. 0 0
O60688 CR933630 - YPEL1 FKSG3 - 0 0 0 0 0 0 0 0 direct interact. 0 0
O75051 NM_025179 - PLXA2 PLXNA2 - 0 0 0 0 0 0 0 0 direct interact. 0 0
O75934 BC022880 7.4510 SPF27 BCAS2 DAM1 0 0 0 0 0 0 0 0 direct interact. 0 0
O95201 NM_003456 - ZN205 ZNF205 ZNF210 0 0 0 0 0 0 0 0 direct interact. 0 0
O95721 NM_004782 6.3671 SNP29 SNAP29 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P05060 BC000375 - SCG1 CHGB - 0 0 0 0 0 0 0 0 direct interact. 0 0
P06858 NM_000237 - LIPL LPL LIPD 0 0 0 0 0 0 0 0 direct interact. 0 0
P0CG48 - - UBC - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P10586 NM_002840 - PTPRF LAR - 0 0 0 0 0 0 0 0 direct interact. 0 0
P11413 X03674 7.5171 G6PD - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P11766 - 7.7121 ADHX ADH5 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P13501 - - CCL5 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P14618 NM_182470 8.9310 KPYM PKM OIP3 0 0 0 0 0 0 0 0 direct interact. 0 0
P15923 NM_003200 - TFE2 TCF3 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P19447 AK127469 6.6059 ERCC3 XPB - 0 0 0 0 0 0 0 0 direct interact. 0 0
P22607 AB209441 - FGFR3 JTK4 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P23471 NM_002851 - PTPRZ - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P26232 AK127226 6.0950 CTNA2 CTNNA2 CAPR 0 0 0 0 0 0 0 0 direct interact. 0 0
P33316 NM_001025248 7.7482 DUT - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P33992 NM_006739 7.6536 MCM5 CDC46 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P39656 NM_005216 7.8912 OST48 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P48147 NM_002726 6.6387 PPCE - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P49448 BC050732 - DHE4 GLUD2 GLUDP1 0 0 0 0 0 0 0 0 direct interact. 0 0
P53365 NM_012402 6.5863 ARFP2 ARFIP2 POR1 0 0 0 0 0 0 0 0 direct interact. 0 0
P54920 NM_003827 7.4669 SNAA - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P55212 NM_001226 6.3496 CASP6 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
P56202 BC048255 - CATW CTSW - 0 0 0 0 0 0 0 0 direct interact. 0 0
P56211 AL833077 - ARP19 ARPP19 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P60660 - - MYL6 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q02880 NM_001068 7.2709 TOP2B - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q07343 NM_001037341 - PDE4B - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q08117 - - AES GRG - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q13263 X97548 8.2502 TIF1B TRIM28 KAP1 0 0 0 0 0 0 0 0 direct interact. 0 0
Q13519 NM_006228 - PNOC - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q15233 NM_007363 8.6193 NONO NRB54 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q15853 NM_003367 - USF2 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q504Y2 BC094697 - PKDCC SGK493 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q53ET0 BC053562 - CRTC2 TORC2 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q53EV1 NM_002871 - Q53EV1 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q59EQ8 AB209753 - Q59EQ8 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q59FX6 NM_002850 - Q59FX6 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q59GG0 AB209149 - Q59GG0 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q6IQ23 NM_175058 - PKHA7 PLEKHA7 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q6NXG8 NM_003959 - Q6NXG8 HIP1R - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q6ZMJ6 AK160386 - Q6ZMJ6 FLJ00420 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q6ZP65 NM_207311 - BICR1 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q6ZQU3 AK128722 - Q6ZQU3 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q7Z3E2 NM_018017 - CC186 C10orf118 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q7Z429 AK127640 - LFG1 GRINA - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q86Y91 BC044933 5.9745 KI18B KIF18B - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q86YD1 NM_017432 - PTOV1 ACID2 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q86Z22 AF466367 - Q86Z22 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q8IVD9 NM_015332 6.5850 NUDC3 NUDCD3 KIAA1068 0 0 0 0 0 0 0 0 direct interact. 0 0
Q8N2K0 NM_001042472 5.8024 ABD12 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q8N5U6 NM_014868 - RNF10 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q8TBC5 NM_023926 - ZSC18 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q8WXG9 AF435925 - GPR98 KIAA0686 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q92900 NM_002911 7.4770 RENT1 UPF1 KIAA0221 0 0 0 0 0 0 0 0 direct interact. 0 0
Q93063 - - EXT2 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q969N2 NM_015937 6.8633 PIGT - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q96HW7 BC015664 6.1340 INT4 INTS4 MSTP093 0 0 0 0 0 0 0 0 direct interact. 0 0
Q96RT7 NM_020461 5.7975 GCP6 TUBGCP6 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q99569 NM_003628 - PKP4 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q99608 NM_002487 - NECD - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q99963 NM_003027 - SH3G3 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9BTT6 NM_018214 - LRRC1 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9BU62 NM_013318 - Q9BU62 BAT2L - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9BZL6 NM_016457 - KPCD2 PRKD2 PKD2 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9H0J4 AL136774 - QRIC2 QRICH2 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9H2D6 NM_001039141 - TARA TRIOBP KIAA1662 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9H3T2 NM_030913 - SEM6C - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9NP58 BC043423 - ABCB6 MTABC3 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9NPA5 NM_018197 - ZF64A ZFP64 ZNF338 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9NT68 - - TEN2 TENM2 KIAA1127 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9NXR8 NM_019071 - ING3 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9P0L9 NM_016112 - PK2L1 PKD2L1 PKD2L 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9ULD4 NM_015695 - BRPF3 - - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9Y2Q5 LAMTOR2 - LTOR2 LAMTOR2 MAPBPIP 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9Y3C8 BC005187 7.2328 UFC1 CGI0126 - 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9Y618 NM_012112 - NCOR2 SMRT CTG26 0 0 0 0 0 0 0 0 direct interact. 0 0
Q9Y6X7 AB020671 - Q9Y6X7 KIAA0864 - 0 0 0 0 0 0 0 0 direct interact. 0 0
P14598 BC002816 - NCF1 NOXO2 - 0 0 0 0 0 0 0 0 0 direct interact..5 0
P78364 NM_004426 - PHC1 EDR1 - 0 0 0 0 0 0 0 0 0 direct interact..5 0
Q9BWG0 AB210026 - Q9BWG0 MYH10 - 0 0 0 0 0 0 0 0 0 direct interact..5 0
Q9H6S3 AK122903 - ES8L2 EPS8L2 EPS8R2 0 0 0 0 0 0 0 0 0 direct interact..5 0
Q8IY33 BC037988 - MILK2 MICALL2 - 0 0 0 0 0 0 0 0 0 direct interact. direct interact.
A6NC98 NM_032251 - CC88B BRLZ - 0 0 0 0 0 0 0 0 0 direct interact. 0
A7J992 NM_017934 - A7J992 PHIP - 0 0 0 0 0 0 0 0 0 direct interact. 0
O14641 NM_004422 - DVL2 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
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UniProt 
AC
RefSeq ID 
UniPEx-
library Name
HL60 
[whole 
cell 
lysate]
JEKO-1 
[whole 
cell 
lysate]
OPM2 
[nuclear 
enriched 
lysate]
U937 
[whole 
cell 
lysate]
SU-DHL-1 
[ whole 
cell lysate]
SU-DHL-1 
[nuclear 
enriched 
lysate]
C/EBP  
aa1-41 
[CR1-2]
C/EBP  
aa1-62 
[CR2-4] 
C/EBP  
aa49-72 
[CR3]
C/EBP  
aa153-
173 
[CR7]
C/EBP  
aa79-196 
[CR4-7]
IP-MS APS
Synonyms
O15371 NM_003753 7.6876 EIF3D EIF3S7 - 0 0 0 0 0 0 0 0 0 direct interact. 0
O43566 NM_006480 6.0393 RGS14 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
O43896 AB014606 - KIF1C - - 0 0 0 0 0 0 0 0 0 direct interact. 0
O60239 NM_004844 - 3BP5 SH3BP5 SAB 0 0 0 0 0 0 0 0 0 direct interact. 0
O75528 BC009240 6.1765 TADA3 ADA3 - 0 0 0 0 0 0 0 0 0 direct interact. 0
O95157 AB032985 - NXPH3 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
P08572 NM_001846 - CO4A2 COL4A2 - 0 0 0 0 0 0 0 0 0 direct interact. 0
P10072 AK128116 - HKR1 ZNF875 - 0 0 0 0 0 0 0 0 0 direct interact. 0
P10645 NM_001275 - CMGA CHGA - 0 0 0 0 0 0 0 0 0 direct interact. 0
P19532 NM_006521 - TFE3 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
P21810 BC004244 - PGS1 BGN SLRR1A 0 0 0 0 0 0 0 0 0 direct interact. 0
P21860 NM_001982 - ERBB3 HER3 - 0 0 0 0 0 0 0 0 0 direct interact. 0
P24385 NM_053056 - CCND1 BCL1 - 0 0 0 0 0 0 0 0 0 direct interact. 0
P25098 NM_001619 6.0836 ARBK1 ADRBK1 BARK 0 0 0 0 0 0 0 0 0 direct interact. 0
P42229 NM_003152 - STA5A STAT5A STAT5 0 0 0 0 0 0 0 0 0 direct interact. 0
P43250 NM_002082 - GRK6 GPRK6 - 0 0 0 0 0 0 0 0 0 direct interact. 0
P48634 NM_080686 7.1212 PRC2A PRRC2A BAT2 0 0 0 0 0 0 0 0 0 direct interact. 0
P50281 NM_004995 - MMP14 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
P50548 AB209271 - ERF - - 0 0 0 0 0 0 0 0 0 direct interact. 0
P53007 L75823 7.6229 TXTP SLC25A1 SLC20A3 0 0 0 0 0 0 0 0 0 direct interact. 0
P54725 NM_005053 7.4935 RD23A RAD23A - 0 0 0 0 0 0 0 0 0 direct interact. 0
P55072 BC110913 8.3107 TERA VCP - 0 0 0 0 0 0 0 0 0 direct interact. 0
P78406 AY349350 7.5120 RAE1L RAE1 MRNP41 0 0 0 0 0 0 0 0 0 direct interact. 0
Q01130 BC070086 8.4192 SRSF2 SFRS2 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q02641 BC037311 - CACB1 CACNB1 CACNLB1 0 0 0 0 0 0 0 0 0 direct interact. 0
Q07955 NM_001078166 - SRSF1 ASF - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q12972 NM_138558 7.1746 PP1R8 PPP1R8 ARD1 0 0 0 0 0 0 0 0 0 direct interact. 0
Q13243 BC040209 7.0695 SRSF5 HRS - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q13867 NM_000386 7.1172 BLMH - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q15056 NM_022170 8.2690 IF4H EIF4H KIAA0038 0 0 0 0 0 0 0 0 0 direct interact. 0
Q15758 U53347 8.6190 AAAT SLC1A5 ASCT2 0 0 0 0 0 0 0 0 0 direct interact. 0
Q16629 AK091425 8.5128 SRSF7 SFRS7 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q16760 NM_152879 - DGKD KIAA0145 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q1ED39 NM_001012991 - KNOP1 C16orf88 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q2L4Q9 NM_001039503 - PRS53 PRSS53 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q59EF5 AB209856 - Q59EF5 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q59FG1 AB209499 - Q59FG1 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q59G26 AB209283 - Q59G26 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q59GG3 AB209146 - Q59GG3 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q5TH69 NM_020340 5.3945 BIG3 ARFGEF3 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q5XKG8 BC026321 - Q5XKG8 ZNF334 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q6VY07 NM_018026 6.2393 PACS1 KIAA1175 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q7Z2K8 BC052950 - GRIN1 GPRIN1 KIAA1893 0 0 0 0 0 0 0 0 0 direct interact. 0
Q86V15 DQ217660 - CASZ1 CST - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8IVH2 NM_001012426 - FOXP4 FKHLA - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8IW90 BC040659 - Q8IW90 MTCH1 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8N2S1 NM_001042544 - LTBP4 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8N5D0 AB028960 - WDTC1 KIAA1037 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8N5V2 NM_019850 - NGEF - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8NDH3 NM_024663 5.9436 PEPL1 NPEPL1 KIAA1974 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8TBB7 NM_003861 - Q8TBB7 WDR22 DCAF5 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8TCX5 NM_052924 - RHPN1 KIAA1929 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8TDD1 NM_024072 6.4960 DDX54 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8TEW0 AF196185 5.6315 PARD3 PAR3 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q8TF61 NM_001080410 - FBX41 FBXO41 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q969S8 NM_032019 - HDA10 HDAC10 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q96BM9 NM_138795 7.5800 ARL8A ARL10B - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q96F46 NM_014339 - I17RA IL17RA IL17R 0 0 0 0 0 0 0 0 0 direct interact. 0
Q96FE7 BC041903 - P3IP1 PIK3IP1 HGFL 0 0 0 0 0 0 0 0 0 direct interact. 0
Q96GS6 AK090438 - AB17A ABHD17A C19orf27 0 0 0 0 0 0 0 0 0 direct interact. 0
Q96RN5 NM_001003891 6.4106 MED15 ARC105 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q99758 NM_001089 - ABCA3 ABC3 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9C0B0 NM_001080419 - UNK KIAA1753 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9H7Z6 M98343 6.0028 KAT8 MOF - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9HBL0 NM_022648 - TENS1 TNS1 TNS 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9NPA3 NM_021242 - M1IP1 MID1IP1 MIG12 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9NSY0 BC071605 - NRBP2 PP9320 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9NYQ6 AF231024 - CELR1 CELSR1 CDHF9 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9UEG4 NM_001080417 - ZN629 ZNF629 KIAA0326 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9UG56 NM_014338 - PISD - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9ULW3 NM_013375 7.3073 ABT1 - - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9Y2V2 NM_001042476 7.4938 CHSP1 CARHSP1 - 0 0 0 0 0 0 0 0 0 direct interact. 0
Q9Y520 NM_015172 6.5005 PRC2C PRRC2C BAT2D1 0 0 0 0 0 0 0 0 0 direct interact. 0
O14908 NM_005716 6.6038 GIPC1 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
O43296 NM_003417 - ZN264 ZNF264 - 0 0 0 0 0 0 0 0 0 0 direct interact.
P50502 NM_003932 8.0970 F10A1 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
P57678 AF177341 6.5901 GEMI4 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
P80404 NM_000663 - GABT - - 0 0 0 0 0 0 0 0 0 0 direct interact.
P84098 BF698920 8.7034 RL19 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
Q86V86 NM_001001852 - PIM3 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
Q92664 AK057993 - TF3A - - 0 0 0 0 0 0 0 0 0 0 direct interact.
Q96FF9 BC011000 - CDCA5 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
Q9BUJ2 NM_007040 7.7783 HNRL1 - - 0 0 0 0 0 0 0 0 0 0 direct interact.
Q9UKS6 AF130979 - PACN3 SH3 - 0 0 0 0 0 0 0 0 0 0 direct interact.
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